

# Index

Page numbers followed by *f* indicate figures; those followed by *t* indicate tables; and those followed by *d* indicate displays. Color figures are referred to by number.

- A**
- Abscess  
amebic, 490  
endobronchial  
in bronchiectasis, 300, 300f, 303  
in chronic bronchitis, 290, 291f  
in pulmonary infarct, Color Fig. 18-3, 174
- Acanthamoeba* infection  
in AIDS, 508  
pulmonary, 492
- Acid rain, Color Fig. 77-1, 888
- Acinic cell tumor, of bronchial glands, Color Fig. 52-3, 605
- Acinus(i)  
anatomic definition of, 6  
development of, 16, 16f-17f  
dysplasia of, congenital, 76
- Acquired immunodeficiency syndrome (AIDS), 503-520. *See also* Immunocompromised patient(s).  
adenovirus infection in, 510  
amebiasis in, 508  
bacillary angiomatosis in, 511-512, 512f  
cat scratch disease in, 511  
CD4 T cells and, 504  
*Chlamydia pneumoniae* infection, TWAR strain in, 511  
coccidioidomycosis in, 509-510  
cytomegaloviral infection in, 510  
definition of, 503  
*Haemophilus influenzae* pneumonia in, 511  
herpesvirus infection in, Color Fig. 45-5, 510  
histoplasmosis in, 508-509  
Kaposi sarcoma in, 514-515, 515f-516f  
lung cancer in, 516-517  
lymphocytic interstitial pneumonia in, 345, 513-514, 514f  
lymphoid lesions in, 640  
malakoplakia in, 512-513, 513f  
*Mycobacterium avium-intracellulare* infection in, 511  
*Mycoplasma fermentans* as cofactor in, Color Fig. 45-6, 504, 504f, 510  
*Mycoplasma pneumoniae* infection in, 510-511  
nocardiosis in, 512  
nontuberculous mycobacterial infections in, 461, 511  
pathogenesis of, 503-504  
*Pneumocystis carinii* pneumonia in, 504-507. *See also* *Pneumocystis carinii* pneumonia.  
pulmonary aspergillosis in, 510  
pulmonary candidiasis in, Color Fig. 45-4, 510, 510f  
pulmonary cryptococcosis in, 508, 509f  
pulmonary cryptosporidiosis, Color Fig. 45-2, 507-508  
pulmonary hypertension in, 517  
pulmonary lymphoma in, 515-516  
Hodgkin, 516  
non-Hodgkin, 515-516  
pulmonary microsporidiosis in, Color Fig. 45-3, 508  
pulmonary strongyloidiasis in, 508, 509f  
rhodococcosis in, 512, 512f  
smooth muscle tumors in, 517, 517f  
streptococcal pneumonia in, 511  
toxoplasmosis in, 507, 508f  
tuberculosis in, 458, 511  
usual and unusual pneumonias in, 511
- Acremonium* pulmonary infection, 485
- Acrylonitrile poisoning, 166
- Actinomycetoma, 447
- Actinomycosis, thoracic, Color Figs. 40-1-40-4, 445-446  
clinical presentation in, 445-446  
pathologic findings in, Color Figs. 40-1-40-4, 446  
species causing, 445  
sulfur granules in, Color Figs. 40-2-40-4, 446
- Adenocarcinoma(s), 531-544  
bronchioloalveolar  
biopsy diagnosis of, complications of, 49-50  
cytologic diagnosis of, 33  
fine needle aspiration in, 34-35, 35f-36f  
in idiopathic interstitial fibrosis, 541, 542f  
bronchogenic. *See also* Carcinoma(s), lung.  
central, 535  
metastatic vs. primary, 535  
cigarette smoking and, future research on, 887  
in nonsmokers, future research on, 887  
peripheral, 531-534  
acinar, 532, 533f  
blastomalike, 534, 535f  
colloid, Color Fig. 47-2, 534, 534f  
endodermal resembling fetal lung, 534, 535f  
immunostains for, 532  
papillary, 532, 533f  
with pleural tropism, 534  
poorly differentiated, Color Fig. 47-1, 532  
scar in, 531, 532f  
signet ring, 534  
with small intestinal differentiation, 534  
unusual histologic subtypes in, Color Fig. 47-2, 534, 534f-535f  
usual histologic subtypes in, Color Fig. 47-1, 532-534, 533f
- Clara cell, mesothelioma vs., 663t
- classification of, 531, 532d
- combined small cell carcinoma and, 559, 562f, 591, 592f
- fine needle aspiration of, 34, 35f
- large cell carcinoma vs., 575, 575f
- mesothelioma vs., 665, 667f

- Adenocarcinoma(s) (*continued*)  
 metastatic, 691–692, 692t  
 mesothelioma vs., 871f, 872  
 mucinous, mesothelioma vs., 663t  
 papillary, of bronchial epithelium,  
 Color Fig. 53-2, 614, 614f
- Adenoid cystic carcinoma  
 of bronchial glands, 599–602,  
 601f–602f  
 clinical findings in, 599  
 diagnosis of, 599  
 histopathologic growth patterns of,  
 601, 602f  
 immunohistochemistry and electron  
 microscopy for, 601–602  
 pathologic findings in, 599, 601,  
 601f  
 treatment and prognosis in, 602  
 of trachea, Color Fig. 73-3, 847, 849f
- Adenoma(s)  
 alveolar (lymphangioma), 541, 541f,  
 683–684, 684f  
 bronchial  
 monomorphic, 598  
 pleomorphic, Color Fig. 52-1, 598,  
 599f–600f  
 mucous gland, 597, 598f–599f  
 low-grade mucoepidermoid car-  
 cinoma vs., 603  
 papillary, 540, 684–685, 685f
- Adenosquamous carcinoma  
 bronchogenic, 532–534, 533f  
 high-grade mucoepidermoid carcinoma  
 of bronchial glands vs., 603,  
 606t
- Adenovirus infection, Color Fig. 42-2,  
 468, 468f  
 in AIDS, 510  
 bronchiolitis obliterans due to,  
 318–319
- Adiaspiromycosis, pulmonary, Color Fig.  
 43-9, 484–485
- Adnexal carcinoma of skin, metastasis  
 from, 704
- Adrenal glands, metastasis to, 697
- $\alpha$ -Adrenergic nasal sprays, pulmonary  
 hypertension due to, 155
- Adult respiratory distress syndrome  
 (ARDS), 125–127  
 causes of, 126, 126d  
 clinical and radiographic features of,  
 126–127, 127f  
 clinicopathologic correlates in, 135  
 diffuse alveolar damage in. *See* Alveolar  
 damage, diffuse (DAD).  
 historical perspective on, 125–126  
 long-standing, healed, 131–132  
 pathogenesis of, 134f, 134–135  
 arachidonic acid metabolites in, 135  
 coagulopathy in, 135  
 mesenchymal cell migration and rep-  
 lication in, 135  
 neutrophil injury in, 134  
 oxygen radicals in, 134  
 sepsis or endotoxin model of, 134,  
 134f  
 pulmonary artery thromboemboli in,  
 132–133  
 pulmonary hemorrhagic infarcts in,  
 133  
 pulmonary hypertension in, 132  
 pulmonary vascular remodeling in,  
 132–134, 133f–134f
- Agammaglobulinemia, bronchiectasis in,  
 304
- Aging lung(s), 276  
 characteristics of, 20–21  
 biochemical, 21  
 functional, 21  
 morphologic, 20–21
- AIDS. *See* Acquired immunodeficiency  
 syndrome (AIDS).
- Air embolism  
 arterial, 190, 193  
 pulmonary, 175–176  
 in scuba divers, 190  
 venous, 191, 193
- Air pollution, 883–884  
 indoor, 887–888
- Air spaces, bronchoalveolar lavage for, 32
- Airway(s)  
 biopsy of, 47–48  
 central, obstruction of, 843  
 fetal development of, 16, 16f  
 growth and development of, mecha-  
 nisms of, 19–20  
 major  
 cell types of, 288, 288f  
 in chronic bronchitis, 287–289,  
 288f–290f  
 diseases of, environmental and occu-  
 pational pollutants and, 884  
 obstruction of  
 in chronic bronchitis, 291–292  
 in emphysema, 292  
 peripheral  
 in chronic bronchitis, 290, 291f  
 cytologic diagnosis for, 32–33  
 small  
 definition of, 317  
 diseases of, 317–322  
 due to cigarette smoking, 400  
 definition of, 317  
 environmental and occupational  
 pollutants and, 884  
 histologic findings in, Color Fig.  
 30-1, 317  
 mineral dust-associated, 321  
 patterns of, 317–321, 318f–322f.  
*See also under* Bronchiolitis.  
 reversible or irreversible, 317  
 upper  
 allergic granulomatosis and angiitis  
 in, 836f–837f, 837  
 disorders of, 829–841, 830d. *See*  
*also individual disorders.*  
 lymphomatoid granulomatosis in,  
 833–837  
 obstructive lesions of, in children,  
 839f, 839–840  
 relapsing polychondritis of, 838f,  
 839  
 Wegener granulomatosis of,  
 829–833
- Airway dysfunction syndrome, reactive,  
 884
- Airway mechanics  
 in normal lungs, 309–311  
 alveolar elastic tension in, 310, 310f  
 benefits of, 310–311  
 cough in, 311  
 during forced exhalation, 309–310  
 large airways in, 311  
 in pathologic lungs, 311
- Alagille syndrome (arteriohepatic dyspla-  
 sia), in children, 90
- Alaria* species, 499  
 pulmonary, 494–495
- Alcian blue, for mesothelioma, 664
- Allergic alveolitis  
 drug-associated, 152, 152f  
 extrinsic. *See* Hypersensitivity pneu-  
 monitis.
- Allergic bronchopulmonary aspergillosis.  
*See* Aspergillosis, allergic bron-  
 chopulmonary.
- Allergic bronchopulmonary fungal dis-  
 ease, 736
- Allergic granulomatosis and angiitis. *See*  
 Churg-Strauss syndrome.
- Alternaria* pulmonary infection, Color  
 Fig. 43-10, 485
- Altitude, high. *See* High altitude; Moun-  
 tain sickness.
- Aluminosis, Color Fig. 37-2, 414–415,  
 415f
- Alveolar adenoma (lymphangioma), 541,  
 541f, 683–684, 684f
- Alveolar capillary(ies)  
 anatomy of, 11  
 dysplasia of, congenital, 89
- Alveolar cell(s), in Fabry disease, inclu-  
 sion bodies in, 105, 107f
- Alveolar damage  
 diffuse (DAD), 125–135. *See also*  
 Adult respiratory distress syn-  
 drome (ARDS).  
 acute bronchopneumonia vs., 135  
 in acute interstitial pneumonia, 326  
 bronchiolitis obliterans organizing  
 pneumonia vs., 135, 136t  
 causes of, 126, 126d  
 in dermatomyositis and polymyositis,  
 785, 787f  
 differential diagnosis of, 135  
 in drug-induced pulmonary disease,  
 150, 150d, 151f  
 exudative phase of, 127–129,  
 128f–129f  
 alveolar epithelial damage in, 128,  
 128f–129f  
 capillary endothelial damage in,  
 128, 129f  
 histologic findings in, 127–128,  
 128f  
 hyaline membranes in, 127–128,  
 128f  
 parenchymal surface in, Color Fig.  
 14-1, 127  
 ultrastructural findings in, 128,  
 128f–129f

- fibrotic phase of, 130–131  
   honeycombing in, 131, 132f  
   large cystic spaces in, 131, 132f  
   pulmonary vascular remodeling in, 133–134, 134f  
 historical perspective on, 125–126  
 iatrogenic, 139–147. *See also* Oxygen toxicity, pulmonary; Radiation pneumonitis.  
 infantile hyaline membrane disease vs., 135  
 in lung transplant rejection, 824  
 due to oxygen toxicity, 139–143.  
   *See also* Oxygen toxicity, pulmonary.  
 pathogenesis of, 134f, 134–135  
   arachidonic acid metabolites in, 135  
   coagulopathy in, 135  
   mesenchymal cell migration and replication in, 135  
   neutrophil injury in, 134  
   oxygen radicals in, 134  
   sepsis or endotoxin model of, 134, 134f  
 pathologic findings in, 127–134  
 proliferative phase of, 129f–131f, 129–130  
   alveolar duct fibrosis in, 129–130, 131f  
   alveolar septal collapse induration in, 130  
   alveolar type I and II cells in, 129, 130f–131f  
   histologic findings in, 129, 130f  
   morphometric findings in, 130  
   pulmonary vascular remodeling in, 133–134, 134f  
   squamous metaplasia in, 129  
   ultrastructural findings in, 129, 131f  
 in pulmonary oxygen toxicity, 142, 143f  
 in smoke inhalation, 185–186  
 usual interstitial pneumonia vs., 135, 136t  
 regional (RAD), in pulmonary oxygen toxicity, 142–143, 143f  
 Alveolar duct(s), anatomy of, 7, 8f–9f  
 Alveolar hemorrhage, diffuse, 723–731  
   antiglomerular basement antibody in, Color Fig. 62-1, 723–724, 724d  
   antineutrophil cytoplasmic antibody in, Color Fig. 62-2, 724–725, 725d  
   classification of, 723  
   drug-induced, 155  
   etiology of, 723–726  
   due to exogenous agents, 729, 729f  
   in immune complex diseases with vasculitis, 728f, 728–729  
   in microscopic polyarteritis, 727–728  
   necrotizing alveolitis in, 725f, 725–726, 726d  
   in systemic lupus erythematosus, 783, 785f  
   with systemic vasculitis, 727–728, 728f  
   due to toxic inhalation, 729, 729f  
   in Wegener granulomatosis, 727, 796  
 Alveolar hemorrhage syndrome(s), 723, 724t, 726–730. *See also individual syndromes (e.g., Goodpasture syndrome).*  
   Wegener granulomatosis vs., 800  
 Alveolar hydatid disease, 496  
 Alveolar hypoxia, right ventricular hypertrophy in, 293  
 Alveolar macrophage(s). *See* Macrophage(s), alveolar.  
 Alveolar microlithiasis, Color Figs. 32-4–32-8, 349–351, 350f–352f  
   blue bodies vs., Color Fig. 32-6, 351  
   calcospherites in, Color Fig. 32-4, 350, 350f  
   chest radiography in, 349–350  
   clinical features of, 349–350  
   corpora amylacea vs., Color Fig. 32-5, 351  
   differential diagnosis of, 351  
   etiology of, 350–351  
   metaplastic ossification vs., 351, 351f–352f  
   metastatic calcification vs., Color Fig. 32-8, 351  
   pathologic findings in, Color Fig. 32-4, 350, 350f  
   Schaumann bodies vs., Color Fig. 32-7, 351  
 Alveolar proteinosis, 361–364  
   advanced, interstitial fibrosis in, 362, 363f  
   in children with gastroesophageal reflux, 365, 365t  
   clinical presentation in, 361  
   conditions associated with, 362–363, 364d  
   gross pathologic findings in, 361, 362f  
   histopathologic findings in, 361–362, 363f  
   lysine protein intolerance and, 366–367  
   multilamellated structure in, 362, 364f  
   pathogenesis of, 363–364  
   in silicosis, Color Fig. 35-3, 388–389  
 Alveolar septa  
   amyloidosis of, diffuse, 351–352, 352f–353f  
   calcinosis of, congenital, Color Fig. 9-2, 87  
   collapse induration of, in diffuse alveolar damage, 130  
 Alveolar type I cell(s)  
   in diffuse alveolar damage  
     exudative phase, 128, 129f  
     proliferative phase, 129, 130f–131f  
   in injury response, 23  
   primary function of, 8–9  
   ultrastructure of, 8  
 Alveolar type II cell(s)  
   cell markers for, 9  
   in cytologic diagnosis, 30  
   in diffuse alveolar damage  
     exudative phase, 128  
     proliferative phase, 129, 130f–131f  
   in injury response, 23  
   lamellar inclusions of, 9, 10f  
   synthesis and secretion by, 9  
   ultrastructure of, 9, 10f  
 Alveolar type III cell(s), 23  
 Alveolar wall  
   thick portion of, 8, 10f  
   thin portion of, 8, 10f  
 Alveolitis  
   allergic, drug-associated, 152, 152f  
   extrinsic allergic. *See* Hypersensitivity pneumonitis.  
   necrotizing, 725f, 725–726, 726d  
     in microscopic polyarteritis, 728, 728f  
     in Wegener granulomatosis, 728, 728f  
   in sarcoidosis, 772f, 772–773  
 Alveolus(i)  
   anatomy of, 7, 8f–9f  
   cells of, 8  
   compensatory overgrowth of, 19  
   consolidation of, 22  
   development of, 17, 17f  
   differentiation of, mechanisms of, 20  
   endothelial cells of, 9–10  
   epithelium of, restoration of, 22–23  
   fibrosis in, 22, 22f  
   injury response in, 22, 22f  
   interstitial cells of, 10  
   in Niemann-Pick disease, foamy cells in, 109, 109f–110f  
   radial count for, 17  
 Alveolus-to-artery ratio, postnatal, 19  
 Ameba, free-living  
   in AIDS, 508  
   pulmonary manifestations of, 492  
 Amebiasis  
   in AIDS, 508  
   pulmonary, Color Fig. 44-1, 490, 491f  
 Amine precursor uptake and decarboxylation (APUD) system, 555  
 Amino acid metabolic disorder(s), 112  
 Aminorex, pulmonary hypertension due to, 155  
 Amiodarone, pulmonary toxicity due to, 150  
 Ammonia, as irritant gas, 167  
 Amniotic bands, of thoracic wall, 91  
 Amniotic fluid embolus(i), pulmonary, 176, 176f  
 Amyloidoma, 718  
 Amyloidosis  
   alveolar-septal, diffuse, 351–352, 352f–353f  
   nodular parenchymal, Color Fig. 32-9, 352, 353f  
   pulmonary, Color Fig. 32-9, 351–352, 352f–353f  
   pulmonary hypertension in, 212f, 213  
   tracheobronchial, 352, 850–851  
 Anatomic dead space, 6–7

- Ancylostoma braziliense*, eosinophilic pneumonia due to, 750, 751t
- Ancylostoma duodenale*, eosinophilic pneumonia due to, 750, 751t
- Aneurysm, pulmonary artery, thrombosis in, Color Fig. 18-2, 172, 173f
- Angiitis, giant cell, disseminated and isolated, 815f, 816
- Angiitis and granulomatosis. *See* Pulmonary angiitis and granulomatosis and individual syndromes (e.g., Wegener granulomatosis).
- allergic. *See* Churg-Strauss syndrome.
- Angiofollicular hyperplasia (Castleman disease), 637
- mediastinal, 859
- Angioimmunoblastic lymphadenopathy, 637
- Angiomatosis, bacillary, in AIDS, 511-512, 512f
- Angiosarcoma, pulmonary, Color Fig. 56-5, 649, 650f
- hemangioma vs., 649
- Kaposi sarcoma vs., Color Fig. 56-5, 649, 650f
- Angiostrongylus cantonensis*, 500, 500f
- Angiotensin-converting enzyme, serum, for diagnosis of sarcoidosis, 775
- Animal handlers, occupational asthma in, 162-163
- Animal protein(s), hypersensitivity pneumonitis due to, 756t
- f-Anisoplenia, 71
- M-Anisoplenia, 71
- O-Anisoplenia, 71
- Ankylosing spondylitis (Marie-Strümpell disease), 788, 876
- Anthrax, pulmonary, 439-440, 440f
- Antiglomerular basement antibody conditions associated with, 724, 724d
- in Goodpasture syndrome, Color Fig. 62-1, 723-724, 724d
- Antimony lung disease, 417
- Antineutrophil cytoplasmic antibody(ies), Color Fig. 62-2, 725, 725d
- in systemic vasculitis, 725, 725d
- in Wegener granulomatosis, 797-798
- Antioxidant enzyme systems, 140, 140f
- $\alpha_1$ -Antitrypsin deficiency, emphysema in, 87, 282-283, 291
- Aorta
- collateral arteries of, 265, 265f
- traumatic injury of, 184
- Aortopulmonary arterial shunt, surgical, pulmonary hypertension after, 269, 270f
- Aortopulmonary collateral artery(ies), 264-265, 265f
- Apical cap(s), 718
- APUD (amine precursor uptake and decarboxylation) system, 555
- Arachidonic acid metabolite(s), in pathogenesis of adult respiratory distress syndrome, 135
- Arc welder's lung, Color Fig. 37-3, 416
- ARDS. *See* Adult respiratory distress syndrome (ARDS); Alveolar damage, diffuse (DAD).
- Arnold Rich lesion(s), in low-flow states, 266, 267f-268f
- Arteriohepatic dysplasia (Alagille syndrome), in children, 90
- Arteriopathy, plexogenic, in pulmonary hypertension of congenital heart disease, 217, 218d
- Arteriovenous fistula, pulmonary
- in children, 89, 90f
- traumatic, 182
- Arteritis, Takayasu, 813, 815, 815f
- Arthritis, rheumatoid. *See* Rheumatoid arthritis.
- ARTICLE association, 65
- ARTICLE-V association, 65
- Asbestos
- amosite, 395, 396d, 396f
- amphibole, 395, 396d, 658f, 661
- chrysotile, 395, 396d, 396f-397f, 661
- lung carcinoma due to, 403
- characteristics of, 658, 659t
- cigarette smoking and, 403, 658
- future research on, 886
- gross location of, 403
- histologic subtypes of, 403
- in nonsmokers, 403
- tissue mineral fiber content analysis in, 406t, 407
- occupational and environmental exposure to, 395-396
- other neoplasias due to, 403
- serpentine, 395, 396d, 661
- varieties of, 395, 396d, 396f-397f, 661
- Asbestos airways disease, 398
- Asbestos body(ies), Color Fig. 36-1, 396-397, 398f
- bronchoalveolar lavage for, 404
- extrapulmonary sites of, 397
- fine needle aspiration for, 404
- in foreign body giant cells, 398, 400f
- future research on, 886
- pathogenesis of, 396-397
- sputum cytology for, 404, 404f
- Asbestosis, 395-410
- asbestos bodies in, 398
- in foreign body giant cells, 398, 400f
- future research on, 886
- clinical manifestations of, 397
- definition of, 885-886
- future research on, 885-887
- histologic features of, 398-400
- histologic severity score for, 399, 400d
- historical, 883
- honeycombing in, 398, 399f
- interstitial fibrosis in, 398, 399f
- mesothelioma in, 400-401, 657-658, 658f, 659t, 660-661. *See also* under Mesothelioma.
- pathologic findings in, Color Fig. 36-2, 398-400, 399f, 400d
- pulmonary fibrosis vs., 400
- pulmonary function testing in, 397-398
- radiography in, 397
- silicosis vs., 400
- small airway disease due to cigarette smoking vs., 400
- tissue mineral fiber content analysis in, 405, 406t
- transbronchial biopsy for, 49, 50f
- usual interstitial pneumonia in, 330, 330f
- lung carcinoma and, 337
- Asbestos-related disease(s)
- analysis of tissue mineral fiber content in, 404-408
- controlled studies on, 405-407, 406t, 407f-408f
- dissolution of organic matrix for, 404
- electron microscopy for, 404, 405f-406f
- light microscopy for, 404
- recovery of fibers for, 404
- site-to-site variation in, 405
- cytopathology in, 404, 404f
- pleural. *See also* Mesothelioma.
- benign, 401-403, 402f
- diffuse fibrosis as, 401, 402f
- parietal plaque as, 401, 402f
- rounded atelectasis as, 401-402, 402f
- Ascariasis, pulmonary, 498, 499f
- Ascaris lumbricoides*, 498, 499f
- Ascaris* species, eosinophilic pneumonia due to, 750, 751t
- Ascaris suum*, 498
- Aspergilloma(s), 483
- in sarcoidosis, 774, 774f
- Aspergillosis
- allergic bronchopulmonary, 483, 733-736
- bronchocentric granulomatosis in, 739
- chest radiography in, 734, 734f
- clinical features of, 733-735, 734d, 734f, 735t
- clinical stages of, 734-735
- definition and prevalence of, 733
- diagnostic criteria for, 734, 734d
- eosinophilic pneumonia in, 751
- laboratory studies in, 734, 734d
- mucoïd impaction in, 735, 736f
- necrotizing granulomas in, 735
- pathogenesis of, 735
- pathologic features of, 735, 735f-737f
- treatment of, 735
- invasive, 483, 483f
- pulmonary, Color Figs. 43-5-43-6, 482-483, 483f-484f
- in AIDS, 510

- Aspergillus flavus*, 483  
*Aspergillus fumigatus*, 483  
 diseases related to, 733  
*Aspergillus* infection, cytologic diagnosis of, 33  
 Asphyxia, in burn inhalational injury, 184–185  
 Asphyxiant gas(es), occupational asthma due to, 166d, 166–167  
 Aspiration, 186–188  
 of acidic gastric contents, 186–187  
 active, 186  
 fine needle. *See* Fine needle aspiration (FNA).  
 of foreign bodies, 187–188  
 of inert fluids, 186  
 of lipid material, 718  
 of oropharyngeal bacterial pathogens, 186  
 of particulate material, 186, 186f  
 silent, 186  
 Aspiration pneumonia, anaerobic, 433, 434f  
 Asteroid body(ies), in sarcoidosis, 771, 771f  
 Asthma, 309–316  
 atopic (extrinsic), Color Fig. 29-1, 311–312, 312f–314f  
 classification of, 309  
 definition of, 309  
 intrinsic, 312–313  
 nonatopic, 312–315  
 occupational, Color Fig. 29-2, 159–163, 315, 315f, 884. *See also individual fumes or gases*; Pneumoconiosis.  
 in animal handlers, 162–163  
 due to asphyxiant gases, 166d, 166–167  
 due to *Bacillus subtilis*, 163  
 baker's asthma as, 163  
 due to biologic enzymes, 163  
 bronchial basement membrane in, Color Fig. 17-2, 161  
 bronchial gland hypertrophy in, Color Fig. 17-6, 161  
 bronchoconstriction in, 161–163  
 immunologic, 162–163  
 inflammatory, 161  
 pharmacologic, 161–162  
 reflex, 161  
 byssinosis as, 162  
 Charcot-Leyden crystals in, Color Fig. 3-2, 161  
 Creola bodies in, 30f, 161  
 Curschmann spirals in, Color Fig. 3-1, 161  
 definition of, 160  
 eosinophilic infiltrate in, Color Figs. 17-3–17-5, 161  
 due to grain dust, 163  
 historical, 159–160, 883  
 hyperresponsiveness of bronchial muscle in, Color Fig. 17-2, 160, 161f  
 irritant and toxic fumes in, 164d, 164–166  
 due to irritant gases, 167d, 167–168  
 due to metal salts, 163  
 mucus plugging in, Color Fig. 17-2, Color Fig. 17-5, 161, 162f  
 due to organophosphate insecticides, 162  
 pathologic findings in, Color Figs. 17-1–17-6, 160f–162f, 160–161  
 pathophysiology of, 161–163  
 prevalence of, 160  
 due to soldering flux, 163  
 pathologic findings in, 311–315  
 sputum in, 30–31  
 viral-induced, 313, 314f, 315  
 Atelectasis  
 acute, pulmonary edema in, 119  
 rounded, 716–717, 870  
 asbestos-related, 401–402, 402f  
 tissue mineral fiber content analysis in, 407  
 clinical features and diagnosis of, 716–717, 717f  
 definition of, 716, 716f  
 pathogenesis of, 717  
 pathologic findings in, 717, 717f  
 synonyms and history of, 716  
 treatment and prognosis in, 717  
 transbronchial biopsy in, 46–47  
 Atherosclerosis, pulmonary artery, in primary pulmonary hypertension, 237, 237f  
 Atria, anatomy of, 7, 9f  
 Autonomic nervous system, of lungs, 12  
 Aviator(s), decompression sickness in, 190  
 Azygos vein anomalies, in children, 90  
 Azzopardi phenomenon (nuclear encrustation), in small cell carcinoma, 557, 560f
- B**  
 Bacillary angiomatosis, in AIDS, 511–512, 512f  
*Bacillus subtilis*, occupational asthma due to, 163  
 Bacterial antigen(s), hypersensitivity pneumonitis due to, 756t  
 Bacterial infection(s). *See also under individual species*; Pneumonia.  
 in AIDS, 511–513  
 cytologic diagnosis of, 33  
 Bacterial pathogen(s), oropharyngeal, aspiration of, 186  
*Bacteroides* pneumonia, Color Fig. 39-1, 433–434  
*Bacteroides* sp., 434f  
 Baker's asthma, 163  
 BAL. *See* Bronchoalveolar lavage (BAL).  
 BALT (bronchus-associated lymphoid tissue), 12, 631, 632f  
 Baritosis, 416–417  
 Barnes syndrome (thoracolyngopelvic dysplasia), 75–76  
 Basal cell(s), bronchial mucosal  
 in cytologic diagnosis, 29  
 hyperplasia of, cytologic diagnosis of, 32  
 Basaloid squamous cell carcinoma (small cell), 549, 551f, 552  
 Bauxite lung (Shaver disease), 415  
*Baylisascaris procyonis*, 499  
*Beauveria bassiana* infection, 485  
 Behçet disease, 813  
 Berylliosis, 411–412, 412f–413f  
 acute vs. chronic, 411  
 chronic, sarcoidosis vs., 776  
 diagnostic criteria for, 411–412  
 historical, 411  
 pathologic findings in, 412, 412f–413f  
 Biopsy, 41–52  
 for airway diseases, 47–48  
 clinical history and, 41  
 for granulomatous conditions, 48, 49f  
 imaging studies and, 41  
 interpretation of, 46–50  
 pitfalls in, 46  
 lung  
 for congenital heart disease, 222–223  
 for *Pneumocystis carinii* pneumonia, 504, 505f  
 nasal septum, for primary ciliary dyskinesia, 101  
 open lung. *See* Open lung biopsy.  
 pleural, 43, 45  
 for tuberculosis, 457  
 for pneumoconiosis, 49, 50f  
 for pulmonary nodules, 47  
 sample processing for, 45d, 45–46  
 analytic methods for inorganic materials in, 46  
 fixation and initial tissue handling in, 45, 45f  
 immunopathologic techniques for, 46  
 polarization microscopy for, 46  
 serial sections for, 45  
 stains for, 45–46  
 ultrastructural techniques for, 46  
 for sarcoidosis, 774–775  
 for small cell carcinoma, 50  
 techniques for, 41–45, 42d. *See also under individual techniques*.  
 fiberoptic bronchoscopy as, 41  
 mediastinoscopy as, 42  
 open lung biopsy for, 42–43, 43f–44f  
 percutaneous transthoracic needle biopsy as, 41–42, 43f  
 rigid bronchoscopy as, 42  
 of tracheobronchial epithelium, for primary ciliary dyskinesia, 101  
 transbronchial. *See* Transbronchial biopsy.  
 for vasculitis, 48–49  
 Birbek granule(s), in pulmonary eosinophilic granuloma, 346, 348f

- Blastoma(s)  
 pleuropulmonary, 877, 878f–879f  
 chest x-ray features of, 619t  
 clinical findings in, 618, 618t  
 pulmonary, 617–624  
 biphasic  
 chest x-ray features of, 619t  
 clinical findings in, 617–619, 618t  
 pathologic findings in, 620, 620f–621f  
 of childhood, 621–624  
 cystic lesions in, 621–623, 622f  
 solid lesions in, 623f, 623–624  
 clinical features of, 617–619, 618f, 618t–619t  
 definition of, 617  
 histogenesis of, 620–621  
 historical, 617  
 immunohistochemical findings in, 620  
 metastasis of, 692  
 pathologic findings in, 619f–621f, 619–621  
 epithelial component of, 619f–620f, 619–620  
 prognosis in, 618–619  
 well-differentiated fetal adenocarcinoma  
 chest x-ray features of, 618, 619t  
 clinical findings in, 617–619, 618t  
 pathologic findings in, 620  
*Blastomyces dermatitidis*, 479  
 Blastomycosis, pulmonary, 479–480, 480f  
*Blastoschizomyces capitatus* pulmonary infection, 485  
 Bleb(s), in interstitial emphysema, 279  
 Bleomycin, pulmonary toxicity due to, Color Fig. 16-1  
 Blood, in cytologic diagnosis, 30  
 Blue bloaters, 281–282  
 Blue body(ies)  
 alveolar microlithiasis vs., Color Fig. 32-6, 351  
 in cytologic diagnosis, 32  
 BO. *See* Bronchiolitis obliterans (BO).  
 Bochdalek hernia, 90  
 Bombesin, in small cell carcinoma, 563  
 Bone  
 benign giant cell tumor of, metastasis from, 708, 708f  
 metastasis from, 704, 705f  
 metastasis to, 694, 696f  
 Bone marrow, metastasis to, 694, 696f  
 Bone marrow embolus(i), pulmonary hypertension due to, 231–233  
 BOOP. *See* Bronchiolitis obliterans organizing pneumonia (BOOP).  
*Bordetella pertussis* pneumonia (whooping cough), 430  
 Botryomycosis, Color Figs. 40-8–40-9, 448–449, 449f  
 bacterial species causing, 448  
 pulmonary  
 diagnosis of, 448–449  
 granules in, Color Fig. 40-8, 448  
 primary, Color Figs. 40-8–40-9, 448, 449f  
 Bouton of Masson, 22  
 Bowel, small, metastasis to, 697  
 Brain, metastasis to, 693–694, 695f  
 Brain embolus(i), pulmonary hypertension due to, 233  
*Branhamella catarrhalis* infection, in smoke inhalation, 185  
 Brass fever (metal fume fever, brass fever, Monday morning fever), 164, 165f  
 Breast, metastasis to, 698  
 Breast carcinoma  
 mesothelioma vs., 663t  
 metastasis from, 703–704, 704f  
 Bronchial adenoma  
 monomorphic, 598  
 pleomorphic, Color Fig. 52-1, 598, 599f–600f  
 Bronchial artery(ies)  
 anatomy of, 11–12, 18f  
 collaterals of, 264, 265f  
 growth and development of, 18–19  
 in pulmonary venous hypertension, 209  
 Bronchial artery collateral(s), in thromboembolic pulmonary hypertension, 229  
 Bronchial asthma. *See* Asthma.  
 Bronchial atresia, 73  
 in mucocele, 301, 302f–303f  
 with mucus plug, 79  
 Bronchial brushings  
 collection, slide prep, and staining for, 27, 28t  
 other cytology specimens vs., 27, 28t  
 Bronchial circulation, 11–12. *See also individual vessels.*  
 in bronchiectasis, 307, 307f  
 Bronchial disease(s), environmental and occupational pollutants and, 884  
 Bronchial epithelium  
 mucoepidermoid carcinoma of, 614  
 papillary adenocarcinoma of, Color Fig. 53-2, 614, 614f  
 Bronchial gland(s)  
 acinic cell tumor of, Color Fig. 52-3, 605  
 adenoid cystic carcinoma of, 599–602, 601f–602f  
 clinical findings in, 599  
 diagnosis of, 599  
 histopathologic growth patterns of, 601, 602f  
 immunohistochemistry and electron microscopy for, 601–602  
 pathologic findings in, 599, 601, 601f  
 treatment and prognosis in, 602  
 cellular structure of, 4–5  
 gland-to-wall ratio for, 288f–289f, 288–289  
 hypertrophy of, in chronic bronchitis, 288, 288f  
 malignant mixed tumors of, 606  
 mucoepidermoid carcinoma of, 603–605  
 differential diagnosis of, 603, 606t  
 high-grade, 603, 605f  
 adenosquamous carcinoma vs., 603, 606t  
 poorly differentiated squamous cell carcinoma vs., 603  
 low-grade, Color Fig. 52-2, 603, 603f–605f  
 mucous gland adenoma vs., 603  
 prognosis in, 605  
 in synthesis of secretory IgA, 5  
 tumors of  
 benign, Color Fig. 51-2, 597–599, 598f–600f  
 malignant, 599–606, 601f–605f  
 Bronchial isomerism syndrome(s), 71–72  
 Bronchial mucosa  
 in cytologic diagnosis, 32, 32f  
 squamous metaplasia of  
 atypical, 32  
 cytologic diagnosis of, 32, 32f  
 Bronchial myoepithelioma, 598–599, 600f  
 Bronchial oncocytoma, 597–598  
 Bronchial stenosis, congenital, with unilateral pulmonary agenesis, 66  
 Bronchial string(s), congenital, 73  
 Bronchial vein(s)  
 anatomy of, 18, 18f  
 in pulmonary venous hypertension, 209  
 Bronchial washings  
 collection, slide prep, and staining for, 27, 28t  
 other cytology specimens vs., 27, 28t  
 Bronchial web(s), congenital, 73  
 Bronchiectasis, 295–308  
 absence of peripheral filling in, 295, 296f  
 in agammaglobulinemia, 304  
 bronchial circulation in, 307, 307f  
 in children, 97–98  
 classification of, 295–299  
 clinical symptoms in, 295  
 collapse in, 301, 301f  
 collateral ventilation in, 299–300  
 cylindrical, 297, 297f  
 in cystic fibrosis, Color Fig. 11-3, 98, 304, 304f, 307, 307f  
 definition of, 295  
 distention in, 301, 302f–303f  
 distribution of, 299  
 dry, 295  
 in Ehlers-Danlos syndrome, 98  
 endobronchial abscess in, 300, 300f, 303  
 endobronchial embolus in, 300–301  
 fungus ball in, 303, 303f  
 generalized, 299  
 in immotile cilia syndrome, 304, 305f  
 infection and inflammation and ulceration in, 300f, 300–301  
 inflammatory cell infiltrate in, 303

- localized (surgical), 299  
 in Macleod syndrome, 305, 306f, 307  
 in Maoris, 98  
 in Marfan syndrome, 98  
 in Mounier-Kuhn disease, 304  
 mucous gland hypertrophy in, 301, 303  
 patent airways in, 301, 303, 303f  
 pathogenesis of, 299f, 299–300, 300d  
 pathologic findings in, 300–303  
 pathophysiology of, 307f, 307–308  
 in pneumonia, 303  
 pulmonary circulation in, 307–308  
 reversible or irreversible, 299, 299f  
 saccular, 297, 297f, 301  
 in sarcoidosis, 774, 774f  
 shape of dilated bronchi in, 297, 297f–299f  
 varicose, 297, 298f  
 wet, 295  
 in Williams-Campbell syndrome, 97, 295, 304–305  
 in yellow nail syndrome, 97–98
- Bronchiectatic cyst(s)**, in cystic fibrosis, 98
- Bronchiole(s)**  
 anatomy of, 7f–8f, 7–8  
 epithelium of  
 cells of, 7–8  
 cell types of, 32  
 in cytologic diagnosis, 33  
 fetal development of, 16, 16f  
 membranous  
 anatomy of, gross, 1  
 geodesic muscle arrangement of, 160, 161f  
 respiratory, anatomy of, 7, 7f–8f  
 gross, 1  
 sarcoidosis, 772f, 773  
 terminal, anatomy of, 7, 7f  
 gross, 1
- Bronchiolitis**  
 adenoviral, 468, 468f  
 chronic, in coal worker's pneumoconiosis, 378–379  
 constrictive, bronchiolitis obliterans organizing pneumonia vs., 358–359, 359f–360f  
 follicular, in chronic bronchitis, Color Fig. 30-2, 290, 319–320, 320f, 636, 636f  
 lymphocytic, in acute lung transplant rejection, 821  
*Mycoplasma pneumoniae*, 471, 471f  
 respiratory, 320, 321f  
 respiratory syncytial viral, 469, 470f  
 in rheumatoid arthritis, 290
- Bronchiolitis obliterans (BO)**, 317–319  
 causes of, 317, 318d  
 in chronic lung transplant rejection, 823, 823f  
 cicatricial phase of, 318, 319f  
 clinical course in, 319  
 in connective tissue disease, 319  
 constrictive, 318  
 end-stage, Color Fig. 30-1, 318
- in hypersensitivity pneumonitis, 761, 763f  
 of immune suppression, 22  
 in organ transplantation, 319  
 pathogenesis of, 317–318, 318f–319f  
 due to penicillamine, 319  
 proliferative phase of, 318, 319f  
 in systemic lupus erythematosus, 783, 784f  
 due to viral infection, 318–319
- Bronchiolitis obliterans organizing pneumonia (BOOP)**, 23, 357–360  
 chronic eosinophilic pneumonia vs., 359, 360t, 750  
 clinical features of, 357  
 constrictive bronchiolitis vs., 358–359, 359f–360f  
 in dermatomyositis and polymyositis, 785, 787f  
 differential diagnosis of, 358  
 diffuse alveolar damage vs., 135, 136t  
 drug-associated, 153, 153d, 154f  
 hypersensitivity pneumonitis vs., 359, 360t  
 in lung transplant rejection, 824  
 open lung biopsy for, 42, 44f  
 pathologic findings in, 357–358, 358f–359f  
 in rheumatoid arthritis, 782, 782f  
 in systemic sclerosis, 784, 786f  
 transbronchial biopsy for, 42, 44f  
 usual interstitial pneumonia vs., 359, 360t
- Bronchioloalveolar adenocarcinoma(s)**  
 biopsy diagnosis of, complications of, 49–50  
 cytologic diagnosis of, 33  
 fine needle aspiration in, 34–35, 35f–36f  
 in idiopathic interstitial fibrosis, 541, 542f
- Bronchioloalveolar carcinoma**, 535–540.  
*See also* Carcinoma(s), bronchioloalveolar.
- Bronchiolus(i)**. *See* Bronchiole(s).
- Bronchitis**  
 chronic, 287–294  
 airways obstruction in, 291–292  
 bronchial gland hypertrophy in, 288, 288f  
 bronchial gland-to-wall ratio in, 288f–289f, 288–289  
 in coal worker's pneumoconiosis, 378–379  
 in coke oven workers, 382  
 collateral ventilation in, 290, 291f  
 cor pulmonale and, 292–293, 293f  
 definition of, 287  
 emphysema and, 291  
 endobronchial abscess in, 290, 291f  
 experimental models of, 288d  
 follicular bronchiolitis and, Color Fig. 30-2, 290, 319–320, 320f, 636, 636f  
 goblet cell hyperplasia in, 288–289, 289f, 290
- lesions of major airways in, 287–289, 288f–290f  
 lesions of peripheral airways in, 290, 291f  
 mucus hypersecretion in, 287, 288d  
 pathologic features of, 287–290  
 pathophysiology of, 291–293  
 pulmonary hypertension in, 209  
 purulent, 287  
 right ventricular hypertrophy in, 292–293, 293f  
 simple, 287  
 lymphocytic, in acute lung transplant rejection, 821  
 occupational, 293  
 osmium, 164–165
- Bronchoalveolar lavage (BAL)**  
 for air spaces, 32  
 for asbestos bodies, 404  
 for hypersensitivity pneumonitis, 764  
 other cytology specimens vs., 27, 28t  
 for sarcoidosis, 775
- Bronchobiliary fistula, congenital**, 72
- Bronchocentric granulomatosis**, 738–741  
 clinical features of, 739  
 pathogenesis and differential diagnosis of, 740–741  
 pathologic features of, 739–740, 740f–741f
- Bronchocentric Wegener granulomatosis**, Color Fig. 68-4, 796, 799f
- Bronchoconstriction**  
 immunologic, 162–163  
 inflammatory, 161  
 pharmacologic, 161–162  
 reflex, 161
- Bronchogenic adenocarcinoma(s)**. *See* Adenocarcinoma(s), bronchogenic.
- Bronchogenic carcinoma, adenosquamous**, 532–534, 533f
- Bronchogenic cyst(s), congenital**, 80, 82f
- Broncholith(s)**, 188
- Bronchomalacia, localized**, 67
- Bronchopleural fistula, in tuberculosis**, 458
- Bronchopneumonia**  
 acute, diffuse alveolar damage vs., 135  
 necrotizing, in herpes simplex virus infection, 467, 467f
- Bronchopulmonary anastomosis**, 12
- Bronchopulmonary aspergillosis, allergic**. *See* Aspergillosis, allergic bronchopulmonary.
- Bronchopulmonary dysplasia**, 95–97. *See also* Oxygen toxicity, pulmonary.  
 acute, 95, 96f–97f  
 dysplastic epithelium in, 95, 96f  
 hyperplastic alveolar type II cells in, 95, 97f  
 squamous metaplasia in, 95, 96f  
 congenital, respiratory air space enlargement in, 276  
 long-standing, healed, 95–96, 98f  
 alveolar morphology in, 141–142, 142f

- Bronchopulmonary dysplasia (*continued*)  
 pathogenesis of, 96  
 barotrauma in, 96  
 oxygen toxicity in, 96  
 pathologic findings in, 141–142, 142f  
 reparative, 95, 97f–98f  
 cobblestoning in, 95, 97f  
 interstitial fibrosis in, 95, 98f  
 maturing squamous metaplasia in, 95, 97f
- Bronchopulmonary-foregut malformation(s)  
 communicating, 73, 73t  
 possible mechanisms of, 81, 83f
- Bronchopulmonary fungal disease, allergic, 736
- Bronchopulmonary segment(s), Color Fig. 1-1, 6
- Bronchoscopy  
 fiberoptic, 41  
 accuracy of, 41  
 complications of, 41  
 rigid, 42
- Bronchus(i)  
 anatomy of, gross, 1  
 basal cells of, 4  
 bridging, in sling left pulmonary artery, 72  
 congenital malformation of, 71–73  
 fetal development of, 16, 16f  
 histology of, 4  
 main, pathology of, 843–852, 844d  
 metastatic lesions of, 849, 850f  
 mucoid impaction of, 736–738  
 chest radiography in, 734f, 737  
 clinical features of, 737  
 diseases associated with, 737  
 pathogenesis of, 738  
 pathologic features of, 737–738, 738f  
 treatment of, 737  
 prearterial, congenital, 72  
 right upper lobe, high origin of, 72, 72f  
 sarcoidosis of, 773  
 tracheal, congenital, 72  
 traumatic injury to, 182–183
- Bronchus-associated lymphoid tissue (BALT), 12, 631, 632f
- Brucellosis, 438–439  
 pathologic diagnosis of, 439  
 transmission and clinical features of, 438–439
- Brugia malayi*  
 eosinophilic pneumonia due to, 750, 751t  
 pulmonary, 497
- Brush cell(s), ultrastructure of, 4
- Bulla(ae), in emphysema, 278–279, 280f–281f
- Bullet(s), in chest trauma, 182  
 migratory, 182, 183f
- Burns  
 inhalational injury in, 184–186  
 asphyxia in, 184–185  
 cyanide poisoning in, 185  
 incidence of mortality in, 184  
 smoke inhalation in, 185–186  
 thermal injury in, 184  
 respiratory tract, 184
- Byssinosis, 162  
 immunologic mechanisms of, 162  
 nonimmunologic mechanisms of, 162  
 pathologic findings in, Color Fig. 29–2, 162, 315
- Byssinosis body(ies), 162
- C**
- Cadmium lung, 166
- Caisson disease (dysbaric osteonecrosis), 190
- Calcification, metastatic, alveolar microlithiasis vs., Color Fig. 32-8, 351
- Calcinosis, of alveola septa and stroma, Color Fig. 9-2, 87
- Calcium oxalate crystal(s), in cytologic diagnosis, 32
- Calcospherite(s)  
 in alveolar microlithiasis, Color Fig. 32-4, 350, 350f  
 in cytologic diagnosis, 31, 31f  
 in pulmonary venous hypertension, 206, 207f
- Canals of Lambert, 12, 300
- Cancer. *See* Carcinoma(s); Tumor(s).
- Candida albicans*, 483
- Candida tropicalis*, 483
- Candidiasis  
 cytologic diagnosis of, 33  
 pulmonary, 483–484  
 in AIDS, Color Fig. 45-4, 510, 510f
- Capillaria aerophila*, 499
- Capillaritis, pulmonary, in systemic lupus erythematosus, 783, 785f
- Capillary hemangiomatosis, in pulmonary venoocclusive disease, 243, 245, 245f
- Caplan syndrome (rheumatoid pneumoconiosis), 377–378, 378f, 392, 718, 781
- Carbon black workers, pneumoconiosis in, 381
- Carbon dioxide  
 as asphyxiant gas, 166  
 in burn inhalational injury, 184–185
- Carbon monoxide asphyxiation, 166–167
- Carcinoid tumor(s), 581–586  
 atypical  
 classification of, 581  
 large cell carcinoma vs., 576  
 metastasis of, 692  
 pathologic features of, 582, 585f  
 prognosis in, 582  
 typical vs., 582–583, 586, 586t  
 carcinoid tumorlets vs., 586  
 classification of, 581, 582d  
 clinical features of, 581–582  
 differential diagnosis of, 582–583, 586, 586t
- electron microscopy for, 586  
 flow cytometry for, 586  
 histochemistry for, 586, 587f  
 immunohistochemistry for, 586  
 large cell carcinoma vs., 576–577  
 malignant melanoma vs., 586  
 metastasis of, 692  
 paraganglioma vs., 583, 598  
 paraganglioma vs., 679  
 pathologic features of, 582, 582f–584f  
 prognosis in, 582  
 thymic, 857  
 of trachea, Color Fig. 73-4, 847, 849f
- Carcinoma(s). *See also under* Tumor(s).  
 adenocarcinoma. *See* Adenocarcinoma(s).  
 adenoid cystic  
 of bronchial glands, 599–602, 601f–602f  
 of trachea, Color Fig. 73-3, 847, 849f  
 adenosquamous  
 bronchogenic, 532–534, 533f  
 high-grade mucoepidermoid carcinoma of bronchial glands vs., 603, 606t  
 breast, mesothelioma vs., 663t  
 bronchioloalveolar, 535–540  
 histologic subtypes of, 535–539  
 intracytoplasmic bodies in, 539  
 Langerhans cells in, 539  
 lepidic, 535f–536f, 535–536  
 Clara cell, 536  
 mucin-producing, 535, 535f–536f  
 multifocal, 536  
 nonmucinous, 536  
 sclerosing, 536  
 ulcerocentric, 536  
 metastasis of, 692  
 multifocality of, 539  
 myoepithelial cells in, 539  
 papillary, Color Figs. 47-3–47-4, 536, 537f–538f  
 papillary nodules resembling, 541  
 prognosis in, 539–540  
 solid, 536–539, 538f  
 embryonal, of mediastinum, Color Fig. 74-5, 857  
 large cell. *See* Large cell carcinoma.  
 lung. *See also* Adenocarcinoma(s), bronchogenic.  
 in AIDS, 516–517  
 due to asbestos exposure, 403  
 characteristics of, 658, 659t  
 cigarette smoking and, 403, 658  
 future research on, 886  
 gross location of, 403  
 histologic subtypes of, 403  
 in nonsmokers, 403  
 tissue mineral fiber content analysis in, 406t, 407  
 in coal worker's, 381  
 focal scarring and, 336  
 mesothelioma vs., 663t  
 metastatic, 691–699. *See also* Metastatic lung cancer.



- pleural involvement in, 872  
 pulmonary vascular embolus due to, 232f  
 silicosis and, 389  
 usual interstitial pneumonia and, 336–337
- lymphoepithelial, 553, 553f  
 metastatic, fine needle aspiration of, 36, 37f
- mucoepidermoid  
 of bronchial epithelium, 614  
 of bronchial glands, 603f–605f, 603–605  
 of trachea, 847, 848f
- neuroendocrine, large cell, 586–589, 588f, 589t. *See also* Large cell carcinoma, neuroendocrine.
- prostatic  
 metastasis from, 703, 704f  
 pulmonary vascular embolus due to, 232f
- renal cell. *See* Renal cell carcinoma.
- scar, 531, 532f
- small cell. *See* Small cell carcinoma.
- squamous cell. *See* Squamous cell carcinoma.
- thymic, 857
- Carcinoma in situ, lung, staging of, 524–525
- Carcinomatosis  
 lymphangitic, 701, 702f  
 pulmonary edema in, 120f  
 meningeal, metastatic, 694
- Carcinosarcoma, pulmonary, 624–627  
 age distribution in, 624, 624f  
 central endobronchial, 625  
 chest radiography in, 624, 625f  
 clinical features of, 624f–625f, 624–625  
 definition of, 624, 624t  
 diagnosis and treatment of, 625  
 differentiated, 626, 626f  
 epithelial components in, 626, 627t  
 histologic findings in, 626–627, 627t  
 historical, 624  
 metastasis of, 692  
 pathologic findings in, 625f–626f, 625–627, 627t  
 sarcomalike, outcome in, 627, 627t  
 solid parenchymal, 625  
 stromal components in, 626, 627t
- Carotid artery(ies), common origin of, tracheal stenosis due to, 66–67, 67f
- Carotid body tumor(s)  
 in chronic mountain sickness, 256, 258f  
 at high altitude, 256f–258f, 258
- Caseous necrosis, in granulomas, 768
- Castleman disease (angiofollicular hyperplasia), 637  
 mediastinal, 859
- Catheterization, central venous, venous air embolism due to, 191
- Cat scratch disease, in AIDS, 511
- CD4 T cell(s), in AIDS, 504
- Ceelen disease. *See* Hemosiderosis, pulmonary, idiopathic.
- Cell(s), of respiratory tract. *See individual cells.*
- Central nervous system  
 metastasis to, 693–694, 695f  
 in small cell carcinoma, 566
- Central venous catheterization, venous air embolism due to, 191
- Ceramic fibers, refractory, lung disease due to, 417t, 418, 418f–419f
- Cerebellum, metastasis to, 694, 695f
- Cervical carcinoma, uterine, metastasis from, 703
- Cervical cleft, congenital midline, 90
- Cesarean delivery, venous air embolism due to, 191
- Cestode(s), 495–497
- CF gene, 98–99. *See also* Cystic fibrosis.
- Chagas disease (trypanosomiasis), pulmonary, 492
- Charcoal, activated, aspiration of, 186
- Charcot-Leyden crystal(s), Color Fig. 3-2, 31  
 in occupational asthma, 161
- Chemical agents, in pulmonary carcinogenesis, 526
- Chemoreceptor(s), at high altitude, 256f–258f, 258
- Chest, flail, 181
- Chest radiography  
 in adult respiratory distress syndrome, 126, 127f  
 in allergic bronchopulmonary aspergillosis, 734, 734f  
 in alveolar microlithiasis, 349–350  
 in asbestosis, 397  
 in cardiogenic pulmonary edema, 121  
 in chronic eosinophilic pneumonia, 747, 748f  
 in Fabry disease, 105, 106f  
 in mucoid impaction of bronchus, 734f, 737  
 in pulmonary blastoma, 618, 619t  
 in pulmonary carcinosarcoma, 624, 625f  
 in radiation pneumonitis, 144, 144f  
 in usual interstitial pneumonia, 327
- Chest trauma, 179–184, 180d  
 blunt, 179  
 bronchi in, 182–183  
 due to bullets, 182  
 clavicular fracture in, 180  
 flail chest in, 181  
 due to foreign bodies, 182  
 hemothorax in, 181  
 due to migratory foreign bodies, 182, 183f  
 open pneumothorax in, 181  
 other types of, 183–184  
 penetrating, 179–180, 180f  
 pulmonary contusions in, 181–182  
 pulmonary hematoma in, Color Fig. 19-1, 181–182, 182f  
 pulmonary laceration in, 181–182  
 rib fracture in, 181
- sternal fracture in, 181  
 subcutaneous emphysema in, 180  
 tension pneumothorax in, 181  
 trachea in, 182–183  
 traumatic arteriovenous fistula in, 182  
 types of, 180d
- Chest wall  
 abnormalities of, in children, 90–91  
 bone abnormalities of, 875–876  
 diseases of, 875–877, 876d  
 Ewing sarcoma of, 877  
 nodular fasciitis of, Color Fig. 76-2, 877, 879f  
 in obesity, 875  
 pseudotumors of, Color Fig. 76-2, 877, 879f  
 rhabdomyosarcoma of, 877  
 in systemic sclerosis, 875  
 tumors of, 876–877
- Chlamydia pneumoniae* infection, TWAR strain, 473  
 in AIDS, 511
- Chlamydia psittaci* infection, 473
- Chlamydia trachomatis* infection, Color Fig. 42-5, 473
- Chlorine, as irritant gas, 167
- Cholesterol granuloma(s), in children with gastroesophageal reflux, 365, 365t
- Cholesterol pneumonia, Color Fig. 33-1, 361
- Chondrosarcoma, 651, 652f  
 epithelioid hemangioendothelioma vs., 650
- Chordoma, metastatic, epithelioid hemangioendothelioma vs., 650
- Choriocarcinoma  
 metastasis from, 703  
 primary, Color Fig. 58-1, 685f–686f, 685–686  
 pulmonary vascular embolus due to, 231
- Chromium exposure, occupational asthma due to, 163
- Chromogranin, in small cell carcinoma, 562, 563f
- Chronic obstructive pulmonary disease (COPD), emphysema in, 281–282. *See also* Emphysema.
- Chrysosporium parvum*, Color Fig. 43-9, 484
- Churg-Strauss syndrome, 805–807  
 clinical manifestations of, 805  
 diagnostic criteria in, 805, 807  
 differential diagnosis of, 807  
 eosinophilic Wegener granulomatosis vs., 800  
 pathologic manifestations of, 805  
 therapy and prognosis in, 807  
 upper airway, 836f–837f, 837  
 Wegener granulomatosis vs., 807
- Chylothorax, 866, 867d
- Cigarette smoking  
 alveolar macrophages in, 30  
 asbestos exposure and, 403, 658  
 bronchogenic adenocarcinoma and, future research on, 887

- Cigarette smoking (*continued*)  
 coal worker's pneumoconiosis and, 380  
 emphysema due to, 283, 887  
 focal scars in, 336  
 goblet cell hyperplasia due to, 32  
 lung cancer due to, 526  
 peribronchiolar fibrosis and, 887  
 respiratory bronchiolitis due to, 320  
 silicosis and, future research on, 887  
 small airway disease due to, asbestosis vs., 400  
 small cell carcinoma and, 556
- Cilia  
 abnormal, in various disorders, 100-101  
 compound, 100, 101f  
 in cystic fibrosis, 98  
 locations of, 99-100  
 in smoke inhalation, 185  
 structure of, 100, 100f
- Ciliary dyskinesia  
 primary, 99-101, 100f-101f  
 biopsy technique in, 101  
 bronchiectasis in, 304, 305f  
 diagnosis of, 101  
 structural abnormalities in, 100  
 terminology in, 99  
 secondary, 100, 101f
- Ciliated cell(s), 4, 4f  
 cilium of, 4, 5f  
 in cytologic diagnosis, 27, 29, 29f  
 multinucleated, 29, 29f  
 ultrastructure of, 4, 5f
- Ciliocytophthoria, 29, 29f  
 in viral infection, 33
- Cilium(a), ultrastructure of, 4, 5f
- Circulation. *See also individual vessels.*  
 bronchial, 11-12  
 pulmonary, 11
- Cirrhosis, muscular pulmonary (pulmonary lymphangiomyomatosis, pulmonary muscular hyperplasia), 86
- Clara cell(s)  
 in cytologic diagnosis, 32-33  
 secretory function of, 7-8  
 ultrastructure of, 7, 9f
- Clara cell adenocarcinoma, mesothelioma vs., 663t
- Clavicular fracture, 180
- Clear Air Act, 883
- Clear cell tumor, 673-675  
 differential diagnosis of, 675  
 gross findings in, 673, 674f  
 incidence and clinical findings in, 673  
 microscopic findings in, 673-675, 674f-676f  
 origin of, 675  
 renal cell carcinoma vs., 675  
 ultrastructural findings in, 674-675, 676f
- Clostridium septicum*, 434f
- Coagulopathy, in pathogenesis of adult respiratory distress syndrome, 135
- Coal, intrinsic toxicity of, 371
- Coal mine dust, constituents of, 371
- Coal rank, 380
- Coal worker's pneumoconiosis, 369-384, 391f-392f, 391-392  
 anthracotic macronodules in, 374, 375f  
 anthracotic micronodules in, 373, 374  
 anthracotic particles in, 369-370  
 lung:lymph node ratio for, 370  
 lymph drainage of, 370  
 macrophages and, 369-370  
 mucociliary elevator for, 369-370  
 sizes of, 369  
 chronic bronchitis and bronchiolitis in, 378-379  
 chronic cor pulmonale in, 380-381  
 cigarette smoking and, 380  
 coal rank in, 380  
 diesel exhaust and, 378-379  
 disorders involved in, 370-371  
 emphysema in, 379f, 379-380  
 centrilobular, 379, 379f  
 focal dust, 373, 374f-375f, 379f, 379-380  
 etiology and diagnosis of, 370-372  
 constituents of coal mine dust in, 371  
 free radicals in, 371  
 fumes from cable fires in, 372  
 intrinsic toxicity of coal in, 371  
 silica in, 371-372, 372f, 391f-392f, 391-392  
 silicosis in, 372  
 historical, 369  
 nodular lesions in, 374, 375f-376f  
 pathologic classification of, 372-382  
 primary (anthracotic) macule in, 372-374, 373f-375f  
 progressive massive fibrosis in, 374-376, 376f-378f  
 pulmonary neoplasms in, 381  
 pulmonary vascular abnormalities in, 380-381  
 quantitation of black lung pigment in, 374  
 rheumatoid pneumoconiosis (Caplan syndrome) in, 377-378, 378f, 392, 718, 781  
 simple, 372  
 in surface miners, 381  
 tuberculosis and, 381
- Cobalt exposure, hard metal lung disease due to, Color Fig. 37-1, 412-414, 414f  
 future research on, 885
- Cocaine, crack  
 alveolar hemorrhage due to, 155  
 inhalation of, pulmonary complications of, 191, 192f
- Coccidioidomycosis, Color Figs. 43-2-43-4, 478-479, 479f  
 acute pneumonia in, 478  
 in AIDS, 509-510  
 cavitary disease in, 478  
 miliary pulmonary disease in, 478  
 pulmonary nodule in, 478
- Coke oven worker(s)  
 centrilobular emphysema in, 382  
 chronic bronchitis in, 382  
 squamous cell carcinoma of lung in, 381, 382
- Collagen vascular disease. *See also individual diseases, (e.g., Rheumatoid arthritis).*  
 eosinophilia in, 752  
 primary pulmonary hypertension in, 236  
 pulmonary involvement in, 781-790, 782d  
 usual interstitial pneumonia in, 330  
 lung carcinoma and, 337
- Collateral artery(ies), systemic, with anastomosis to pulmonary artery, 264-265, 265f
- Collateral ventilation, 12, 13f  
 in bronchiectasis, 299-300  
 in chronic bronchitis, 290, 291f
- Colloidal iron, for mesothelioma, 664
- Colloid osmotic pressure, decreased, pulmonary edema due to, 119
- Colon carcinoma, metastasis from, 702, 703f
- Computed tomography (CT)  
 in adult respiratory distress syndrome, 126, 127f  
 in usual interstitial pneumonia, 327
- Congenital malformation(s)  
 of bronchi, 71-73  
 of epiglottis, 63  
 of hyoid bone, 63  
 of larynx, 63-65  
 of lungs, 73-76  
 of thyroid cartilage, 63  
 of trachea, 64-68
- Congestive heart failure, chronic, pulmonary artery thrombosis in, 172
- Congestive vasculopathy, pulmonary, in congenital heart disease, 223
- Connective tissue disease. *See also individual types, (e.g., Systemic sclerosis).*  
 bronchiolitis obliterans in, 319  
 pulmonary hypertension in, 209, 210f, 212, 236-237
- Contusion(s), pulmonary, 181-182
- Copper fever (metal fume fever, brass fever, Monday morning fever), 164, 165f
- Corpora amylacea  
 alveolar microlithiasis vs., Color Fig. 32-5, 351  
 in cytologic diagnosis, 31
- Cor pulmonale  
 chronic, in coal worker's pneumoconiosis, 380-381  
 chronic bronchitis and, 292-293, 293f  
 definition of, 292  
 in emphysema, 282  
 in schistosomiasis, 494
- Corrosion casts, technique for, 57, 59
- Cotton workers. *See* Byssinosis.
- Cough, airway mechanics of, 311
- Coxiella burnetii*, 472

- Crack cocaine  
 alveolar hemorrhage due to, 155  
 inhalation of, pulmonary complications of, 191, 192f
- Creola body(ies)  
 cytologic diagnosis of, 29, 30f  
 in occupational asthma, 30f, 161
- CREST syndrome, 783-784. *See also* Systemic sclerosis.  
 pulmonary hypertension in, 209, 212
- Cricopharyngeal ring and bar, congenital, 65
- Crossover lung segment, 76
- Cryptococcosis, pulmonary, Color Fig. 43-8, 484  
 in AIDS, 508, 509f  
*Cryptococcus albidus*, 484  
*Cryptococcus laurentii*, 484  
*Cryptococcus neoformans*, 484  
 Cryptogenic organizing pneumonitis. *See* Bronchiolitis obliterans organizing pneumonia (BOOP).
- Cryptosporidiosis, pulmonary, 492  
 in AIDS, Color Fig. 45-2, 507-508
- Curschmann spiral(s)  
 in cytologic diagnosis, Color Fig. 3-1, 30  
 in occupational asthma, Color Fig. 3-1, 161
- Currularia* pulmonary infection, Color Fig. 43-10, 485
- Cyanide poisoning, 166  
 in burn inhalational injury, 185
- Cyst(s)  
 bronchiectatic, in cystic fibrosis, 98  
 bronchogenic, congenital, 80, 82f  
 mediastinal, 859  
 neurenteric, congenital, 80, 82f  
 in pulmonary hydatid disease, Color Fig. 44-2, 496, 496f  
 septal, congenital, due to chronic interstitial emphysema, 80  
 subpleural, in Down syndrome, 83, 83f  
 thymic, multilocular, 859
- Cystadenoma (cystic tumor), mucinous, pulmonary, 540f, 540-541
- Cystic adenomatoid malformation, congenital, 79-80, 81f-82f
- Cysticercosis, pulmonary, 496-497
- Cystic fibrosis, 98-99  
 bronchiectasis in, Color Fig. 11-3, 98, 304, 304f, 307, 307f  
 bronchiectatic cysts in, 98  
 CF gene in, 98-99  
 cilia in, 98  
 history of, 98  
 in males, 86  
 membrane transport in, 99  
 of pancreas, 86  
 pulmonary bacterial infections in, 98  
 respiratory tract involvement in, 98, 99f
- Cystic fibrosis transmembrane conductance regulator, 86, 98-99
- Cystic lung lesions, congenital, 79-83  
 in Down syndrome, 83, 83f
- Cystine storage disease (Lignac-Fanconi disease, cystinosis), 112
- Cytokeratin(s), in small cell carcinoma, 561, 563f
- Cytology, 27-39  
 cells studies in, 27-30  
 extrinsic elements in, 31-32, 32f  
 intrinsic elements in, Color Figs. 3-1-3-2, 30-31, 31f  
 noncellular elements in, 30-32  
 principles of, 32-33  
 for air spaces, 33  
 for bronchial mucosa, 32, 32f  
 for peripheral airways, 32-33  
 in pulmonary infections, 33  
 specimen collection procedures for, 27, 28t  
 specimen preparation methods for, 27, 28t  
 technical aspects of, 27, 28t
- Cytomegalovirus infection, in AIDS, 510
- Cytomegalovirus pneumonia, 465-466, 466f  
 in immunocompromised patients, 465  
 viral inclusions in, 466, 466f
- D**
- DAD. *See* Alveolar damage, diffuse (DAD).
- Death, acute pulmonary, 179-199, 180d. *See also under individual causes.*  
 in acute pulmonary thromboembolism, Color Fig. 19-4, 191, 194  
 in arterial air embolism, 193  
 due to aspiration injury, 186-188  
 in bronchial asthma, 191  
 drug-related, Color Fig. 19-2, 190-191, 192f-193f  
 in embolization of gastric contents, 193  
 due to immersion injury, 188-190  
 in infectious pneumonia, 194  
 due to inhalation injury, 184-186  
 due to mechanical chest trauma, 179-184, 180d  
 due to natural causes, 191-195  
 in primary pulmonary hypertension, 193-194, 195f  
 in sudden infant death syndrome, 194-195, 196d. *See also* Sudden infant death syndrome (SIDS).  
 in venous air embolism, 191, 193
- Decidual embolus(i), pulmonary, 176
- Decompression sickness  
 in aviators, 190  
 in scuba divers, 190, 191f
- Deep venous thrombosis, in pulmonary thromboembolism, Color Fig. 19-4, 171, 191, 194f
- Deferoxamine, bronchiolitis obliterans organizing pneumonia due to, 153, 154f
- Dermatomyositis and polymyositis, 785, 788  
 bronchiolitis obliterans organizing pneumonia in, 785, 787f  
 diffuse alveolar damage in, 785, 787f  
 pulmonary hypertension in, 212, 785, 788f
- Diaphragm  
 abnormalities of, in children, 90-91  
 accessory, 91, 879  
 congenital defects of, 879  
 diseases of, 876d, 877-880  
 eventration of, congenital, 90-91  
 hernia of, congenital, Color Fig. 10-1, 90-91, 91f  
 paralysis of, 878-879, 880t  
 rupture of, 183  
 traumatic rupture of, 879  
 tumors of, 879-880
- Diesel exhaust  
 coal worker's pneumoconiosis and, 378-379  
 inhalation of, 166
- Dietary factors, in pulmonary carcinogenesis, 527
- DiGeorge anomaly, thyroid cartilage hypoplasia in, 63
- Diphenylhydantoin, lymphoid interstitial pneumonia due to, 153, 154f
- Diphtheria, 441
- Diphtherial pneumonia, 429
- Dirofilaria immitis*, 497
- Dirofilariasis  
 eosinophilic pneumonia in, 751t  
 pulmonary, 497-498, 498f
- Dissection, of specimens  
 autopsy, 54f-57f, 55  
 technique for, 53, 55f
- Diverticulum(a)  
 of trachea, 844  
 vallecular, 63
- Diving reflex, 189
- DNA ploidy and cytogenetics in, in small cell carcinoma, 564-565
- Down syndrome  
 midtracheal stenosis with ring tracheal cartilages in, 66  
 peripheral cystic lung syndrome of, 83, 83f
- Drowned lung syndrome, 119
- Drowning, 188-189  
 diving reflex and, 189  
 forensic findings in, 189  
 immersion hypothermia and, 189  
 incidence of, 188  
 pathologic findings in, 189, 190f  
 pathophysiology of, 189  
 sea water vs. fresh water, 189  
 in seizure disorders, 188  
 sequence of events in, 188  
 terminology for, 188, 189d
- Drug abuse, intravenous  
 pulmonary hypertension in, 229f-230f, 229-230  
 talc deposits due to, Color Figs. 19-2 and 35-4, 390

- Drug abuse, intravenous (*continued*)  
 talc granuloma in, 229f–230f,  
 229–230
- Drug-induced pulmonary disease,  
 149–157  
 alveolar hemorrhage as, 155  
 asbestosis vs., 400  
 diffuse alveolar damage in, 150, 150d,  
 151f  
 disorders mimicking, 149, 150d  
 eosinophilic pneumonia as, 751  
 hypersensitivity reactions in, 152–153  
 allergic alveolitis as, 152, 152f  
 bronchiolitis obliterans as, 153,  
 153d, 154f  
 eosinophilic pneumonia as, Color  
 Fig. 16-2, 152, 153d, 153f  
 lymphoid interstitial pneumonia as,  
 152–153, 154f  
 sarcoidal reaction as, 153  
 miscellaneous, 156, 156d, 156f  
 patterns of, 149, 150d  
 pulmonary hypertension as, 155, 155f  
 pulmonary vasculitis as, 155  
 usual interstitial pneumonia with  
 fibrosis as, Color Fig. 16-1,  
 149–150, 150d, 151f  
 cytotoxic drugs causing, Color Fig.  
 16-1, 149, 150d  
 noncytotoxic drugs causing, 150,  
 150d, 151f  
 vasculopathy in, 155, 155f–156f
- Drug-related deaths, acute pulmonary,  
 Color Fig. 19-2, 190–191,  
 192f–193f
- Drug therapy, intravenous, pulmonary  
 complications of, 191
- Ductus arteriosus, patent (PDA), at high  
 altitude, 250
- Dysbaric osteonecrosis (Caisson disease),  
 190
- E**
- Eaton-Lambert syndrome, in small cell  
 carcinoma, 566
- Echinococcosis (hydatid disease)  
 alveolar, 496  
 pulmonary, Color Fig. 44-2, 495–496,  
 496f  
 cysts in, Color Fig. 44-2, 496, 496f
- Echinococcus granulosus*, 495  
*Echinococcus multilocularis*, 495  
*Echinococcus vogeli*, 495
- Ectopia(s)  
 of lungs, 74  
 metastasis vs., 708–709
- Ectopia cordis, 91
- Edema, pulmonary. *See* Pulmonary  
 edema.
- Effusion(s), pleural, 864–866, 865d
- Ehlers-Danlos syndrome, bronchiectasis  
 in, 98
- Electron microscopy, for biopsy speci-  
 mens, 46
- Ellis-van Creveld syndrome, 71, 75
- Embolism  
 bone marrow, pulmonary hypertension  
 due to, 231–233  
 brain, pulmonary hypertension due to,  
 233  
 endobronchial, in bronchiectasis,  
 300–301  
 gastric contents, 193  
 liver, pulmonary hypertension due to,  
 233  
 nonthrombotic, chronic pulmonary  
 hypertension in, 229–230  
 pulmonary  
 air, 175–176, 193  
 in scuba divers, 190  
 amniotic fluid, 176, 176f  
 decidual, 176  
 fat, 175, 175f  
 nonthrombotic, 174–176  
 trophoblast, 176, 177f  
 pulmonary venous, air, 191, 193  
 tumor, pulmonary hypertension due  
 to, 230–231, 232f
- Embryonal carcinoma, of mediastinum,  
 Color Fig. 74-5, 857
- Emphysema, 275–286  
 airways obstruction in, 292  
 bullous, 278–279, 280f–281f  
 centriacinar, 277, 277f–278f  
 centrilobular, 277  
 cigarette smoking in, 887  
 in coal worker's pneumoconiosis,  
 379, 379f  
 in coke oven workers, 382  
 interstitial fibrosis vs., 336  
 risks of lung cancer in, 527, 527f  
 chronic bronchitis and, 291  
 classification of, difficulties with,  
 279–280  
 clinical correlates in, 281–282  
 congenital, 79, 80f  
 $\alpha_1$ -antitrypsin deficiency in, 87  
 chronic interstitial, pulmonary septal  
 cysts in, 80  
 compensatory and obstructive, 79  
 hypoplastic, 79  
 lobar, Color Fig. 8-1, 79, 80f  
 in COPD, 281–282  
 cor pulmonale in, 282  
 definitions in, 275–276  
 dynamic airway behavior in, 311  
 epidemiology of, 283–284  
 expiratory airflow obstruction in, 281  
 dynamic collapse of small airways in,  
 281  
 small airway disease in, 281  
 focal, 277  
 focal dust, in coal worker's pneu-  
 moconiosis, 373, 374f–375f  
 grades of severity in, 277  
 histologic findings in, 276–277  
 historical, 275  
 honeycomb lung vs., 276  
 interstitial  
 bleb in, 279  
 definition of, 276  
 irregular, 278, 280f
- left heart abnormalities in, 282  
 panacinar, 277–278, 278f–279f  
 paraseptal, 276f, 278  
 pathogenesis of, 282–283, 283f  
 $\alpha_1$ -antitrypsin deficiency in,  
 282–283, 291  
 cigarette smoking in, 283, 887  
 protease-antiprotease hypothesis in,  
 282–283  
 pathology specimens for study of, 275  
 pulmonary function tests in, 281  
 pulmonary hypertension in, 209  
 in sarcoidosis, 774  
 "senile," 276. *See also* Aging lung(s).  
 steroid-treated, complications of, 282  
 subcutaneous  
 due to chest trauma, 180  
 definition of, 276  
 type A (pink puffers), 281  
 type B (blue bloaters), 281–282  
 types of, 276d, 276f, 276–280
- Encephalitis, toxoplasmal, in AIDS, 507  
*Encephalitozoon hellem*, 508
- Endobronchial abscess  
 in bronchiectasis, 300, 300f, 303  
 in chronic bronchitis, 290, 291f
- Endobronchial embolus, in bronchi-  
 ectasis, 300–301
- Endometrial stromal sarcoma, metastasis  
 from, 706, 706f
- Endothelium, alveolar  
 cell marker for, 10  
 ultrastructure of, 9–10
- Endotoxin lung injury, inhalational, 164
- Entamoeba histolytica*, 490
- Enterobius vermicularis*, Color Figs.  
 44-3–44-4, 500
- Enterocytozoon bienersi*, 508
- Environmental lung disease, 883–888.  
*See also* Asthma, occupational;  
 Pneumoconiosis.  
 governmental regulations and, 884  
 historical, 883  
 research problems in, 883–884
- Enzyme(s), biologic, occupational asthma  
 due to, 163
- Eosinophilia  
 in bronchocentric granulomatosis,  
 739–740, 741f  
 in collagen vascular disease, 752  
 in sarcoidosis, 752  
 secondary, 752d  
 tropical (Weingarten syndrome), 497,  
 750–751
- Eosinophilic granuloma, pulmonary,  
 Color Fig. 32-3, 345–347,  
 346f–348f  
 Birbek granules in, 346, 348f  
 clinical manifestations of, 346  
 histopathologic findings in, 346,  
 346f–348f  
 Langerhans cells in, Color Fig. 32-3,  
 346
- Eosinophilic infiltrate  
 in lung transplant rejection, 824  
 in occupational asthma, Color Figs.  
 17-3–17-5, 161

- Eosinophilic leukemia, 752
- Eosinophilic pleuritis, reactive, 869, 870f
- Eosinophilic pneumonia, 745–753
- acute, 745–747
    - progressive, 746–747, 747f
    - transient (Löffler syndrome), 745, 746d, 746f
    - parasite-associated, 750
  - in allergic bronchopulmonary aspergillosis, 751
  - chronic, Color Fig. 64-1, 747–750, 748f–750f
    - bronchiolitis obliterans organizing pneumonia vs., 359, 360t, 750
    - chest radiography in, 747, 748f
    - diagnostic criteria for, 747
    - eosinophil-depleted, 749, 750f
    - exclusions for diagnosis of, 747
    - overlap syndromes in, 750
    - pathologic findings in, Color Fig. 64-1, 748–749, 749f
    - steroid therapy in, 747–748
  - classification of, 745, 746d
  - drug-related, Color Fig. 16-2, 152, 152d, 153f, 751
  - future research on, 885
  - infection-associated, 751
  - parasite-related, 750–751, 751t
  - in rheumatoid arthritis, 752
  - vasculitis-associated, 751
- Eosinophilic Wegener granulomatosis, Color Fig. 68-3, 794, 796, 798f
- Churg-Strauss syndrome vs., 800
- Ependymoma, 686
- Epiglottis, congenital malformations of, 63
- Epithelial-mesenchymal tumor(s), mixed, 617–629. *See also* Blastoma(s); Carcinosarcoma, pulmonary; Teratoma(s).
- other types of, 628
- Epithelial neoplasms, metastasis from, 701–704
- Epithelioid cell(s), in granulomas, 767
- Epithelioid hemangioendothelioma, pulmonary, 649–650
- chondrosarcoma vs., 650
  - hamartoma vs., 650
  - metastatic chordoma vs., 650
- Epithelium. *See also individual cell types.*
- of airway, cell types of, 288, 288f
  - of alveolus
    - in injury response, 22, 22f
    - restoration of, 22–23
  - of bronchiolus
    - cell types of, 32
    - in cytologic diagnosis, 33
  - of lung
    - expanding, 3–4
    - in injury response, 21–22
      - with intact basement membrane, 21
    - restoration and obliteration of, 22–23
    - with ulcerated basement membrane, 21–22
- Epstein-Barr virus infection, 469–470
- ERB oncogene, in pulmonary carcinogenesis, 528, 528t
- Erythrocyte(s), in cytologic diagnosis, 30, 31
- Escherichia coli* pneumonia, Color Fig. 38-15, 430
- Esophagus, perforation of, 183
- Estrogen(s), pulmonary thromboembolism due to, 171
- Ethiodol, alveolar hemorrhage due to, 155
- Ewing sarcoma, of chest wall, 877
- Extracorporeal membrane oxygenation, hyaline membrane disease in, 94
- Extramedullary hematopoiesis, pulmonary, 638
- Extrapleural tumor(s), benign, 668–669
- Extrapulmonary tumor(s), metastasis from, 701–710. *See also under* Metastasis.
- F**
- Fabry disease (glycosphingolipid lipidoses), 105–106
- alveolar epithelial cell inclusion bodies in, 105, 107f
  - chest roentgenograms in, 105, 106f
  - endothelial and alveolar laminated intracellular inclusions (zebra bodies) in, 105, 107f
  - PAS positivity in, Color Fig. 12-1, 105
  - strong birefringency of neurons in, Color Fig. 12-2, 105
  - ventilation perfusion scans in, 105, 106f
- Farmer's lung, 164, 755
- future research on, 885
  - silo unloader's syndrome vs., 163
- Fasciitis, nodular, of chest wall, Color Fig. 76-2, 877, 879f
- Fasciola hepatica*, pulmonary, 494
- Fat embolus(i), pulmonary, 175, 175f
- Fenfluramine, pulmonary hypertension due to, 155
- Ferruginous body(ies), 397
- in cytologic diagnosis, 31–32
  - elemental fiber composition in, Color Fig. 36-1, 407–408, 408f
- Fetal hemoglobin, increased, in sudden infant death syndrome, 195
- Fiberoptic bronchoscopy. *See* Bronchoscopy, fiberoptic.
- Fibrochondrolipoma, Color Fig. 56-6, 653, 653f–654f
- Fibroma(s), submesothelial, 856
- Fibrosarcoma, pulmonary, 647
- Fibrosing mediastinitis, pulmonary hypertension in, 213
- Fibrosis
- alveolar, 22, 22f
  - interstitial. *See also* Interstitial pneumonia, usual (UIP).
    - adenocarcinoma in, 541, 542f
    - in asbestosis, 398, 399f
    - bronchioloalveolar adenocarcinoma in, 541, 542f
    - risks of lung cancer in, 527
    - in systemic sclerosis, 784, 786f
- peribronchiolar
- cigarette smoking and, 887
  - in rheumatoid arthritis, 22
- pleural, 869–870
- diffuse, asbestos-related, 401, 402f
  - future research on, 886
- progressive massive
- in coal worker's pneumoconiosis, 374–376, 376f–378f
  - histologic findings in, 375, 377f
  - pathogenesis of, 376
  - silica in, 372
  - in silicosis, Color Fig. 35-2, 388
  - silicotic nodule vs., 375
  - tuberculosis vs., 375, 378f
- pulmonary
- in childhood, 86–87
  - idiopathic. *See* Interstitial pneumonia, usual (UIP).
  - pulmonary hypertension in, 211f–212f, 213
  - in rheumatoid arthritis, 782, 782f
  - in sarcoidosis, 773–774, 774f
  - radiation, localized, 718
- Fibrous glass, lung disease due to, 417t, 418
- Fibrous tumor
- intrapulmonary localized, Color Fig. 56-2, 647, 647f
    - benign vs. malignant, 647
    - leiomyoma vs., 646
  - mediastinal, 856
  - solitary pleural, 666–668
    - gross findings in, 667, 667f
    - histogenesis of, 667
    - malignant, 667, 668f–669f
    - microscopic findings in, 667, 668f
    - ultrastructural studies in, 667–668
- Filariasis
- pulmonary, 497, 497f
  - tropical eosinophilia due to, 750–751
- Fine needle aspiration (FNA), 33–36, 41–42
- for adenocarcinoma, 34, 35f
  - for asbestos bodies, 404
  - for bronchioloalveolar carcinoma, 34–35, 35f–36f
  - collection, slide prep, and staining for, 27, 28t
  - for hamartoma, 36, 37f
  - interpretation of, 34
  - for large cell carcinoma, 35–36
  - for metastatic neoplasms, 36, 37f–38f
  - for nonepithelial tumors, 36, 37f
  - for non-small cell carcinoma, 49–50
  - other cytology specimens vs., 27, 28t
  - for squamous cell carcinoma, Color Fig. 3-4, 34
  - technique for, 34
  - for thymoma, 43
  - for tumor cell type, 49–50

- Fissure(s), pulmonary  
 anatomy of, gross, 1  
 congenital abnormalities of, 74, 74f  
 locations of, 74
- Fistula(s)  
 arteriovenous, pulmonary  
 in children, 89, 90f  
 traumatic, 182  
 bronchobiliary, congenital, 72  
 bronchopleural, in tuberculosis, 458  
 tracheoarterial, 845, 846f  
 tracheoesophageal, 846, 847f
- Fixation  
 formalin vapor, 55–57  
 glycol-formalin, 57  
 of specimens  
 autopsy, 55, 56f  
 in distended state, Color Fig. 5-1, 53  
 Heard mechanical device for, 55, 56f  
 intrabronchial formalin perfusion for, 53, 54f  
 surgical pathology, 54
- Fixative(s), for biopsy specimens, 45, 45f
- Flail chest, 181
- Fluid(s), inert, aspiration of, 186
- FNA. *See* Fine needle aspiration (FNA).
- Folded lung syndrome, 401
- Follicular bronchiolitis, in chronic bronchitis, Color Fig. 30-2, 290, 319–320, 320f, 636, 636f
- Foreign body(ies)  
 aspiration of, 187–188, 188f  
 migratory, in chest, 182, 182f
- Forensic pathology. *See under* Death, acute pulmonary.
- Formaldehyde, occupational asthma due to, 166
- Formalin vapor fixation, 55–57
- Fracture(s)  
 clavicular, 180  
 rib, 181  
 sternal, 181
- Freyer cell(s). *See* Kulchitsky-like cell(s).
- Friedländer pneumonia (*Klebsiella pneumoniae*), 430
- Fume(s), irritant and toxic  
 diffuse alveolar hemorrhage due to, 729, 729f  
 occupational asthma due to, 164d, 164–166
- Fungal antigen(s), hypersensitivity pneumonitis due to, 756t
- Fungal infection(s), 477–487. *See also under individual fungi.*  
 in AIDS, 508–510  
 allergic bronchopulmonary, 736  
 cytologic diagnosis of, 33  
 of immunocompromised patients, 482–484, 485
- Fungus ball, 483  
 in bronchiectasis, 303, 303f
- Fusarium* species, 485
- Fusobacterium nucleatum*, 434f
- G**
- Gallium scanning, for diagnosis of sarcoidosis, 775
- GM<sub>1</sub> Gangliosidosis, 111
- Gangrene, of lung, 434–435, 435f
- Gas(es), occupational asthma due to  
 asphyxiant, 166d, 166–167  
 irritant, 167d, 167–168
- Gastric acid, aspiration of (Mendelson syndrome), 186–187
- Gastric contents, embolization of, 193
- Gastroesophageal reflux, interstitial lung disease and, in children, 364–366  
 biopsy results in, 365  
 cholesterol granulomas in, Color Fig. 33-2, 365  
 clinical and roentgenographic features of, 364, 365t  
 endogenous lipid pneumonia in, 365, 366f  
 pathogenesis of, 366–367, 367f  
 pulmonary alveolar proteinosis in, 365, 366f
- Gastrointestinal tract carcinoma(s), metastasis from, 702, 703f
- Gaucher body(ies), 107, 109f
- Gaucher cell(s), 107, 108f–109f
- Gaucher disease (glucosylceramide lipidosis), 106–107  
 biochemical findings in, 107  
 clinical manifestations of, 106–107  
 diagnosis of, 107  
 pathologic findings in, 107, 108f–109f
- Gene, CF, 98–99. *See also* Cystic fibrosis.
- Genitourinary tract carcinomas, metastasis from, 703, 703f–704f
- Geotrichum candidum*, 485
- Germ cell tumor(s), of mediastinum, Color Fig. 74-5, 857–858, 858f
- Giant cell(s), multinucleated, in cytologic diagnosis, 30, 31f
- Giant cell angiitis, disseminated and isolated, 815f, 816
- Giant cell interstitial pneumonia, 343–344, 344f–345f  
 differential diagnosis of, 344  
 histopathologic findings in, 344, 344f–345f  
 in occupational exposure to hard metal, Color Fig. 37-1, 343–344, 413–414, 414f  
 viral-related, 344, 345f
- Giant cell tumor of bone, benign, metastasis from, 708, 708f
- Glucosylceramide lipidosis. *See* Gaucher disease (glucosylceramide lipidosis).
- Glycogen storage disease, Color Fig. 12-3, 111–112
- Glycol-formalin fixation, 57
- Glycosphingolipid lipidosis. *See* Fabry disease (glycosphingolipid lipidosis).
- GM<sub>1</sub> gangliosidosis, 111  
*Gnathostoma spinigerum*, 499
- Goblet cell(s)  
 in cytologic diagnosis, 29, 30f  
 hyperplasia of  
 in chronic bronchitis, 288–289, 289f, 290  
 in cigarette smokers, 32  
 cytologic diagnosis of, 32  
 in normal airway, 287–288, 288f  
 ultrastructure of, 4, 5f
- Goldenhar anomaly, 66
- Golden pneumonia, Color Fig. 33-1, 361
- Gold therapy, usual interstitial pneumonia due to, 330
- Goodpasture syndrome, 726–727  
 antiglomerular basement antibody in, Color Fig. 62-1, 723–724, 724d  
 clinical features of, 724t  
 historical, 723  
 pulmonary manifestations of, 726  
 pulmonary pathologic findings in, 726, 726f  
 renal manifestations of, 726  
 renal pathologic findings in, 727, 727f
- Grain dust, occupational asthma due to, 163
- Granuloma(s)  
 biopsy for, 48, 49f  
 caseous necrosis in, 768  
 cholesterol, in children with gastroesophageal reflux, 365, 365t  
 definition and function of, 767  
 eosinophilic, pulmonary, Color Fig. 32-3, 345–347, 346f–348f  
 Birbek granules in, 346, 348f  
 clinical manifestations of, 346  
 histopathologic findings in, 346, 346f–348f  
 Langerhans cells in, Color Fig. 32-3, 346  
 epithelioid, 767  
 formation of, mechanisms of, 767–768, 769f  
 lipid, 718  
 necrotizing  
 in allergic bronchopulmonary aspergillosis, 735  
 mechanism of, 768  
 open lung biopsy for, 42, 43f  
 pulmonary hyalinizing, 718  
 in sarcoidosis, 769, 770f, 771–772, 772f  
 talc, in intravenous drug abuse, 229f–230f, 229–230
- Granulomatosis  
 angiitis and. *See* Pulmonary angiitis and granulomatosis and individual syndromes, (*e.g.*, Wegener granulomatosis).  
 allergic. *See* Churg-Strauss syndrome.  
 bronchocentric, 738–741  
 in allergic bronchopulmonary aspergillosis, 739  
 clinical features of, 739

- eosinophilia in, 739-740, 741f  
 fungal hyphae in, 739-740  
 future research on, 885  
 pathogenesis and differential diagnosis of, 740-741  
 pathologic features of, 739-740, 740f-741f  
 treatment and prognosis in, 739  
 Wegener granulomatosis vs., 800
- lymphomatoid, 634, 635f  
 clinical manifestations of, 833, 833f  
 diagnosis of, 833-834  
 Epstein-Barr viral genome in, 836  
 as lymphoproliferative disorder, 837  
 pathologic findings in, 834f-835f, 834-836  
 spectrum of clinical behavior in, 833  
 terminology for, 833  
 of upper airway, 833-837  
 Wegener granulomatosis vs., 833, 834
- necrotizing sarcoid, 776, 803-805  
 classical sarcoidosis vs., 805  
 clinical course in, 803, 805  
 clinical manifestations of, 803  
 differential diagnosis of, 805  
 infectious granulomatous disease vs., 805  
 pathologic manifestations of, 803, 804f  
 Wegener granulomatosis vs., 798, 805
- Wegener. *See* Wegener granulomatosis.
- Granulomatous disease. *See also individual types (e.g., Tuberculosis).*  
 infectious  
 necrotizing sarcoid granulomatosis vs., 805  
 sarcoidosis vs., 776  
 pulmonary  
 classification of, 767, 768d  
 incidence of, 767  
 pulmonary hypertension in, 209  
 Wegener granulomatosis vs., 798
- Granulomatous pleuritis, 869
- Graphite workers, pneumoconiosis in, 381, 382f
- Gray-iron foundry worker's lung, Color Fig. 37-4, 416
- Gumma(s), syphilitic, 441
- H**
- Haemophilus influenzae* pneumonia, 429  
 in AIDS, 511
- Hair spray exposure, lung disease due to, 419-420
- Halicephalobus delectrix*, 500
- Hamartoma  
 cartilaginous, benign, 653  
 epithelioid hemangioendothelioma vs., 650  
 fine needle aspiration of, 36, 37f
- Hamazaki-Wesenberg body(ies), in sarcoidosis, Color Fig. 66-1, 771
- Hamman-Rich syndrome, definition of, 326
- Handguns, in chest trauma, 182
- Hard metal lung disease, Color Fig. 37-1, 343-344, 412-414, 414f  
 future research on, 885
- Head and neck cancer, metastasis from, 702, 702f
- Heard mechanical device, for fixation of autopsy specimens, 55, 56f
- Heart, traumatic injury of, 183-184
- Heart disease, congenital  
 at high altitude, 250, 252, 253f-254f  
 pulmonary arteriole muscularization in, 250, 253f  
 pulmonary intimal fibrosis in, 250, 254f  
 pulmonary medial hypertrophy in, 250, 254f  
 lung biopsy in, 222-223  
 pulmonary congestive vasculopathy in, 223  
 pulmonary hypertension in, 217-223.  
*See also* Pulmonary hypertension, in congenital heart disease.
- Heart-lung transplantation, 819. *See also* Transplantation.
- Helminthic infection(s), 492-500. *See also individual species.*
- Hemangioendothelioma, epithelioid, pulmonary, 649-650  
 chondrosarcoma vs., 650  
 hamartoma vs., 650  
 metastatic chordoma vs., 650
- Hemangioma  
 pulmonary, in children, 89  
 pulmonary angiosarcoma vs., 649  
 sclerosing, 680-682  
 differential diagnosis of, 682  
 gross and microscopic findings in, 680  
 hemorrhagic, 680-681  
 immunohistochemical studies in, 681  
 inflammatory infiltrate in, 681, 681f  
 inflammatory pseudotumor vs., 715-716  
 locations of, 680  
 origin of, 682  
 papillary, 680, 681f  
 sclerotic, 681, 681f  
 solid, 680, 680f  
 ultrastructural findings in, 681-682
- Hemangiomas, capillary, in pulmonary venoocclusive disease, 243, 245, 245f
- Hemangiopericytoma, pulmonary, 650
- Hematite miner's lung, 416
- Hematoma(s), pulmonary, Color Fig. 19-1, 181-182, 182f
- Hematopoiesis, extramedullary, pulmonary, 638
- Hemiazygos vein anomalies, in children, 90
- Hemitruncus pulmonary artery, 89-90
- Hemoglobin, fetal, increased, in sudden infant death syndrome, 195
- Hemorrhage, alveolar, diffuse. *See* Alveolar hemorrhage, diffuse.
- Hemosiderosis, pulmonary  
 in hereditary hemorrhagic telangiectasia, 102, 102f  
 idiopathic, 101-102, 729f, 729-730  
 clinical features of, 729  
 diagnosis of, 729f, 729-730  
 pathogenesis of, 730  
 primary, in children, Color Fig. 9-3, 87, 87f  
 secondary, in children, Color Fig. 9-4, 87-88  
 in thalassemia, 102
- Hemothorax, 865, 866f  
 in chest trauma, 181
- Hepatization, red or gray, in pneumococcal pneumonia, Color Figs. 38-1-38-2, 426, 426f
- Hepatoma(s), pulmonary vascular embolus due to, 231
- Hernia  
 Bochdalek, 90  
 diaphragmatic, congenital, Color Fig. 10-1, 90-91, 91f  
 Morgagni, 90
- Heroin overdose, acute pulmonary edema due to, 190-191, 192f
- Herpes simplex virus infection, 466-467, 467f  
 diagnosis of, 467  
 necrotizing bronchopneumonia in, 467, 467f  
 necrotizing tracheobronchitis in, 467  
 viral inclusions in, 467
- Herpesvirus infection, in AIDS, Color Fig. 45-5, 510
- High altitude. *See also* Mountain sickness.  
 carotid body tumors at, 256f-258f, 258  
 chemoreceptor pathology at, 256f-258f, 258  
 congenital heart disease at, 250, 252, 253f-254f  
 geographic areas of, 247  
 patent ductus arteriosus at, 250  
 pathologic conditions at, 247, 248d  
 pulmonary edema at, 120-121, 136, 253-255  
 pulmonary hypertension at, 247-250.  
*See also under* Pulmonary hypertension.
- Hilar lymphadenopathy, bilateral, in sarcoidosis, 768
- Hilus, anatomy of, gross, 1
- Histiocytic neoplasm(s), malignant, 638
- Histiocytoma, malignant fibrous, 650-651  
 benign fibrous histiocytoma vs., 651  
 metastatic, 38f  
 pleomorphic carcinoma vs., 650-651
- Histoplasma capsulatum*, 477
- Histoplasmosis, Color Fig. 43-1, 477-478, 478f  
 in AIDS, 508-509  
 clinical presentation in, 477  
 collapsed yeast forms in, 478, 478f  
 fibrocaceous nodules in, Color Fig. 43-1, 477  
 infiltrative, 478, 478f

- HIV infection. *See also* Acquired immunodeficiency syndrome (AIDS).  
 molecular biology of, 503–504
- Hodgkin lymphoma  
 of mediastinum, 858  
 pulmonary  
   in AIDS, 516  
   primary vs. secondary, 637, 637f  
   Wegener granulomatosis vs., 800
- Honeycomb lung, 334–335, 337d  
 antecedents of, 334, 335d  
 in asbestosis, 398, 399f  
 in diffuse alveolar damage, 131, 132f  
 emphysema vs., 276  
 gross pathologic findings in, 334  
 histopathologic findings in, 334–335  
 lung cancer and, 336–337  
 pathogenesis of, 22, 23f  
 in sarcoidosis, 774, 774f  
 in systemic sclerosis, 784, 786f  
 in usual interstitial pneumonia, 328, 329f
- Horner syndrome, in metastasis, 691
- Horseshoe lung, 76
- Hughes-Stovin syndrome, 813
- Human immunodeficiency virus infection. *See also* Acquired immunodeficiency syndrome (AIDS).  
 molecular biology of, 503–504
- Human papillomavirus infection, in  
 squamous cell carcinoma, 548
- Hyaline membrane(s)  
 in diffuse alveolar damage, 127–128, 128f  
 in pulmonary oxygen toxicity, 143, 143f
- Hyaline membrane disease, 93–95  
 bilirubin staining in, Color Fig. 11-2, 93  
 in cesarean births, 94  
 in extracorporeal membrane oxygenation, 94  
 gross appearance in, Color Fig. 11-1  
 in  $\beta$ -hemolytic group B streptococcal infection, 93–94  
 infantile, diffuse alveolar damage vs., 135  
 morphologic stages of, 93, 94f–95f  
 surfactant in, 94–95
- Hyalinizing granuloma, pulmonary, 718
- Hydatid disease (echinococcosis)  
 alveolar, 496  
 pulmonary, Color Fig. 44-2, 495–496, 496f  
   cysts in, Color Fig. 44-2, 496, 496f
- Hydrofluoric acid, inhalation of, 166
- Hydrogen sulfide poisoning, 166
- Hysteroscopy, venous air embolism due to, 191, 193
- Hyoid bone, congenital malformations of, 63
- Hyper eosinophilic syndrome, 752
- Hyperlucency, of lung  
 congenital (Swyer-James syndrome, Macleod syndrome), 82–83  
 bronchiectasis in, 305, 306f, 307
- unilateral, as complication of radiation therapy, 145
- Hypersensitivity lung disease, drug-associated, 152–153
- Hypersensitivity pneumonitis, 164, 755–765  
 animal proteins causing, 756t  
 bacterial antigens causing, 756t  
 bronchiolitis obliterans organizing pneumonia vs., 359, 360t  
 bronchoalveolar lavage in, 764  
 causes of, 755, 756t–757t  
 clinical features of, 755  
 differential diagnosis of, 762, 764, 764t  
 etiology and pathogenesis of, 756t–757t, 757–758, 758f  
 fungal antigens causing, 756t  
 insect proteins causing, 756t  
 laboratory findings in, 755, 757  
 lymphoid interstitial pneumonia vs., 764  
 pathogenesis of, future research on, 885  
 pathologic features of, Color Fig. 65-1, 758–762, 759f–763f  
   bronchiolitis obliterans in, 761, 763f  
   electron microscopic, 758, 761f–762f  
   fibrotic changes in, 761  
   foam cells in, 758, 760f  
   immunoglobulins in, Color Fig. 65-1, 761, 763f  
   lymphoplasmacytic infiltrate in, 758, 759f  
   non-necrotizing granulomas in, 758, 760f  
   organizing intraalveolar bud in, 758, 762f  
   small airways in, 761, 763f  
   vascular lesions in, 761–762  
 regression vs. progression factors in, 757–758, 758f  
 sarcoidosis vs., 762, 764, 764t, 776  
 T-cell subsets in, 761  
 usual interstitial pneumonia vs., 764
- Hypersensitivity vasculitis, 812d, 812–813, 814f
- Hypertension, pulmonary. *See* Pulmonary hypertension.
- Hypothermia, immersion, 189
- Hypoxia  
 alveolar  
   in pulmonary hypertension, 293  
   right ventricular hypertrophy in, 293  
 chronic, in sudden infant death syndrome, 195
- I**
- Immersion hypothermia, 189
- Immersion injury. *See also* Drowning; Near-drowning.  
 acute pulmonary death due to, 188–190
- Immotile cilia syndrome (Kartagener syndrome), 71, 86, 99. *See also* Ciliary dyskinesia, primary.
- Immune complex disease, with vasculitis, diffuse alveolar hemorrhage in, 728f, 728–729
- Immunocompromised patient(s). *See also* Acquired immunodeficiency syndrome (AIDS).  
 aspergillosis in, Color Figs. 43-5–43-6, 482–483, 483f–484f  
 cytomegalovirus pneumonia in, 465  
 fungal infections of, 482–484, 485  
 herpes simplex virus respiratory infection in, 465  
 lymphoid lesions in, 639–640  
 toxoplasmosis in, 489  
 transbronchial biopsy in, 46, 47f  
 varicella-zoster viral pneumonia in, Color Fig. 42-1, 467–468
- Immunoglobulin A (IgA), secretory, branchial gland synthesis of, 5
- Immunopathologic techniques, for biopsy specimens, 46
- Immunostain(s), for bronchogenic adenocarcinoma(s), 532
- Imprint smears, other cytology specimens vs., 27, 28t
- Inborn errors of metabolism, involving lungs, 105, 106d
- Indoor air pollution, 887–888
- Infarction, pulmonary, Color Fig. 18-3, 174, 174f  
 in adult respiratory distress syndrome, 133  
 lung abscess in, Color Fig. 18-3, 174
- Infection(s). *See also under specific type by diagnosis or organism.*  
 pulmonary, cytologic diagnosis of, 33
- Infiltrate(s)  
 acute pulmonary, transbronchial biopsy for, 46, 47f  
 chronic interstitial, transbronchial biopsy for, 46–47
- Inflammatory pseudotumor, 711–716  
 differential diagnosis of, 715–716  
 etiology of, 715  
 fibrous histiocytoma type, 714f, 714  
 historical, 711  
 lymphoma vs., 715  
 lymphoplasmacytic type, 714f, 714  
 organizing pneumonia type, 712–713, 713f  
 pathologic findings in, 711–715  
   electron microscopic, 714–715  
   gross, 711–712, 712f  
   immunohistochemical, 715  
   light microscopic, 712–714, 713f–715f  
 pseudolymphoma vs., 715  
 pulmonary plasmacytoma vs., 715  
 sclerosing hemangioma vs., 715–716  
 sites and incidence of, 711  
 studies on, summary of, 711, 712t  
 synonyms for, 711  
 treatment and prognosis in, 716



- Influenza virus infection(s), Color Fig. 42-3, 468-469  
 necrotizing tracheobronchitis as, 469  
 pneumonia as, Color Fig. 42-3, 469
- Inhalation injury, 159-169, 160d. *See also individual disorders and irritants.*  
 in thermal burns, 184-186. *See also under Burns.*
- Iniencephaly, ectopia of lungs in, 74
- Injury, response to, 21-23  
 disruption of homeostasis as, 21  
 epithelial loss with intact basement membrane as, 21  
 epithelial loss with ulceration of basement membrane as, 21-22
- Innominate artery(ies), anomalous origin of, tracheal stenosis due to, 66-67, 67f
- Inorganic dust exposure, alveolar macrophages in, 30
- Inorganic materials, in biopsy specimens, analytic methods for, 46
- Insecticide(s), organophosphate, occupational asthma due to, 162
- Insect protein(s), hypersensitivity pneumonitis due to, 756f
- $\beta$ -Interferon, sarcoidal reaction to, 153
- Interstitial emphysema  
 bleb in, 279  
 definition of, 276
- Interstitial fibrosis. *See also Interstitial pneumonia, usual (UIP).*  
 adenocarcinoma in, 541, 542f  
 in asbestosis, 398, 399f  
 bronchioloalveolar adenocarcinoma in, 541, 542f  
 risks of lung cancer in, 527  
 in systemic sclerosis, 784, 786f
- Interstitial infiltrate(s), chronic, transbronchial biopsy for, 46-47
- Interstitial lung disease  
 chronic, open lung biopsy for, 42, 43, 44f  
 gastroesophageal reflux and, in children, 364-366  
 biopsy results in, 365  
 clinical and roentgenographic features of, 364, 365t  
 pathogenesis of, 366-367, 367f  
 mixed intraalveolar and, 357-368. *See also individual types [e.g., Bronchiolitis obliterans organizing pneumonia (BOOP)].*
- Interstitial pneumonia, 325-339  
 acute (AIP), Color Figs. 31-1-31-3, 326t, 326-327, 327f-328f  
 chronic interstitial pneumonia vs., 326, 326t  
 diffuse alveolar damage in, 326  
 pathologic findings in, Color Figs. 31-1-31-3, 326-327, 327f-328f
- chronic  
 acute interstitial pneumonia vs., 326, 326t  
 with specific histologic features, 341-355, 342d  
 concepts and terminology in, 326  
 desquamative, Color Figs. 32-1-32-2, 341-342, 342d, 342f-343f  
 asbestosis vs., 400  
 etiologies of, 342, 343d  
 gross pathologic findings in, 342, 342f  
 histopathologic findings in, Color Figs. 31-1-32-2, 342, 343f  
 lesions that mimic, 342d, 342-343  
 usual interstitial pneumonia vs., 341-342
- desquamativelike reaction, 342d, 342-343
- diffuse, in rheumatoid arthritis, 782, 782f
- giant cell, 343-344, 344f-345f  
 differential diagnosis of, 344  
 histopathologic findings in, 344, 344f-345f  
 in occupational exposure to hard metal, Color Fig. 37-1, 343-344, 413-414, 414f  
 viral-related, 344, 345f
- lymphocytic (LIP), 344-345, 345f, 635-636, 636f  
 in AIDS, 345, 513-514, 514f  
 drug-associated, 152-153, 154f  
 histopathologic findings in, 344-345, 345f  
 hypersensitivity pneumonitis vs., 764  
 as lymphoproliferative disorder, 345  
 in rheumatoid arthritis, 782, 783f  
 in systemic lupus erythematosus, 783, 784f
- progressing to pulmonary fibrosis, mastocytosis in, 87
- usual (UIP), 327-330  
 in asbestosis, 330, 330f  
 bronchiolitis obliterans organizing pneumonia vs., 359, 360t  
 chemodectomas in, 334, 335f  
 chest radiography in, 327  
 clinical presentation in, 327  
 in collagen-vascular disease, 330  
 computed tomography in, 327  
 desquamative interstitial pneumonia vs., 341-342  
 differential diagnosis of, 328  
 diffuse alveolar damage vs., 135, 136t  
 drug-induced, Color Fig. 16-1, 149-150, 150d, 151f  
 cytotoxic, Color Fig. 16-1, 149, 150d  
 alveolar cellular atypia in, Color Fig. 16-1, 149  
 chronic inflammation in, 149  
 fibrosis in, 149  
 noncytotoxic, 150, 150d, 151f  
 due to gold or penicillamine therapy, 330  
 gross pathology in, 327-328, 329f  
 histopathologic findings in, 328, 329f
- honeycomb lung with cobblestoning in, 328, 329f
- hypersensitivity pneumonitis vs., 764
- intimal fibrosis and medial hypertrophy in, 333, 333f
- lung carcinoma and, 336-337
- meningotheial-like body in, 334, 336f
- metaplastic squamous epithelium in, 332f-333f, 333
- pathogenesis of, 329-330
- in progressive systemic sclerosis, 330
- pulmonary scarring in, nonspecific features of, 332f-336f, 333-334
- in rheumatoid arthritis, 330, 782, 782f
- smooth muscle proliferation in, 333-334, 334f
- special studies for, 331
- synonyms for, 326
- in systemic lupus erythematosus, 330, 783
- transbronchial vs. open lung biopsy for, 331
- tumorlets in, 334, 334f-335f
- Interstitial pneumonia-like pattern, usual, 330-331, 331f-332f, 331t
- Interstitialium, alveolar, 10
- Intraalveolar disease, mixed interstitial and, 357-368. *See also individual types, e.g., Bronchiolitis obliterans organizing pneumonia (BOOP).*
- Intrapulmonary lymph node(s), 638
- Intrapulmonary thymoma, 638
- Intrathoracic rib, in children, 90
- Intubation, tracheal, complications of, Color Fig. 73-1, 845, 845f
- Iron, colloidal, for mesothelioma, 664
- Irritant fume(s), occupational asthma due to, 164d, 164-166
- Irritant gas(es), occupational asthma due to, 167d, 167-168
- Ischemic heart disease, pulmonary venous hypertension in, 204, 208f
- Isocyanate(s), occupational asthma due to, 163
- Ivemark asplenia syndrome, 71
- J**  
 Jeune syndromes type 1 and 2, 75
- K**  
 Kaolinite, 391  
 Kaolin workers, pneumoconiosis in, 390-391  
 Kaposi sarcoma, 514-515, 515f-516f  
 epidemic, in AIDS, 515  
 pulmonary, 515, 515f-516f  
 pulmonary angiosarcoma vs., Color Fig. 56-5, 649, 650f

- Kartagener syndrome (immotile cilia syndrome), 71, 86, 99. *See also* Ciliary dyskinesia, primary.
- Katayama fever, in schistosomiasis, 494
- K cell(s). *See* Kulchitsky-like cell(s) (K cell; Freyter cell).
- Ketouria, branched chain (maple syrup urine disease, leucinosi), 112
- Kidney(s), intrathoracic, 91
- Klebsiella pneumoniae* (Friedländer) pneumonia, 430
- Klippel-Feil syndrome, ectopia of lungs in, 74
- Kluyveromyces fragilis*, 485
- Kulchitsky cell(s)  
in small cell carcinoma, 555–556  
ultrastructure of, 4, 6f
- Kulchitsky-like cell(s) (K cell, Freyter cell), in cytologic diagnosis, 29
- Kviem-Siltzbach test, for sarcoidosis, 775
- Kyphoscoliosis, 875–876
- Kyphosis, 875
- L**
- Laceration(s), pulmonary, 181–182
- Lagochichascri minor*, 500
- Langerhans cell(s)  
in bronchioloalveolar carcinoma, 539  
in pulmonary eosinophilic granuloma, Color Fig. 32-3, 346
- Large cell carcinoma, 571–579  
adenocarcinoma vs., 575, 575f  
carcinoid tumors vs., 576–577  
clear cell, metastatic renal cell adenocarcinoma vs., 578  
clinical manifestations of, 578  
differential diagnosis of, 574–578  
fine needle aspiration in, 35–36  
large cell neuroendocrine carcinoma vs., 587, 588t  
mesothelioma vs., 577–578  
metastasis of, 691–692, 692t  
mixed small cell and, 559, 562f, 591  
neuroendocrine, 586–589  
clinical features of, 586  
differential diagnosis of, 587  
electron microscopy for, 589  
flow cytometry for, 589  
immunohistochemistry for, 589  
large cell carcinoma vs., 587  
pathologic features of, 587, 588f  
small cell carcinoma vs., 587, 588t  
with neuroendocrine differentiation, 587. *See also* Large cell carcinoma, neuroendocrine.  
pathologic findings in, 571–574  
cell clustering in, 571, 572f  
cellular margins in, 572, 573f  
clear cytoplasm in, 572, 573f  
diffuse sheets or broad cords in, 571, 572f  
giant cell, 572–573  
immunocytochemical, 573–574  
light microscopy in, 571–573, 572f–573f  
loss of cohesion in, 571, 572f  
nuclear features in, 571–572, 572f  
pleomorphic variant in, 572–573, 573f  
ultrastructural, 573, 574f  
pleomorphic, differential diagnosis of, 578  
small cell carcinoma vs., 575–576, 577f  
squamous cell carcinoma vs., 575, 576f  
undifferentiated, definition of, 571
- Larsen syndrome, congenital pulmonary hypoplasia in, 76
- Larva migrans, visceral, 499
- Laryngeal atresia, congenital, 64
- Laryngeal cleft, congenital, 63–64  
occult posterior, 64
- Laryngeal web, congenital, 64
- Laryngocele(s), congenital, 65
- Laryngomalacia, congenital, 63, 65
- Laryngotracheal papillomatosis, juvenile, 612–613  
squamous cell carcinoma arising in, 613, 613f
- Laryngotracheoesophageal cleft, congenital, 63–64
- Larynx  
in burn inhalational injury, 184  
congenital malformations of, 63–65  
embryonic development of, 63, 64f
- Lavage, bronchoalveolar. *See* Bronchoalveolar lavage (BAL).
- Left heart abnormality(ies), in emphysema, 282
- Left ventricular diastolic dysfunction, pulmonary venous hypertension in, 204–205
- Left ventricular diverticulum syndrome, 91
- Left ventricular systolic dysfunction, pulmonary venous hypertension in, 204
- Legionellosis, Color Fig. 39-2, 435–437, 436f–437f  
clinical presentation in, 435  
diagnosis and treatment in, 436–437  
gross pathologic findings in, 435–436, 436f  
microscopic pathologic findings in, Color Fig. 39-2, 436, 436f–437f  
virulence factors in, 435
- Leiomyoma(s)  
benign metastasizing, 707, 708f  
pulmonary, 645–646, 646f  
intrapulmonary localized fibrous tumor vs., 646  
neurofibroma vs., 645
- Leiomyosarcoma  
pulmonary, Color Fig. 56-3, 647–648, 648f  
uterine, metastasis from, 705
- Leishmania donovani*, 492
- Leishmaniasis, pulmonary, 492
- Leptospirosis, 441
- Leucinosi (maple syrup urine disease, branched chain ketonuria), 112
- Leukemia  
eosinophilic, 752  
pulmonary involvement in, 637–638, 638f
- Leukodystrophy, metachromatic (sulfatide lipidosis), 111
- Lignac-Fanconi disease (cystine storage disease, cystinosis), 112
- Limb(s), metastasis to, 698
- Lines of Zahn, in pulmonary thromboembolism, Color Fig. 18-2, 172
- LIP. *See* Interstitial pneumonia, lymphocytic (LIP).
- Lipid material(s), aspiration of, 718
- Lipidosis  
glucosylceramide. *See* Gaucher disease (glucosylceramide lipidosis).  
glycosphingolipid. *See* Fabry disease (glycosphingolipid lipidosis).  
sphingomyelin-cholesterol. *See* Niemann-Pick disease (sphingomyelin-cholesterol lipidosis).  
sulfatide (metachromatic leukodystrophy), 111
- Lipoid granuloma, 718
- Lipoid pneumonia, endogenous, Color Fig. 33-1, 360–361, 361d, 362f–362f  
in children with gastroesophageal reflux, 365, 365t
- Lipoma, pulmonary, Color Fig. 56-1, 646–647
- Liposarcoma, 651
- Listeriosis, 440–441
- Liver, metastasis to, 694, 696f–697f, 697
- Liver embolus(i), pulmonary hypertension due to, 233
- Lobe(s)  
anatomy of, gross, 1  
congenital polyalveolar, 79, 80f
- Lobule(s)  
primary, definition of, 6  
secondary, anatomic definition of, Color Fig. 1-2, 6, 6f
- Lochgoilhead fever, 435
- Löffler-like syndrome, in schistosomiasis, 494
- Löffler syndrome (acute transient eosinophilic pneumonia), 745, 746d, 746f  
future research on, 885  
parasite-associated, 750
- Low-flow states. *See* Pulmonary circulation, low flow.
- Lung(s)  
aging, 276  
characteristics of, 20–21  
biochemical, 21  
functional, 21  
morphologic, 20–21  
anatomy of, gross, 1  
arc welder's, Color Fig. 37-3, 416

- bauxite (Shaver disease), 415  
 carcinoma of. *See* Carcinoma(s), lung.  
 congenital malformation of, 73–76  
 connective tissues of, 11  
   axial, 11  
   parenchymatous, 11  
   peripheral, 11  
 ectopia of, 74  
 elastic fibers of, 11  
 embryonic development of, 15, 17f  
 epithelium of, in injury response, res-  
   toration and obliteration of,  
   22–23  
 fetal development of, 15–19  
   canalicular stage of, 15, 16f  
   pseudoglandular stage of, 15, 16f  
   terminal sac or alveolar stage of, 15,  
   16f  
 fibrous skeleton of, 11  
 gray-iron foundry worker's, Color Fig.  
   37-4, 416  
 growth and development of, 19  
   mechanisms of, 19–20  
 hematite miner's, 416  
 honeycomb. *See* Honeycomb lung.  
 horseshoe, 76  
 hyperlucency of  
   congenital (Swyer-James syndrome,  
   Macleod syndrome), 83  
   bronchiectasis in, 305, 306f, 307  
   unilateral, as complication of radia-  
   tion therapy, 145  
 injury response in, 21–23  
 lymph nodes in, 526f  
 neural supply of, 12  
 neuroglial nodules of, 76  
 organogenesis of, 15–19  
 perinatal adaptation of, 19  
 resection of, compensatory overgrowth  
   in, 19  
 reticulin fibers of, 11  
 rhabdomyomatous dysplasia of, 76  
 sandstorm, 350  
 smooth muscle bundles of, 11  
 squamous cell carcinoma of, in coke  
   oven workers, 381, 382  
 structure and function of, 1–14  
 transplantation of. *See under* Transplan-  
   tation.  
 vasculature of, 11–12. *See also* *individ-*  
   *ual vessels.*  
   mechanisms of growth and develop-  
   ment of, 20  
 weight of, 1  
 Lung cancer. *See* Carcinoma(s);  
   Tumor(s).  
 Lupus erythematosus, systemic, 782–783  
   bronchiolitis obliterans in, 783, 784f  
   lymphocytic interstitial pneumonia in,  
   783, 784f  
   pulmonary hypertension in, 212  
   pulmonary vascular disease in, 783,  
   785f–786f  
   usual interstitial pneumonia in, 330,  
   783  
 Lymphadenopathy  
   angiimmunoblastic, 637  
   bilateral hilar, in sarcoidosis, 768  
 Lymphangiectasia, pulmonary, congeni-  
   tal, Color Fig. 9-1, 85, 872,  
   872f  
 Lymphangioliomyomatosis, pulmonary,  
   347–348, 349f–350f  
   atypical smooth muscle cells in, 348  
   clinical manifestations of, 347  
   pathologic findings in, 347–348,  
   349f–350f  
   therapy in, 348  
 Lymphangioma(s), pulmonary (alveolar  
   adenoma), 541, 541f,  
   683–684, 684f  
 Lymphangiomyomatosis, pulmonary,  
   congenital (pulmonary muscular  
   hyperplasia, muscular pulmo-  
   nary cirrhosis), 86  
 Lymphangitic carcinomatosis, 701, 702f  
   pulmonary edema in, 120f  
 Lymphatic(s), pulmonary  
   anatomy of, 12, 17–18  
   deep, 17  
   in pulmonary venous hypertension,  
   209  
   superficial, 17  
 Lymph node(s)  
   intrapulmonary, 638  
   in lung, 526f  
   in mediastinum, 526f  
   metastasis to, 693, 693f–694f. *See also*  
   Metastatic lung cancer.  
 Lymphocytic angiitis and granulomatosis,  
   benign, 634, 635f, 836  
 Lymphocytic interstitial pneumonia  
   (LIP), 152–153, 154f,  
   344–345, 345f. *See also* Intersti-  
   tial pneumonia, lymphocytic  
   (LIP).  
 Lymphoepithelial carcinoma, 553, 553f  
 Lymphoid hyperplasia, drug-associated,  
   152, 152f  
 Lymphoid lesion(s)  
   angiocentric, 634–635, 635f  
   in immunocompromised patients,  
   639–640  
   of lung, benign and malignant, 631,  
   632d  
 Lymphoma(s), 631–635  
   angiocentric, 634  
   angiotrophic, 635  
   arising in MALT (maltoma), 633  
   classification of, difficulties in, 633,  
   634d  
   diffuse large cell, of mediastinum, 858,  
   859f  
   Hodgkin  
     of mediastinum, 858  
     pulmonary  
       in AIDS, 516  
       primary vs. secondary, 637, 637f  
       Wegener granulomatosis vs., 800  
   inflammatory pseudotumor vs., 715  
   large cell immunoblastic, 633, 634f  
   lymphoblastic, of mediastinum, 858  
   non-Hodgkin, pulmonary, in AIDS,  
     515–516  
   primary vs. secondary, 633–634  
   pseudolymphoma vs., 631–632, 632t,  
   633f  
   T-cell, 634  
 Lymphomatoid granulomatosis. *See*  
   Granulomatosis, lymphomatoid.  
 Lymphomatosis, intravascular, 635  
 Lymphoproliferative disease. *See also* *indi-*  
   *vidual types [e.g. Lymphoma(s)].*  
   evaluation of, Color Figs. 55-1–55-2,  
   639, 639d  
   immunomicroscopy for, Color Fig.  
   55-1, 639  
   light chains in, Color Fig. 55-2, 639  
   molecular biology in, 639  
   lymphomatoid granulomatosis as,  
   836–837  
   Wegener granulomatosis vs., 798–800  
**M**  
 Macleod syndrome (Swyer-James syn-  
   drome, hyperlucency of lung),  
   83  
   bronchiectasis in, 305, 306f, 307  
 Macrophage(s)  
   alveolar, 10–11, 11f  
   in cigarette smokers, 30  
   in cytologic diagnosis, 30  
   in inorganic dust exposure, 30  
   pigmented, in respiratory bronchiolitis,  
   320, 321f  
 Majewski syndrome, 75  
 Malakoplakia, in AIDS, 512–513, 513f  
 Malaria, pulmonary, 490–491, 491f  
*Malassezia furfur* pulmonary infection,  
   485, 486f  
 Malinosculation, 89  
 Maltoma(s), 633  
*Mammomonogamus laryngeus*, 500  
 Manganese pneumonitis, 166  
*Mansonella perstans*, 500  
 Maple bark stripper's disease, 762. *See*  
   also Hypersensitivity pneu-  
   monitis.  
 Maple syrup urine disease (leucinosi-  
   s, branched chain ketonuria), 112  
 Marfan syndrome, bronchiectasis in, 98  
 Marie-Strümpell disease (ankylosing  
   spondylitis), 788, 876  
 Mast cell tumor(s), pulmonary, 638–639  
 Mastocytosis, in interstitial pneumonitis,  
   progressing to pulmonary  
   fibrosis, 87  
 Measles pneumonia, Color Fig. 42-4,  
   469  
 Meat particle(s), in cytologic diagnosis,  
   31  
 Mediastinitis  
   fibrosing, pulmonary hypertension in,  
   213  
   due to infectious agents, 853  
   noninfectious sclerosing, 853–854,  
   854f–855f

- Mediastinoscopy, 42  
 Mediastinum  
   benign neoplasms of, 854–856  
   benign neurogenic tumor of, Color Fig. 74-3, 856, 856f  
   cysts of, 859  
     congenital vs. acquired, 859  
   embryonal carcinoma of, Color Fig. 74-5, 857  
   germ cell tumors of, Color Fig. 74-5, 857–858, 858f  
   infectious and reactive inflammatory conditions of, 853–854  
   lymph nodes in, 526f  
   lymphomas of, 858–859, 859f  
   malignant neoplasms of, 856–859  
   metastasis to, 859  
   pathology of, 853–861, 854t  
   sarcoma of, 858  
   seminoma of, 857, 858f  
   solid fibrous tumors of, 856  
   teratoma of, mature, Color Fig. 74-2, 855–856  
   thymoma of, Color Fig. 74-1, 854–855, 855f–856f  
   tumoral invasion of, 859  
 Melanoma, malignant  
   carcinoid tumor vs., 586  
   metastatic, 682, 706, 707f  
   primary, 682–683  
     differential diagnosis of, 682–683  
     origin of, 683  
     pathologic findings in, 682, 683f  
 Melioidosis, 440  
 Membranous bronchiole(s). *See* Bronchiole(s).  
 Mendelson syndrome (gastric acid aspiration), 186–187  
 Meningeal carcinomatosis, metastatic, 694  
 Meningioma  
   benign metastasizing, 707–708, 708f  
   pulmonary, primary, 677–679  
     immunohistochemical staining in, 679, 679f  
     location of, 677–678  
     origin of, 679  
     pathologic findings in, 678, 678f–679f  
     ultrastructural findings in, 678–679  
 Meningothelial-like nodule(s), minute pulmonary, 675–677, 677f–678f  
   differential diagnosis of, 677  
   historical, 675  
   locations of, 675  
   origin of, 676–677  
   pathologic findings in, 676, 677f–678f  
 Mercury pneumonitis, 165  
 Mesenchymal tumor(s), 645–656, 646t.  
   *See also individual types.*  
   benign, 645–647  
   combined, Color Fig. 56-6, 653, 653f–654f  
   malignant, 647–655  
   mesothelioma in situ vs., 660, 660t  
   nonepithelial abnormalities in, 660, 660t  
   lubrication by, 658  
   normal reaction to injury in, 658–659  
   regeneration of, 658–659  
 Metachromatic leukodystrophy (sulfatide lipidosis), 111  
 Metal fume fever (copper fever, brass fever, Monday morning fever), 164, 165f  
 Metalloconiosis, 411–422  
 Metal salts, occupational asthma due to, 163  
 Metastasis  
   from adnexal carcinoma of skin, 704  
   from adult soft tissue sarcoma, 704–705, 705f–706f  
   from benign giant cell tumor of bone, 708, 708f  
   from benign metastasizing leiomyoma, 707, 708f  
   from benign metastasizing meningioma, 707–708, 708f  
   from bone, 704, 705f  
   from breast carcinoma, 703–704, 704f  
   from cervical carcinoma, 703  
   from childhood sarcomas, 706, 707f  
   from choriocarcinoma, 703  
   from colon carcinoma, 702, 703f  
   ectopias vs., 708–709  
   from endometrial stromal sarcoma, 706, 706f  
   from epithelial neoplasms, 701–704  
   from extrapulmonary tumors, 701–710  
     primary vs., 701  
     prognostic indicators in, 701  
     resection of, 701  
   from female reproductive tract sarcomas, 705–706, 706f  
   fine needle aspiration for, 36, 37f–38f  
   from gastrointestinal carcinomas, 702, 703f  
   from genitourinary tract carcinomas, 703, 703f–704f  
   from head and neck cancer, 702, 702f  
   from malignant melanoma, 682, 706, 707f  
   to mediastinum, 859  
   from osteogenic sarcoma, 704, 705f  
   from ovarian carcinoma, 703  
   from papillary thyroid carcinoma, 614f, 614–615, 702, 702f  
   from prostatic carcinoma, 703, 704f  
   from renal cell carcinoma, 703, 703f  
     to bronchus, 849, 850f  
     clear cell large cell carcinoma vs., 578  
     fine needle aspiration of, 37f  
   from salivary gland tumors, 702  
   from testicular carcinoma, 703  
   from thymoma, 704  
   from urinary bladder transitional cell carcinoma, 703  
   from uterine carcinoma, 703  
 Mesenchymoma, 655  
 Mesothelial cell(s), ultrastructure of, 13  
 Mesothelioma, 401, 660–666  
   adenocarcinoma vs., 665, 667f  
   asbestos-related, 400–401, 657–658, 658f, 659t, 660–661  
   benign, 666–669  
     cystic, 668–669  
   biphasic, Color Fig. 57-6, 661, 662t, 663  
   clinical features in, Color Figs. 57-2–57-6, 661–663, 662f–663f, 662t  
     lung encasement as, Color Fig. 57-3, 661  
     pleural masses as, Color Fig. 57-2, 661  
   diagnosis of, 658, 663–666  
     Alcian blue for, 664  
     CEA testing in, 664  
     colloidal iron for, 664  
     electron microscopy for, 665, 665f–666f  
     EMA positivity in, 664–665, 665f  
     histochemical special stains for, 664  
     immunocytochemistry for, 663–664  
     mucicarmine for, 664  
     periodic acid-Schiff with diastase for, 664  
   reactive mesothelial cells vs., 663–664  
   ultrastructural features in, 665, 665f–666f  
   vimentin positivity in, 664  
   differential diagnosis of, electron microscopy in, 662, 663t  
   epidemiology of, 661  
   epithelioid, 661, 662t  
   etiology of, 660–661  
   fibrous, 856  
   histologic features of, 401  
   large cell carcinoma vs., 577–578  
   lymphohistiocytoid, 662  
   metastatic adenocarcinoma vs., 871f, 872  
   papillary, 668  
   pathogenesis of, future research on, 886  
   pericardial, 401  
   peritoneal, 401  
   pleural fibroplasia vs., 871, 871f  
   sarcomatoid, Color Fig. 57-5, 661, 662, 662t  
     ultrastructure of, 665–666  
   in situ, 660, 661f  
   atypical mesothelial hyperplasia vs., 660, 660t  
   tissue mineral fiber content analysis in, 405, 406t, 407f  
   tubulopapillary, Color Fig. 57-4, 662  
 Mesothelium  
   embryonic derivation of, 658  
   hyperplasia of, atypical, 659–660, 660t  
   epithelial abnormalities in, 659–660, 660t

- from uterine leiomyosarcoma, 705  
from Wilms tumor, 706, 707f
- Metastatic adenocarcinoma, mesothelioma vs., 871f, 872
- Metastatic calcification, alveolar microlithiasis vs., Color Fig. 32-8, 351
- Metastatic lung cancer, 691–699  
to adrenal glands, 697  
to bone, 694, 696f  
to bone marrow, 694, 696f  
to breast, 698  
to central nervous system, 693–694, 695f  
extrathoracic, symptoms of, 691  
intrathoracic, symptoms of, 691  
to limbs, 698  
to liver, 694, 696f–697f, 697  
to lymph nodes, 693, 693f–694f  
cancer staging and, 693  
determination of primary in, 693, 694f  
histopathologic findings in, 693, 693f  
locations of, 693  
patterns of spread in, 691  
hematogenous, 691  
by histologic type, 691–692, 692t  
lymphogenous, 691  
by organ systems, 692–698  
tubular, 691  
to pleura, 697–698  
to skin, 698, 698f  
to small bowel, 697  
to testis, 698  
to thyroid gland, 698
- Metastrongylus elongatus*, 500
- Methane, as asphyxiant or explosive gas, 166
- Michaelis-Guttman body(ies), in malakoplakia, 512, 513f
- Microlithiasis  
alveolar, Color Figs. 32-4–32-8, 349–351, 350f–352f. *See also* Alveolar microlithiasis.  
pulmonary, idiopathic, 85
- Microscopy  
electron, for biopsy specimens, 46  
polarization, for biopsy specimens, 46
- Microsporidiosis, pulmonary, in AIDS, Color Fig. 45-3, 508
- Microvascular sample, other cytology specimens vs., 27, 28t
- Midtracheal stenosis, with ring tracheal cartilages, in Down syndrome, 66
- Mineral dust-associated small airway disease, 321
- Mineral fiber(s), man-made, 417t, 417–419
- Mineral wool fibers, lung disease due to, 417t, 419
- Mitral stenosis  
pulmonary intravascular pressure in, 204, 205f  
pulmonary venous hypertension in, 204, 206f–207f
- Monday morning fever (metal fume fever, copper fever, brass fever), 164
- Monge disease. *See* Mountain sickness.
- Morgagni hernia, 90
- Mounier-Kuhn syndrome (tracheobronchomegaly), 85  
bronchiectasis in, 304
- Mountain sickness. *See also* High altitude.  
acute, 255  
malignant cerebral, 255  
chronic (Monge disease), 255–258  
blunted hypoxic ventilatory response in, 256, 258  
carotid body tumor in, 256, 258f  
classifications of, 256  
clinical findings in, 255  
historical, 255  
laboratory findings in, 255–256  
in Peru, 255, 257f  
treatment of, 256
- Moxalactam, alveolar hemorrhage due to, 155
- Mucicarmine, for mesothelioma, 664
- Mucinous cystic tumor (cystadenoma), pulmonary, 540f, 540–541
- Mucocele, bronchial atresia in, 301, 302f–303f
- Mucociliary apparatus, cellular structure of, 5–6
- Mucoepidermoid carcinoma  
of bronchial epithelium, 614  
of bronchial glands, 603–605  
differential diagnosis of, 603, 606t  
high-grade, 603, 605f  
adenosquamous carcinoma vs., 603, 606t  
poorly differentiated squamous cell carcinoma vs., 603  
low-grade, Color Fig. 52-2, 603, 603f–605f  
mucous gland adenoma vs., 603  
prognosis in, 605  
of trachea, 847, 848f
- Mucopolysaccharidosis(es), 110–111
- Mucormycosis, pulmonary, Color Fig. 43-7, 484
- Mucostasis. *See also* Curschmann spiral(s).  
in cytologic diagnosis, 30
- Mucous cell(s). *See* Goblet cell(s).
- Mucous gland(s)  
hypertrophy of  
in bronchiectasis, 301, 303  
gland-to-wall ratio for, 301, 303  
in normal airway, 287–288
- Mucous gland adenoma, 597, 598f–599f  
low-grade mucoepidermoid carcinoma vs., 603
- Mucous granular cell(s)  
bronchial mucosal, in cytologic diagnosis, 29–30  
bronchiolar epithelial, in cytologic diagnosis, 32–33
- Mucus hypersecretion  
in chronic bronchitis, 287, 288d  
experimental models of, 288d
- Muscular pulmonary cirrhosis (pulmonary lymphangiomyomatosis, pulmonary muscular hyperplasia), 86
- Mycetoma  
*Acremonium*, 485  
*Pseudoallescheria boydii*, 485
- Mycobacteria  
classification of, 451, 452t  
histologic identification of, 453  
nontuberculous, 451, 452t, 458–462  
in AIDS, 511  
chronic progressive pulmonary disease due to, 459–460, 460f–461f  
radiographic features of, 460  
tuberculosis vs., 460, 460f–461f  
disseminated disease due to, 460–462, 461f  
in AIDS, 461  
in non-AIDS patients, 460–461  
organisms in, 460  
pathologic findings in, 461f, 462  
tuberculosis complex, 451, 452t  
*Mycobacterium avium-intracellulare*, 459  
*Mycobacterium avium-intracellulare* infection  
in AIDS, 511  
cytologic diagnosis of, Color Fig. 3-3, 33  
*Mycobacterium gordonae* infection, in AIDS, 511  
*Mycobacterium kansasii* infection, in AIDS, 511  
*Mycobacterium tuberculosis*, 451–452, 453.  
*See also under* Tuberculosis.  
drug resistant, 511
- MYC oncogene, in pulmonary carcinogenesis, 528, 528t
- Mycoplasma fermentans*, as cofactor in AIDS, Color Fig. 45-6, 504, 504f, 510
- Mycoplasma pneumoniae* infection, 470–471, 471f  
in AIDS, 510–511
- Mycotoxicosis, pulmonary (organic toxic dust syndrome, silo unloader's syndrome), 163
- Myoepithelioma, bronchial, 598–599, 600f
- N**
- Naegleria fowleri*  
in AIDS, 508  
pulmonary, 492
- Nasal involvement, in Wegener granulomatosis, 797, 799f, 829, 830f
- Nasal septum, biopsy of, in primary ciliary dyskinesia, 101
- Near-drowning, 188–189  
delayed pulmonary manifestations in, 189  
pathologic findings in, 189  
pathophysiology of, 189  
terminology for, 188, 189d

- Necator americanus*, eosinophilic pneumonia due to, 750, 751t
- Nematode(s), 497–500  
pulmonary eosinophilia due to, 750, 751t
- Neoplasm(s), malignant, pulmonary hypertension in, 213, 213f
- Netrotizing vasculitis, drug-induced, 155
- Neural supply, of lung(s), 12
- Neurenteric cyst(s), congenital, 80, 82f
- Neurilemoma(s), 652
- Neuroectodermal tumor(s)  
malignant peripheral, thoracopulmonary, Color Fig. 76-1, 876–877, 877f  
primary, 652, 653f
- Neuroendocrine carcinoma, large cell, 586–589, 588f, 589t
- Neuroendocrine cells, pulmonary, idiopathic diffuse hyperplasia of, 586
- Neuroendocrine system, diffuse, embryonic derivation of, 555
- Neuroendocrine tumor(s). *See also* Carcinoid tumor(s); Small cell carcinoma.  
classification of, 581, 582d  
high-grade, 586–594  
low-grade, 581–586
- Neuroepithelial body(ies), 556  
ultrastructure of, 4
- Neurofibroma(s), 652  
pulmonary, leiomyoma vs., 645
- Neurogenic tumor(s), 652
- Neuroglial nodule(s), of lung, 76
- Neuron-specific enolase, in small cell carcinoma, 561–562
- Neutrophil(s)  
in pathogenesis of adult respiratory distress syndrome, 134  
in pathogenesis of pulmonary oxygen toxicity, 149
- Nickel sulfate, occupational asthma due to, 163
- Niemann-Pick disease (sphingomyelin-cholesterol lipidosis), 107–109  
alveolar foamy cells in, 109, 109f–110f  
biochemical findings in, 109  
clinical features of, 107–109  
diagnosis of, 109  
pulmonary pathologic findings in, 109, 109f–110f
- Nitric acid, as irritant gas, 167–168
- Nitrofurantoin  
bronchiolitis obliterans organizing pneumonia due to, 154f  
lymphoid interstitial pneumonia due to, 153, 154f
- Nitrogen, as asphyxiant gas, 166
- Nitrogen oxides, as irritant gases, 167–168
- Nocardia asteroides* infection, cytologic diagnosis of, 33
- Nocardiosis  
in AIDS, 512  
pulmonary, Color Figs. 40-5–40-6, 446f, 446–447  
clinical presentation in, 446  
diagnosis of, 447  
gross and microscopic findings in, 446, 446f–447f  
stains for organisms in, Color Figs. 40-5–40-6, 446–447
- Nodular fasciitis, of chest wall, Color Fig. 76-2, 877, 879f
- Nodule(s)  
anthracotic, 373, 374, 375f  
fibrocaceous, in histoplasmosis, Color Fig. 43-1, 477  
neuroglial, of lung, 76  
papillary, resembling bronchioloalveolar carcinoma, 541  
pulmonary  
biopsy for, 47  
in coccidioidomycosis, 478  
rheumatoid, 718  
silicotic, Color Fig. 35-1, 388, 388f–389f  
progressive massive fibrosis vs., 375
- Nonepithelial tumors, fine needle aspiration in, 36, 37f
- Non-small cell carcinoma  
fine needle aspiration for, 49–50  
transbronchial biopsy for, 49–50
- Nuclear encrustation (Azzopardi phenomenon), in small cell carcinoma, 557, 560f
- O**
- Oat cell carcinoma. *See* Small cell carcinoma.
- Obesity, respiratory complications of, 875
- Obesity hypoventilation syndrome, 875
- Occupational lung disease(s), 883–888.  
*See also* Asthma, occupational; Pneumoconiosis.  
occupational asthma as, 159–163  
occupational bronchitis as, 293
- Oil mist(s), lung disease due to, Color Fig. 37-5, 420, 420f
- Oligohydramnios, of renal agenesis, bilateral pulmonary hypoplasia in, 74–75
- Onchocerca volvulus*, 497
- Onchocercosis, pulmonary, 497
- Oncocytoma  
bronchial, 597–598  
carcinoid tumor vs., 583, 598
- Oncogene(s), in pulmonary carcinogenesis, 528t, 528–529
- Open lung biopsy, 42–43, 43f–44f  
for bronchiolitis obliterans organizing pneumonia, 42, 44f  
for granulomas, 42, 43f  
indications for, 42–43  
limited thoracotomy for, 42  
for pneumoconiosis, 49  
for pulmonary hypertension, 48–49  
thoracoscopy for, 42  
for usual interstitial pneumonia, 331
- Opisthorchis viverrini*, pulmonary, 495
- Opitz syndrome, 64
- Opportunistic infection(s). *See also* individual organisms; Immunocompromised patient(s).  
cytologic diagnosis of, 33
- Oral contraceptive(s)  
pulmonary hypertension due to, 155  
pulmonary thromboembolism due to, 171
- Organic toxic dust syndrome (pulmonary mycotoxicosis, silo unloader's syndrome), 163
- Organophosphate insecticide(s), occupational asthma due to, 162
- Oromandibular limb hypogenesis syndrome, congenital pulmonary hypoplasia in, 76
- Oropharyngeal bacterial pathogen(s), aspiration of, 186
- Osler-Weber-Rendu disease (hereditary hemorrhagic telangiectasia), pulmonary hemosiderosis in, 102, 102f
- Osmium bronchitis, 164–165
- Ossification, metaplastic, alveolar microlithiasis vs., 351, 351f–352f
- Osteogenesis imperfecta, congenital pulmonary hypoplasia in, 76
- Osteogenic sarcoma, metastasis from, 704, 705f
- Osteonecrosis, dysbaric (Caisson disease), 190
- Osteosarcoma, 651–652
- Ovarian carcinoma, metastasis from, 703
- Overlap syndrome, pulmonary hypertension in, 212
- Oxygen free radical(s)  
in pathogenesis of adult respiratory distress syndrome, 134  
in pulmonary oxygen toxicity, 140, 140f
- Oxygen toxicity, pulmonary, 139–143  
in animal models, 141  
clinical findings in, 142  
diffuse alveolar damage in, 142, 143f  
historical perspective on, 139–140  
hyaline membrane deposition in, 143, 143f  
mechanisms of, 140  
neonatal. *See* Bronchopulmonary dysplasia.  
neutrophils in, 140  
oxygen free-radical theory of, 140, 140f  
pathologic findings in, 142–143, 143f  
regional alveolar damage in, 142, 143f
- Ozone, 168, 884–885
- P**
- Panbronchiolitis, diffuse, 290, 320, 322f, 636–637

- Pancoast tumor  
 metastasis of, 691  
 squamous cell, 546–547, 548f
- Pancreas, cystic fibrosis of, 86
- Papillary adenocarcinoma, of bronchial epithelium, Color Fig. 53-2, 614, 614f
- Papillary adenoma, 540, 684–685, 685f
- Papillary nodule(s), resembling bronchioloalveolar carcinoma, 541
- Papillary squamous cell carcinoma, 613–614
- Papillary thyroid carcinoma, metastatic, 614f, 614–615, 702, 702f
- Papillary tumor(s), of surface epithelium, 609–615  
 benign, 609–612  
 classification of, 609, 611d  
 malignant, 613–615  
 pathologic findings in, 609, 610f  
 potentially malignant, 612–613
- Papilloma(s)  
 mixed, Color Fig. 53-1, 612, 612f  
 squamous, 609, 611f, 611–612  
 clinical findings in, 609, 611  
 histologic findings in, 611f, 611–612  
 transitional, 612
- Papillomatosis, laryngotracheal, juvenile, 612–613  
 squamous cell carcinoma arising in, 613, 613f
- Paracoccidioides brasiliensis*, 480
- Paracoccidioidomycosis, pulmonary, 480–481, 481f
- Paraganglioma, pulmonary, primary, 679  
 carcinoid tumor vs., 679
- Paragonimiasis, pulmonary, 492–493, 493f–494f
- Paragonimus westermani*, 492  
 eosinophilic pneumonia due to, 751t
- Parainfluenza virus infection, 469
- Paralysis, of diaphragm, 878–879, 880t
- Paraneoplastic syndromes, in small cell carcinoma, 566
- Paraquat  
 pulmonary toxicity due to, Color Fig. 19-3, 150, 191, 193f  
 toxic exposure to, 166
- Parasite-related eosinophilic pneumonia, 750–751, 751t
- Parasitic infection(s). *See individual organisms.*
- Parasympathetic nervous supply, of lungs, 12
- Parenchymal amyloidosis, nodular, Color Fig. 32-9, 352, 353f
- Parenchymal lung disease(s). *See also individual types, e.g., Emphysema.*  
 pulmonary hypertension in, 209–213
- Parrot fever (psittacosis), 473
- Particulate matter, aspiration of, 186, 187f
- Patent ductus arteriosus (PDA), at high altitude, 250
- Pathology, forensic. *See under Death, acute pulmonary.*
- Peanut(s), aspiration of, 187
- Pectus carinatum, 91
- Pectus excavatum, 91
- Pelvic vein thrombosis, in pulmonary thromboembolism, 171
- Penicillamine  
 alveolar hemorrhage due to, 155  
 bronchiolitis obliterans due to, 319  
 usual interstitial pneumonia due to, 330
- Penicillium marneffei* pulmonary infection, 485
- Pentalogy of Cantrell, 91
- Peptostreptococcus* pneumonia, 433
- Perchloroethylene gas, occupational exposure to, 315, 315f
- Percutaneous transthoracic needle biopsy, 41–42, 43f. *See also* Fine needle aspiration (FNA).
- Peribronchiolar fibrosis  
 cigarette smoking and, 887  
 in rheumatoid arthritis, 22
- Pericardial mesothelioma, 401
- Periodic acid-Schiff with diastase, for mesothelioma, 664
- Peritoneal mesothelioma, 401
- Phaeohyphomycosis, pulmonary, Color Fig. 43-10, 485
- Phenformin, pulmonary hypertension due to, 155
- Phosgene, as irritant gas, 168
- Physical agents, in pulmonary carcinogenesis, 526–527
- Pigeon breeder's lung, 164, 762. *See also* Hypersensitivity pneumonitis.
- Pilot(s), decompression sickness in, 190
- Pink puffers, 281
- Plague, 437–438, 438f  
 bubonic, 437  
 pneumonic, 437  
 precautions for, 438
- Plasma cell neoplasm(s), 638, 638f
- Plasmacytoma, pulmonary, 638, 638f  
 inflammatory pseudotumor vs., 715
- Plasmodium falciparum* malaria, 490–491
- Platinum exposure, occupational asthma due to, 163
- Pleura  
 anatomy of, 12–13, 13f  
 blood supply of, 13  
 developmental and functional aspects of, 863–864  
 embryonic origin of, 12–13  
 fibroinflammatory processes of, 868f–870f, 868–869  
 metastasis to, 697  
 neural supply of, 13  
 normal structure of, 863, 864f  
 pathology of, 863–873  
 in sarcoidosis, 772f, 773  
 stomata of, 13
- Pleural adhesion(s), in chronic lung transplant rejection, 824
- Pleural biopsy, 43, 45  
 in tuberculosis, 457
- Pleural cavity, anatomy of, 13
- Pleural disease(s)  
 asbestos-related. *See also* Mesothelioma.  
 benign, 401–403, 402f  
 diffuse pleural fibrosis as, 401, 402f  
 parietal pleural plaque as, 401, 402f  
 rounded atelectasis as, 401–402, 402f  
 cytology of, 867, 868d  
 histology of, 867–868  
 signs and symptoms of, 864
- Pleural effusion(s), 864–866, 865d  
 chylothorax as, 866, 867d  
 exudate, 865, 865t  
 hemothorax as, 865, 866f  
 pyothorax as, 865, 866f–867f  
 transudate, 864–865, 865d, 865t  
 in tuberculosis, 457–458
- Pleural fibrosis, 869–870  
 diffuse, asbestos-related, 401, 402f  
 future research on, 886
- Pleural neoplasia, 870–872, 871f. *See also* Mesothelioma.
- Pleural plaque, parietal, Color Figs. 75-1–75-2, 870, 870f  
 asbestos-related, 401, 402f  
 future research on, 886  
 tissue mineral fiber content analysis in, 405, 406t, 407
- Pleuritis  
 eosinophilic, reactive, 869, 870f  
 fibrinous, 868, 868f  
 granulomatous, 869  
 in rheumatoid arthritis, 781, 782f  
 tuberculosis, 869, 869f  
 in tuberculosis, 456–458, 457f
- Pleuropulmonary blastoma, 877, 878f–879f
- Plexogenic arteriopathy, in pulmonary hypertension of congenital heart disease, 217, 218d
- Pneumococcal pneumonia, Color Figs. 38-1–38-2, 425–427, 426f  
 clinical findings in, 425–426  
 complications of, 426–427  
 pathologic findings in, Color Figs. 38-1–38-2, 426, 426f  
 red or gray hepatization in, Color Figs. 38-1–38-2, 426, 426f
- Pneumoconiosis. *See also individual types;*  
 Asthma, occupational.  
 aluminosis as, 414–415  
 antimony lung disease as, 417  
 asbestosis as, 395–410  
 baritosis as, 416–417  
 berylliosis as, 411–412  
 biopsy for, 49, 50f  
 in carbon black workers, 381  
 coal worker's, 369–384  
 due to fibrous glass, 417–419  
 in graphite workers, 381, 382f  
 hard metal lung disease as, 343–344, 412–414  
 historical, 387, 883  
 kaolin worker's, 390–391  
 due to man-made mineral fibers, 417–419

- Pneumoconiosis (*continued*)  
 metalloconiosis as, 411–422  
 due to mineral wool fibers, 419  
 mixed dust, 371–372  
 nonasbestos mineral fibers in, 392  
 due to oil mists, 420  
 particle clearance in, 387–388  
 particle deposition in, 387  
 pathogenetic factors in, 387  
 rare, 411–422, 412d  
 due to refractory ceramic fibers, 418  
 rheumatoid (Caplan's syndrome),  
 377–378, 378f, 392, 718, 781  
 siderosis as, 416  
 silicatosis as, 390–392  
 silicosis as, 388–389  
 stannosis as, 416  
 thesaurosis as, 419–420  
 due to vinyl chloride, 419  
 welder's, 416  
 zirconium lung disease as, 417
- Pneumocystis carinii* pneumonia, 504–507  
 atypical manifestations of, 505  
 cavitation in, 505–506, 506f–507f  
 in children, 504  
 clinical manifestations of, 504  
 cytologic diagnosis of, 33  
 diagnosis of, 504–505, 506f  
 dissemination of, 507  
 granulomatous response in, Color Fig.  
 45-1, 506  
 gross pathologic findings in, 504, 505f  
 incidence of, 504  
 lung biopsy in, 504, 505f  
 lymphoplasmacytic interstitial infiltrate  
 in, 506  
 pulmonary pathology in, 505  
 pulmonary vascular dissection in, 506,  
 507f
- Pneumocyte(s). *See* Alveolar type I  
 cell(s); Alveolar type II cell(s).
- Pneumonia. *See also under individual  
 pathogens.*  
 adenoviral, Color Fig. 42-2, 468  
 anaerobic, Color Fig. 39-1, 433–434,  
 434d, 434f  
 aspiration, anaerobic, 433, 434f  
 bacterial, unusual, 435–440  
*Bacteroides*, Color Fig. 39-1, 433–434  
*Bordetella pertussis* (whooping cough),  
 430  
 bronchiectasis in, 303  
 cholesterol, Color Fig. 33-1, 361  
 coccidioidomycosis, 478  
 cytomegalovirus, 465–466, 466f  
 in immunocompromised patients,  
 465  
 viral inclusions in, 466, 466f  
 diphtherial, 429  
 eosinophilic. *See* Eosinophilic pneu-  
 monia.  
*Escherichia coli*, Color Fig. 38-15, 430  
 golden, Color Fig. 33-1, 361  
 gram-negative, 426d, 429–430  
 gram-positive, 425–429, 426d  
*Haemophilus influenzae*, 429  
 in AIDS, 511  
 infectious, death due to, 194  
 influenza, Color Fig. 42-3, 469  
 interstitial. *See* Interstitial pneumonia.  
*Klebsiella pneumoniae* (Friedländer),  
 430  
 lipid, endogenous, Color Fig. 33-1,  
 360–361, 361d, 362f–362f  
 in children with gastroesophageal  
 reflux, 365, 365t  
 measles, Color Fig. 42-4, 469  
*Mycoplasma pneumoniae*, 470–471,  
 471f  
 organizing, bronchiolitis obliterans. *See*  
 Bronchiolitis obliterans organiz-  
 ing pneumonia (BOOP).  
*Peptostreptococcus*, 433  
 pneumococcal, Color Figs. 38-1–38-2,  
 425–427, 426f  
*Pneumocystis carinii*, 504–507  
*Proteus*, 441  
*Pseudomonas aeruginosa*, Color Figs.  
 38-9–38-12, 429–430  
 Q fever, 472  
 respiratory syncytial viral, 469, 470f  
*Serratia*, 429  
 staphylococcal, Color Figs. 38-5–38-7,  
 427–429, 428f  
 streptococcal, Color Figs. 38-3–38-4,  
 427, 427f  
 in AIDS, 511  
 tuberculous granulomatous, 452, 453f  
 tularemia, 438, 439f  
 usual and unusual, in AIDS, 511  
 varicella-zoster viral, Color Fig. 42-1,  
 467–468
- Pneumonia alba, 441
- Pneumonitis  
 cryptogenic organizing. *See* Bron-  
 chiolitis obliterans organizing  
 pneumonia (BOOP).  
 hypersensitivity. *See* Hypersensitivity  
 pneumonitis.  
 interstitial, progressing to pulmonary  
 fibrosis, mastocytosis in, 87  
 manganese, 166  
 mercury, 165  
 radiation. *See* Radiation pneumonitis.  
 in schistosomiasis, 494  
 trimetallic anhydride, 165
- Pneumothorax, 866–867, 867f, 868d  
 open, 181  
 spontaneous, congenital, 86  
 tension, 181
- Poland syndrome, 91
- Pollen grain(s), in cytologic diagnosis, 31
- Pollution, air, 883–884  
 indoor, 887–888
- Polyarteritis, microscopic  
 diffuse alveolar hemorrhage in,  
 727–728  
 necrotizing alveolitis in, 728, 728f  
 Wegener granulomatosis vs., 800
- Polyarteritis nodosa, 811–812,  
 812f–813f  
 pulmonary, 812, 812f–813f
- Polychondritis, relapsing  
 tracheobronchial, 849  
 upper airway, 838f, 839
- Polymer fume fever, 164
- Polymyositis. *See* Dermatomyositis and  
 polymyositis.
- Polysplenia syndrome, 71
- Polyvinylchloride fume fever, 164
- Pompe disease, Color Fig. 12-3,  
 111–112
- P53 oncogene, in pulmonary carcinogen-  
 esis, 528, 528t
- Pontiac fever, 435
- Pores of Kohn, 300  
 anatomy of, 12, 13f
- Portacaval shunt, primary pulmonary  
 hypertension in, 237
- Postmortem lung specimen(s). *See under*  
 Specimen(s).
- Prostatic carcinoma  
 metastasis from, 703, 704f  
 pulmonary vascular embolus due to,  
 232f
- Protease-antiprotease hypothesis, in  
 emphysema, 282–283
- Proteinosis, alveolar, 361–364. *See also*  
 Alveolar proteinosis.
- Proteus* pneumonia, 441
- Prototheca wickerhamii*, 486
- Protothecosis, pulmonary, 486
- Protozoal infection(s), pulmonary,  
 489–492. *See also individual  
 species.*
- Psammoma body(ies), in cytologic diag-  
 nosis, 31
- Pseudoallescheria boydii* pulmonary infec-  
 tion, 485
- Pseudoasbestos body(ies), Color Fig.  
 36-1, 397, 398f
- Pseudolymphoma  
 inflammatory pseudotumor vs., 715  
 lymphoma vs., 631–632, 632t, 633f
- Pseudomonas aeruginosa* pneumonia, Color  
 Figs. 38-9–38-12, 429–430
- Pseudomonas* infection, in smoke inhala-  
 tion, 185
- Pseudotumor(s)  
 of chest wall, Color Fig. 76-2, 877,  
 879f  
 inflammatory, 711–716. *See also*  
 Inflammatory pseudotumor.
- Psittacosis (parrot fever), 473
- Pulmonary agenesis  
 bilateral, 76  
 unilateral  
 bronchial stenosis with, 66  
 pulmonary hypoplasia with, 76  
 tracheal stenosis with, 66
- Pulmonary alveolar proteinosis. *See*  
 Alveolar proteinosis.
- Pulmonary angitis and granulomatosis,  
 791–809  
 benign lymphocytic, 634, 635f, 837  
 Churg-Strauss syndrome as. *See* Churg-  
 Strauss syndrome.  
 in sarcoidosis, 773, 773f  
 Wegener granulomatosis as. *See*  
 Wegener granulomatosis.



- Pulmonary arteriole(s)  
 in high-altitude pulmonary hypertension, 249–250, 251f–253f  
 muscularization of  
 in congenital heart disease at high altitude, 250, 253f  
 in pulmonary hypertension of congenital heart disease, 218, 219f  
 in thromboembolic pulmonary hypertension, 226–227, 228f
- Pulmonary arteriovenous fistula(s)  
 in children, 89, 90f  
 traumatic, 182
- Pulmonary artery(ies)  
 absence of, congenital, 89  
 alveolar, postnatal growth of, 19  
 atherosclerosis of, in primary pulmonary hypertension, 237, 237f  
 in chronic lung transplant rejection, 823–824, 824f  
 conventional, 17  
 distensibility of, perinatal, 19  
 elastic, anatomy of, 11  
 growth and development of, 17, 18f  
 hemitruncus, 89–90  
 hypermuscularization of, in adult respiratory distress syndrome, 134  
 intraacinar, growth and development of, 17, 18f  
 muscular, anatomy of, 11  
 in pulmonary hypertension. *See under* Pulmonary hypertension.  
 in pulmonary venous hypertension, 207, 207f–208f, 209  
 sarcoma of, Color Fig. 56-4, 648, 648f  
 pulmonary hypertension in, 213, 213f  
 stenosis of, types and locations of, 262, 263f  
 supernumerary, 17  
 talc deposits in, due to intravenous drug abuse, Color Fig. 19-2  
 thrombosis in. *See* Thrombosis, pulmonary artery.
- Pulmonary capillaritis, in systemic lupus erythematosus, 783, 785f
- Pulmonary capillary(ies), in thromboembolic pulmonary hypertension, 229
- Pulmonary circulation, 11. *See also individual vessels.*  
 in bronchiectasis, 307–308  
 low flow  
 after correction of, pathology of conduits in, 270–271, 271d  
 causes of, 261–262, 262d  
 before correction of, 261–271, 262d  
 Arnold Rich lesions in, 266, 267f–268f  
 extrapulmonary arteries in, 264  
 intrapulmonary arterial circulation and, 265–266, 266f–268f  
 pathologic findings in, 264–266  
 systemic collaterals and, 264–265, 265f  
 hypertensive pulmonary vascular disease in, 267, 268f–269f  
 pathophysiology of, 262, 264  
 systemic-pulmonary shunt operations for, 267–268, 269t, 270f
- Pulmonary congestive vasculopathy, in congenital heart disease, 223
- Pulmonary contusion(s), 181–182
- Pulmonary dysplasia, fibrocystic, congenital, 86–87
- Pulmonary edema  
 in acute atelectasis, 119  
 alveolar, Color Fig. 13-1, 118  
 cardiogenic, 117–123  
 acute, histologic features of, Color Fig. 13-1, 119f, 121  
 causes of, 117–121  
 chest radiography in, 121  
 chronic passive congestion in, Color Fig. 13-3, 121–122, 122f  
 brown induration in, Color Fig. 13-3, 122  
 hypertensive vascular changes in, 122  
 metaplastic ossification in, 122, 122f  
 clinical features of, 121  
 fibrinous, 121, 122f  
 fluffy or granular edema fluid in, 121, 121f  
 frothy edema fluid in, 121  
 pathogenetic mechanisms of, 117, 118t  
 pathologic features of, Color Fig. 13-3, 119f, 121f–122f, 121–122  
 due to decreased colloid osmotic pressure, 119  
 due to decreased interstitial pressure, 119  
 due to heroin overdose, 190–191, 192f  
 at high altitude, 253–255  
 historical, 253  
 pathogenesis of, 253  
 pathologic findings in, 253  
 at high-altitude, 120–121, 136  
 due to increased capillary permeability, Color Fig. 13-2, 118  
 due to increased capillary pressure, Color Fig. 13-1, 117–118, 118f–119f  
 interstitial, 117–118, 119f  
 in lymphangitic carcinomatosis, 120f  
 due to lymphatic insufficiency, 118–119, 120f  
 miscellaneous causes of, 120–121  
 neurogenic, 121, 136–137, 137f  
 noncardiogenic, 125–138  
 causes of, 135–136, 136d  
 definition of, 125  
 histopathologic findings in, 136  
 miscellaneous syndrome of, 135–137  
 pathophysiology of, 204  
 perivascular, 117–118, 119f  
 permeability, 125  
 reexpansion, 137  
 in smoke inhalation, 185
- Pulmonary embolism. *See* Embolism, pulmonary.
- Pulmonary eosinophilic granuloma, Color Fig. 32-3, 345–347, 346f–348f  
 Birbek granules in, 346, 348f  
 clinical manifestations of, 346  
 histopathologic findings in, 346, 346f–348f  
 Langerhans cells in, Color Fig. 32-3, 346
- Pulmonary fibrosis. *See* Fibrosis, pulmonary.
- Pulmonary function test(s)  
 in asbestosis, 397–398  
 in emphysema, 281
- Pulmonary hematoma, Color Fig. 19-1, 181–182, 182f
- Pulmonary hypertension  
 in adult respiratory distress syndrome, 132  
 after aortopulmonary arterial shunt surgery, 269, 270f  
 after systemic-pulmonary shunt operations, 268, 270f  
 in AIDS, 517  
 in amyloidosis, 212f, 213  
 due to bone marrow emboli, 231–233, 233f  
 chronic, in nonthrombotic embolism, 229–230  
 in chronic bronchitis, 209  
 in congenital heart disease, 217–223  
 bronchopulmonary anastomoses in, 222  
 cellular intimal proliferation in, 218–219, 219f  
 concentric intimal fibrosis in, 219, 220f  
 dilatation lesions in, 220  
 elastic pulmonary arterial changes in, 217  
 endothelial changes in, 221–222  
 fibrinoid necrosis in, 219, 220f  
 generalized and uniform dilatation in, 222  
 incidence of, 217, 218t  
 intimal longitudinal smooth muscle in, 221, 222f  
 medial hypertrophy in, 217–218  
 necrotizing arteritis in, 219  
 pathologic findings in, 217–222  
 plexiform lesions in, 219–220, 220f–221f  
 plexogenic arteriopathy in, 217, 218d  
 pulmonary arteriole muscularization in, 218, 219f  
 reversibility of, 222  
 tortuosity in, 221, 221f  
 types of malformations in, 217, 218d  
 in connective tissue disease, 209, 210f, 212, 236–237  
 in corrected tetralogy of Fallot, 268, 270f

- Pulmonary hypertension (*continued*)  
 in CREST syndrome, 209, 212  
 in dermatomyositis and polymyositis, 785, 788f  
 due to drug toxicity, 155, 155f  
 in emphysema, 209  
 in fibrosing mediastinitis, 213  
 in granulomatous disease, 209  
 high-altitude, 247–250  
   due to acute hypoxia, 248  
   elastic configuration of pulmonary trunk in, 248–249, 249f–250f  
   right ventricular hypertrophy in, 248, 248f  
   small pulmonary arteries and arterioles in, 249–250, 251f–253f  
 in intravenous drug abuse, 229f–230f, 229–230  
 in low-flow states, 267, 268f–269f  
 in malignant neoplasms, 213, 213f  
 miscellaneous causes of, 213  
 open lung biopsy for, 48–49  
 in overlap syndrome, 212  
 in parenchymal lung diseases, 209–213  
 pathogenesis of, hypoxia in, 293  
 plexigenic, pulmonary intravascular pressure in, 204, 205f  
 primary, 235–240  
   arteritis in, 238, 240f  
   clinical features of, 236–237  
   concentric intimal fibroelastosis in, 238, 239f  
   congenital, 86  
   death due to, 193–194, 195f  
   definition of, 235  
   diagnosis of, role of pathologist in, 243–244  
   differential diagnosis of, 239  
   dilatation lesions in, 238, 238f–239f  
   etiology of, 235–236  
   intimal thickening in, 238–239, 241f  
   luminal thrombosis in, 239  
   medial hypertrophy in, 238, 241f  
   in mixed connective tissue disorders, 236–237  
   pathologic features of, 237f–241f, 237–239  
   plexiform lesions in, 237, 237f–238f  
   in portacaval shunt, 237  
   pulmonary artery atherosclerosis in, 237, 237f  
   pulmonary venoocclusive disease vs., 235, 236d  
   right ventricular hypertrophy in, 237, 237f  
   thromboembolic pulmonary hypertension vs., 227–229, 228t  
   ultrastructure and immunohistochemistry in, 239–240  
 in pulmonary fibrosis, 211f–212f, 213  
 in pulmonary schistosomiasis, 230, 231f  
 in rheumatoid arthritis, 211f, 212  
 in sarcoidosis, 209, 210f  
 in scleroderma (systemic sclerosis), 209, 210f, 212, 236, 784–785, 787f  
 secondary, underlying conditions in, 236d  
 in systemic lupus erythematosus, 212, 783, 786f  
 in systemic sclerosis, 784–785, 787f  
 thromboembolic, 225–229  
   elastic artery pathology in, 225–226, 226f–227f  
   muscular artery and arteriole pathology in, 226–227, 228f  
   primary pulmonary hypertension vs., 227–229, 228t  
   pulmonary capillaries, veins, bronchial artery collaterals in, 229  
 due to tissue emboli, 233  
 in tuberculosis, 209  
 due to tumor emboli, 230–231, 232f  
 in uncorrected tetralogy of Fallot, 267, 268f–269f  
 venous  
   arterial pathology in, 207, 207f–208f, 209  
   bronchial vessel pathology in, 209  
   etiology of, 204d, 204–205  
   in ischemic heart disease, 204, 208f  
   in left ventricular diastolic dysfunction, 204–205  
   in left ventricular systolic dysfunction, 204  
   lymphatic channel pathology in, 209  
   microliths (calcospherites) in, 206, 207f  
   in mitral stenosis, 204, 206f–207f  
   parenchymal pathology in, 205–206, 208f  
   pulmonary intravascular pressure in, 203–205, 205f  
   venous pathology in, 206–207, 208f  
 Pulmonary hypoplasia, congenital  
   bilateral, 74–75, 75f  
   causes of, 74  
   pathogenesis of, 74–75  
   compensatory lung growth in, 74  
   in skeletal dysplasia, 75–76  
   unilateral, pulmonary agenesis and, 76  
 Pulmonary infarct(s), Color Fig. 18-3, 174, 174f  
   lung abscess in, Color Fig. 18-3, 174  
 Pulmonary intravascular pressure(s), normal, 203–204, 205f  
 Pulmonary isomerism syndrome(s), 71–72  
 Pulmonary laceration(s), 181–182  
 Pulmonary muscular hyperplasia (pulmonary lymphangiomyomatosis, muscular pulmonary cirrhosis), 86  
 Pulmonary thromboembolism. *See* Thromboembolism, pulmonary.  
 Pulmonary valve atresia  
   with intact ventricular septum, 262  
   in tetralogy of Fallot, 262, 263f  
 Pulmonary valve stenosis  
   with intact ventricular septum, 261, 262d  
   in tetralogy of Fallot, 262, 262d  
 Pulmonary vascular disease, in systemic lupus erythematosus, 783, 785f–786f  
 Pulmonary vasculitis  
   classification of, 811d  
   drug-induced, 155  
   in rheumatoid arthritis, 782, 783f  
   in systemic lupus erythematosus, 783, 785f  
 Pulmonary vein(s)  
   anatomy of, 11, 18, 18f  
   axial, 18  
   in chronic lung transplant rejection, 823–824, 824f  
   conventional, 18  
   growth and development of, 18  
   supernumerary, 18  
   in thromboembolic pulmonary hypertension, 229  
 Pulmonary venoocclusive disease, 240–245  
   capillary hemangiomatosis in, 243, 245, 245f  
   clinical features of, 241  
   definitions in, 240  
   diagnosis of, role of pathologist in, 243–244  
   drug-induced, 155, 156f  
   etiology of, 240  
   pathologic features of, 241, 242f–244f, 243  
   primary pulmonary hypertension vs., 235, 236d  
 Pulmonary venous hypertension. *See* Pulmonary hypertension, venous.  
 Pulmonary venous thrombosis, 173  
 Pyothorax, 865, 866f–867f
- Q**  
 Q fever, 472  
 pneumonia due to, 472
- R**  
 Radiation fibrosis, localized, 718  
 Radiation pneumonitis, 143–145  
   acute, 144, 145f  
   asbestosis vs., 400  
   chest radiography in, 144, 144f  
   clinical features of, 144, 144f  
   experimental features of, 144  
   fibrotic, 144–145, 146f  
   historical perspective on, 143  
   mechanisms of injury in, 143–144  
   pathologic findings in, 144f–146f, 144–145  
   unilateral lung hyperlucency in, 145  
   unusual complications of, 145  
 Radiography, chest. *See* Chest radiography.  
 Radon  
   lung cancer due to, 526–527, 887  
   small cell carcinoma due to, 556

- Rain, acid, Color Fig. 77-1, 888
- RAS oncogene, in pulmonary carcinogenesis, 528, 528t
- RB1 oncogene, in pulmonary carcinogenesis, 528, 528t
- Reactive airway dysfunction syndrome, 884
- Renal agenesis, oligohydramnios of, bilateral pulmonary hypoplasia in, 74–75
- Renal cell carcinoma  
clear cell tumor vs., 675  
mesothelioma vs., 662, 663t  
metastatic, 703, 703f  
to bronchus, 849, 850f  
clear cell large cell carcinoma vs., 578  
fine needle aspiration of, 37f  
pulmonary vascular embolus due to, 231
- Resected lung specimen(s). *See* Specimen(s).
- Reserve cell(s), bronchial mucosal, in cytologic diagnosis, 29–30
- Respiratory air space enlargement, 275, 276d. *See also* Emphysema.  
acquired simple, 276  
in bronchopulmonary dysplasia, 276  
congenital simple, 276
- Respiratory bronchiolitis-associated interstitial lung disease, 343
- Respiratory distress syndrome, adult (ARDS). *See* Adult respiratory distress syndrome (ARDS); Alveolar damage, diffuse (DAD).
- Respiratory syncytial virus infection, 469, 470f  
bronchiolitis in, 469, 470f  
bronchiolitis obliterans in, 318–319  
pneumonia in, 469, 470f
- Respiratory tract  
cells of. *See individual cells.*  
congenital development of, 73
- Reticulosis, polymorphic, 833, 834
- Retinol, risks of lung cancer and, 527
- Rhabdomyosarcoma  
of chest wall, 877  
pulmonary, 648–649, 649f
- Rheumatoid arthritis, 781–782  
bronchiolitis in, 290  
diffuse interstitial pneumonitis and fibrosis in, 782, 782f–783f  
eosinophilic pneumonia in, 752  
peribronchiolar fibrosis in, 22  
pleuritis in, 781, 782f  
pulmonary hypertension in, 211f, 212  
usual interstitial pneumonia in, 330, 782, 782f  
Wegener granulomatosis vs., 800
- Rheumatoid nodule(s), 718
- Rheumatoid pneumoconiosis (Caplan syndrome), 377–378, 378f, 392, 718, 781
- Rhinosporidiosis, pulmonary, 485
- Rhinosporidium seeberi* infection, 485
- Rhizopus arrhizus*, Color Fig. 43-7, 484
- Rhodococcosis, in AIDS, 512, 512f
- Rhodococcus equi*, 512
- Rhodotorula rubra*, 485
- Rib(s)  
fracture of, 181  
intrathoracic, in children, 90
- Rickettsial infection(s), 471–472, 472f
- Rickettsia rickettsii*, 471
- Right ventricular hypertrophy  
in alveolar hypoxia, 293  
in chronic bronchitis, 292–293, 293f  
in high-altitude pulmonary hypertension, 248, 248f  
measurement of degree of, technique for, 293  
in primary pulmonary hypertension, 237, 237f
- Rocky Mountain spotted fever, 471–472, 472f  
diagnosis of, 471–472  
pulmonary manifestations of, 471, 472f
- Rounded atelectasis. *See* Atelectasis, rounded.
- S**
- Saccharomyces cerevisiae*, 485
- Saldino-Noonan syndrome, 75
- Salivary gland tumor(s), metastasis from, 702
- Sandstorm lung, 350
- Sarcoidosis, 768–776  
alveolitis in, 772f, 772–773  
aspergillomas in, 774, 774f  
bilateral hilar lymphadenopathy in, 768  
bronchial involvement in, 773  
bronchiectasis in, 774, 774f  
bronchiolar involvement in, 772f, 773  
chronic beryllium disease vs., 776  
clinical aspects of, 768–769  
diagnosis in, 774–775  
biopsy for, 774–775  
bronchoalveolar lavage for, 775  
gallium scanning for, 775  
Kviem-Siltzbach test for, 775  
serum angiotensin-converting enzyme for, 775  
differential diagnosis in, 775–776  
emphysema in, 774  
end-stage, 774, 774f  
eosinophilia in, 752  
etiology of, 768  
future research on, 885  
granulomas in, 771–772, 772f  
granulomatous pulmonary angiitis in, 773, 773f  
honeycombing in, 774, 774f  
hypersensitivity pneumonitis vs., 762, 764, 764t, 776  
infectious granuloma vs., 776  
necrotizing sarcoid granulomatosis vs., 805
- pathologic findings in, Color Fig. 66-1, 769–771, 770f–771f  
apoptotic bodies in, 770, 770f  
asteroid bodies in, 771, 771f  
birefringent crystals in, 771, 771f  
granuloma in, 769, 770f  
Hamazaki-Wesenberg bodies in, Color Fig. 66-1, 771  
necrosis in, 770, 770f  
Schaumann bodies in, 771, 771f  
pleural involvement in, 772f, 773  
prognosis in, 769  
pulmonary fibrosis in, 773–774, 774f  
pulmonary hypertension in, 209, 210f  
pulmonary involvement in, 771–774  
transbronchial biopsy for, 48, 49f  
Wegener granulomatosis vs., 776
- Sarcoma  
childhood, metastasis from, 706, 707f  
endometrial stromal, metastasis from, 706, 706f  
Ewing, of chest wall, 877  
female reproductive tract, metastasis from, 705–706, 706f  
Kaposi, 514–515, 515f–516f  
epidemic, in AIDS, 515  
pulmonary, 515, 515f–516f  
pulmonary angiosarcoma vs., Color Fig. 56-5, 649, 650f  
of mediastinum, 858  
metastatic, fine needle aspiration of, 36, 38f  
osteogenic, metastasis from, 704, 705f  
pulmonary artery, Color Fig. 56-4, 648, 648f  
pulmonary hypertension in, 213, 213f  
soft tissue, adult, metastasis from, 704–705, 705f–706f
- Scar(s)  
in cigarette smokers' lungs, 336  
focal, 335–336, 337f–338f  
lung cancer and, 336  
subpleural, 336, 337f–338f
- Scar carcinoma, 531, 532f
- Schaumann body(ies)  
alveolar microlithiasis vs., Color Fig. 32-7, 351  
in sarcoidosis, 771, 771f
- Schistosoma haematobium*, 494
- Schistosoma mansoni*, 494, 495f
- Schistosoma* species, eosinophilic pneumonia due to, 751t
- Schistosomiasis  
cor pulmonale in, 494  
eggs in, 494, 495f  
Katayama fever in, 494  
Loeffler-like syndrome in, 494  
pneumonitis in, 494  
pulmonary, 493–494, 495f  
life cycle in, 493–494  
pulmonary hypertension in, 230, 231f
- Schizophyllum commune*, 485
- Schönlein-Henoch syndrome, pulmonary involvement in, 813, 814f

- Schwannoma(s), 652  
 Scimitar syndrome, 71  
 Scleroderma. *See* Systemic sclerosis.  
 Sclerosing hemangioma. *See* Hemangioma, sclerosing.  
 Sclerosis, systemic. *See* Systemic sclerosis.  
 Scoliosis, 875  
*Scopulariopsis brevicaulis*, 485  
 Scuba diver(s)  
   air embolism in, 190  
   decompression sickness in, 190, 191f  
 Seizure disorders, drowning in, 188  
 Seminoma, of mediastinum, 857, 858f  
 "Senile" emphysema, 276. *See also* Aging lung(s).  
 Sensory nervous system, of lungs, 12  
 Septa, pulmonary  
   abnormal congenital, 74  
   cysts of, due to chronic interstitial emphysema, 80  
 Sequestration, pulmonary, congenital, Color Fig. 8-2, 80-81, 82f-83f  
   extralobar, Color Fig. 8-2, 80-81, 83f  
   intraalobar, 80-81, 82f-83f  
*Serratia* pneumonia, 429  
 Shaver disease (bauxite lung), 415  
 Shingles (zoster), 467  
 Short-pancreas syndrome, 71  
 Short trunk, short rib, polydactyly syndrome(s), congenital pulmonary hypoplasia in, 75  
 Siderosilicosis, 416  
 Siderosis, Color Figs. 37-3-37-4, 416  
 SIDS. *See* Sudden infant death syndrome (SIDS).  
 Silica, in progressive massive fibrosis, 372  
 Silica particle(s), in cytologic diagnosis, 31  
 Silicatoses, 390f-391f, 390-392  
 Silicone gel exposure, systemic sclerosis and, 885  
 Silicosis, 388-389  
   alveolar proteinosis in, Color Fig. 35-3, 388-389  
   asbestosis vs., 400  
   cigarette smoking and, future research on, 887  
   in coal worker's pneumoconiosis, 371-372, 372f, 391f-392f, 391-392  
   conglomerate, Color Fig. 35-1, 388, 389  
   cytokines and eicosanoids in, 388  
   future research on, 886-887  
   historical, 883  
   lung cancer and, 389  
   mechanisms of tissue injury in, 388  
   pathologic diagnosis of, 389, 389f  
   progressive massive fibrosis in, Color Fig. 35-2, 388  
   silicotic nodules in, Color Fig. 35-1, 388, 388f-389f  
   tuberculosis in, 389  
   types of silica in, 388  
 Silicotic nodule(s), Color Fig. 35-1, 388, 388f-389f  
   progressive massive fibrosis vs., 375  
 Silo filler's disease, nitrogen oxide inhalation in, 167  
 Silo unloader's syndrome (pulmonary mycotoxicosis, organic toxic dust syndrome), 163  
 Single mediastinal unilobar lung, 72  
 Situs inversus, 71  
 Skeletal dysplasia, congenital, pulmonary hypoplasia in, 75-76  
 Skin  
   adnexal carcinoma of, metastasis from, 704  
   metastasis to, 698, 698f  
 Sling left pulmonary artery, 72  
   bridging bronchus in, 72  
   isomerism syndromes vs., 71  
   tracheal stenosis with ring cartilage in, 72  
 Small airway(s). *See* Airway(s), small.  
 Small bowel, metastasis to, 697  
 Small cell carcinoma, 555-570, 589-594  
   biopsy for, 50  
   cigarette smoking and, 556  
   classification of, 589  
   clinical course and treatment in, 566-567  
   clinical features of, 565-566, 589  
   CNS involvement in, 566  
   combined (mixed)  
     adenocarcinoma and, 559, 562f, 591, 592f  
     glandular differentiation in, 559, 562f, 591, 592f  
     spindle cell carcinoma and, 591, 593f  
     squamous differentiation in, 549, 551f, 552, 559, 562f, 591, 592f  
   crush artifact in, 591, 593f, 594  
   differential diagnosis of, 591, 594  
   DNA ploidy and cytogenetics in, 564-565  
   Eaton-Lambert syndrome in, 566  
   electron microscopy in, 564, 564f-565f, 591  
   fine needle aspiration in, 35, 36f  
   histogenesis of, 555-556  
     Kulchitsky cells in, 555-556  
     neuroendocrine, 556  
   histologic subtypes in, 556t, 556-557  
   immunohistochemistry in, 561-563, 591  
     for bombesin, 563  
     for chromogranin, 562, 563f  
     for cytokeratins, 561, 563f  
     for Leu-7, 563  
     for neuron-specific enolase, 561-562  
     for synaptophysin, 562-563  
   incidence of, 555  
   large cell carcinoma vs., 575-576, 577f  
   large cell neuroendocrine carcinoma vs., 587, 588t  
   metastasis of, 565-566, 691-692, 692t  
   mixed large cell and, 559, 562f, 591  
   paraneoplastic syndromes in, 566  
   pathogenesis of, 556  
   pathologic findings in, 557-564, 589-591, 590f-593f  
     architectural pattern in, 557, 558f-559f  
     crush artifact in, 557, 558f  
     gross, 557, 557f-558f  
     microscopic, 557-564  
     necrosis in, 557, 559f  
     nuclear encrustation (Azzopardi phenomenon) in, 557, 560f  
     nuclear pleomorphism in, 557, 559  
     oval-to-fusiform cells in, 557, 561f  
     oval-to-polygonal cells in, 557, 560f  
     rosette formation in, 557, 560f  
     spindled cells in, 557, 561f  
   in radon exposure, 556  
   staging of, 566, 589  
   tumor cell size in, 589, 591  
   in uranium miners, 556  
 Smoke inhalation, 185-186  
   cilia poisoning in, 185  
   diffuse alveolar damage in, 185-186  
   infection in, 185  
   pulmonary edema in, 185  
   sequelae of, 186  
 Smoking, tobacco. *See* Cigarette smoking.  
 Smooth muscle tumor(s), in AIDS, 517, 517f  
 Smudge cell(s), in adenoviral pneumonia, Color Fig. 42-2, 468  
 Soft tissue sarcoma, adult, metastasis from, 704-705, 705f-706f  
 Soldering flux, occupational asthma due to, 163  
 Sparganosis, pulmonary, 496  
*Sparganum* species, eosinophilic pneumonia due to, 751t  
 Specimen(s)  
   autopsy, 54-55  
   dissection of, 54f-57f, 55  
   fixation of, 55, 56f  
   biology, preparation methods for, 45f, 45-46  
   corrosion casts for, 57, 59  
   cytology, collection and preparation methods for, 27, 28t  
   dissection technique for, 53, 55f  
   fixation of  
     in distended state, Color Fig. 5-1, 53  
     in emphysema, 275  
     intrabronchial formalin perfusion for, 53, 54f  
     special procedures for, 55-57  
   formalin vapor fixation for, 55-57  
   glycol-formalin fixation for, 57  
   injection methods for, Color Fig. 5-2, 57, 59, 59f  
   paper-mounted sections for, 57, 58f  
   preparation technique for, 53

- surgical pathology  
 fixation for, 54  
 techniques for handling, 53-54
- Sphingomyelin-cholesterol lipidosis. *See* Niemann-Pick disease.
- Spinal deformity, 875-876
- Spindle cell carcinoma  
 mixed small cell and, 591, 593f  
 mixed squamous cell and, Color Fig. 48-10, 552f, 552-553
- Spirometra* species, 496, 499
- Spondylitis, ankylosing (Marie-Strümpell disease), 788, 876
- Sporothrix cyanescens*, 481
- Sporothrix schenckii*, 482
- Sporotrichosis, pulmonary, Color Fig. 43-4, 481-482, 482f
- Sputum cytology  
 for asbestos bodies, 404, 404f  
 for asthma, 30-31  
 collection, slide prep, and staining for, 27, 28t  
 other cytology specimens vs., 27, 28t
- Squamous cell carcinoma, 545-554  
 basaloid (small cell), 549, 551f, 552  
 chemotherapy for, 549, 550f  
 combined small cell carcinoma and, 559, 562f  
 fine needle aspiration of, Color Fig. 3-4, 34  
 histogenesis of, Color Fig. 48-1, 548  
 human papillomavirus infection in, 548  
 in juvenile laryngotracheal papillomatosis, 613, 613f  
 keratinizing, 545  
 large cell carcinoma vs., 575, 576f  
 of lung, in coke oven workers, 381, 382  
 metastasis of, 691-692, 692t  
 moderately differentiated, 545  
 multiple primary, 548f, 548-549  
 non-keratinizing, 545  
 Pancoast tumor and, 546-547, 548f  
 papillary, 613-614  
 pathologic findings in, 545d, 545-546, 546f-547f  
 gross, 545, 546f  
 histologic, 545-546, 547f  
 peripheral, 546, 547f  
 cavitation in, 546, 547f  
 poorly differentiated, 545, 547f  
 high-grade mucoepidermoid carcinoma of bronchial gland vs., 603  
 prognosis in, 549  
 flow cytometry for, 549  
 metastasis in, 549  
 spontaneous regression in, 549  
 unusual behavior and, 549  
 in situ, Color Fig. 48-1, 54548  
 small cell carcinoma mixed with, 549, 551f, 552, 591, 592f  
 special subtypes of, 549-553  
 spindle cell, Color Fig. 48-10, 552f, 552-553  
 of trachea, Color Fig. 73-2, 545, 847, 848f  
 treatment and follow-up in, 549, 550f  
 unusual associations in, 546-548, 548f  
 well-differentiated, 545, 547f
- Squamous metaplasia, bronchial mucosal atypical, 32
- Cytologic diagnosis of, 32, 32f
- Squamous papilloma(s), 609, 611f, 611-612  
 clinical findings in, 609, 611  
 histologic findings in, 611f, 611-612
- Stain(s)  
 for biopsy specimens, 45-46  
 cytologic, for bacteria, 32
- Stannosis, 416
- Staphylococcal pneumonia, Color Figs. 38-5-38-7, 427-429, 428f  
 clinical features of, 427-428  
 in infants and children, Color Figs. 38-6-38-7, 428  
 pathologic findings in, Color Figs. 38-5-38-7, 428f, 428-429
- Starch granule(s), in cytologic diagnosis, 31
- Status asthmaticus, Color Fig. 17-1, 160  
 case study in, Color Fig. 29-1, 311-312, 312f-314f  
 death due to, 191
- Sternal fracture, 181
- Streptococcal infection,  $\beta$ -hemolytic group B, hyaline membrane disease in, 93-94
- Streptococcal pneumonia, Color Figs. 38-3-38-4, 427, 427f  
 in AIDS, 511
- Streptococcus pneumoniae*, 425
- Streptomyces* infection(s), Color Fig. 40-7, 447, 448f
- Strongyloides stercoralis*, 498
- Strongyloides stercoralis* infection, cytologic diagnosis of, 33
- Strongyloidiasis  
 eosinophilic pneumonia due to, 750, 751t  
 pulmonary, 498  
 in AIDS, 508, 509f
- Subcutaneous emphysema, definition of, 276
- Submesothelial fibroma, 856a
- Subpleural cyst(s), in Down syndrome, 83, 83f
- Subpleural scar(s), 336, 337f-338f
- Subpulmonic stenosis, 261, 262d
- Sudden infant death syndrome (SIDS), 194-195  
 chronic hypoxia in, 195  
 common causes of, 196d  
 definition of, 194  
 etiology and pathogenesis of, 194  
 incidence of, 194  
 increased fetal hemoglobin in, 195  
 pulmonary pathology in, 194, 196d  
 gross findings in, 196d  
 histologic findings in, 196d
- Sugar tumor, 673. *See also* Clear cell tumor.
- Sulfatide lipidosis (metachromatic leukodystrophy), 111
- Sulfur dioxide, as irritant gas, 168
- Sulfur granule(s), in thoracic actinomycosis, Color Figs. 40-2-40-4, 446
- Surfactant  
 biochemical constituents of, 94  
 deficient production of, 95  
 in hyaline membrane disease, 94-95  
 in neonatal respiratory transition, 94  
 protein B deficiency in, 88
- Swyer-James syndrome (hyperlucency of lung, Macleod syndrome), 83  
 bronchiectasis in, 305, 306f, 307
- Sympathetic nervous supply, of lungs, 12
- Synaptophysin, in small cell carcinoma, 562-563
- Syphilis  
 congenital, 441  
 tracheobronchial, 441
- Syphilitic gumma(s), 441
- Systemic-pulmonary shunt operation(s)  
 hypertensive pulmonary vascular disease after, 268, 270f  
 for low-flow states, 267-268, 269t, 270f
- Systemic sclerosis  
 bronchiolitis obliterans organizing pneumonia in, 784, 786f  
 chest wall in, 875  
 progressive, usual interstitial pneumonia in, 330  
 pulmonary hypertension in, 209, 210f, 212, 236, 784-785, 787f  
 pulmonary involvement in, 783-784  
 silicone gel exposure and, 885  
 usual interstitial fibrosis with honeycombing in, 784, 786f
- T**
- TACRD association, 65
- Taenia solium*, pulmonary, 496-497
- Takayasu arteritis, 813, 815, 815f
- Talc, inhalation of, 390-391
- Talc deposits, in pulmonary artery, due to intravenous drug abuse, Color Fig. 19-2, Color Fig. 35-4, 390
- Talc granuloma, in intravenous drug abuse, 229f-230f, 229-230
- Talcosis, future research on, 887
- T cell(s), CD4, in AIDS, 504
- Telangiectasia, hereditary hemorrhagic (Osler-Weber-Rendu disease), pulmonary hemosiderosis in, 102, 102f
- Teratocarcinoma, mediastinal, Color Fig. 74-5, 857
- Teratoma(s)  
 mediastinal, Color Fig. 74-2, 855-856  
 pulmonary, Color Fig. 54-1, 627-628, 628f

- Teratoma(s), pulmonary (*continued*)  
 clinical features of, 627  
 completely mature, 627–628, 628f  
 differential diagnosis in, Color Fig. 54-1, 628  
 malignant, 627–628  
 metastatic, 627  
 treatment of, 628
- Terminal respiratory unit, definition of, 6
- Testicular carcinoma, metastasis from, 703
- Testis, metastasis to, 698
- Tetralogy of Fallot  
 corrected, pulmonary hypertension in, 268, 270f  
 pulmonary artery thrombosis in, 173  
 pulmonary valve atresia in, 262, 263f  
 pulmonary valve stenosis in, 262, 262d  
 uncorrected, pulmonary hypertension in, 267, 268f–269f
- Thalassemia, pulmonary hemosiderosis in, Color Fig. 9-4, 88, 102
- Thanatophoric dysplasia, with cloverleaf skull, 75
- Thesauriosis, 419–420
- Thoracic injury. *See* Chest trauma.
- Thoracic wall, amniotic bands of, 91
- Thoracoabdominal enteric duplication, 91
- Thoracolyngopelvic dysplasia (Barnes syndrome), 75–76
- Thoracopulmonary neuroectodermal tumor(s), Color Fig. 76-1, 876–877, 877f
- Thromboembolism, pulmonary  
 acute, 171–172  
 clinical features of, 172  
 death due to, Color Fig. 19-4, 191, 194f  
 definition and predisposing factors in, 171  
 locations for, 171–172  
 pathologic features of, Color Fig. 18-1, 172, 172f–173f  
 sources of, Color Fig. 19-4, 171, 191, 194f  
 in adult respiratory distress syndrome, 132–133  
 old  
 intimal bands or webs in, 172, 173f  
 lines of Zahn in, Color Fig. 18-2, 172  
 organized fibrosis in, 172, 172f  
 pulmonary hypertension in, 225–229. *See also under* Pulmonary hypertension.
- Thrombosis  
 deep venous, in pulmonary thromboembolism, Color Fig. 19-4, 171, 191, 194f  
 pelvic vein, in pulmonary thromboembolism, 171  
 pulmonary artery, 172–174  
 causes of, Color Fig. 18-2, 172, 173f  
 in chronic congestive heart failure, 172  
 gross findings in, 172–173  
 microscopic findings in, 173–174  
 in pulmonary artery aneurysm, Color Fig. 18-2, 172, 173f  
 in tetralogy of Fallot, 173  
 pulmonary venous, 173
- Thymic carcinoid, 857
- Thymic carcinoma, 857
- Thymic cyst, multilocular, 859
- Thymic epithelial neoplasm(s), malignant, Color Fig. 74-3, 856–857, 857f
- Thymolipoma, 859–860
- Thymoma, Color Fig. 74-1, 854–855, 855f–856f  
 atypical, 857  
 encapsulation of, Color Fig. 74-1, 854  
 epithelial, 855, 856f  
 fine needle aspiration for, 43  
 intrapulmonary, 638  
 lymphocytic, 855, 855f  
 metastasis from, 704  
 spindle cell, 855  
 type II malignant, 857  
 type I malignant, Color Fig. 74-4, 857, 857f
- Thyroid carcinoma, papillary, metastatic, 614f, 614–615, 702, 702f
- Thyroid cartilage, congenital malformations of, 63
- Thyroid gland, metastasis to, 698
- Tobacco use. *See* Cigarette smoking.
- Toluene diisocyanate, occupational asthma due to, 163
- Tonsils, hypertrophy of, 839, 839f
- Torulopsis glabrata* pulmonary infection, 485
- Toxic fume(s)  
 diffuse alveolar hemorrhage due to, 729, 729f  
 occupational asthma due to, 164d, 164–166
- Toxocara canis*, 499  
 eosinophilic pneumonia due to, 750, 751t
- Toxocara cati*, 499  
 eosinophilic pneumonia due to, 750, 751t
- Toxoplasma gondii*, 489
- Toxoplasmosis  
 encephalitis, in AIDS, 507  
 pulmonary, 489, 490f  
 in AIDS, 507, 508f
- Trachea  
 adenoid cystic carcinoma of, Color Fig. 73-3, 847, 849f  
 anatomy of, gross, 1  
 basal cells of, 4  
 carcinoid tumor of, Color Fig. 73-4, 847, 849f  
 cell types of, 4  
 congenital malformations of, 64–68  
 diverticulosis of, 844  
 epithelium of, 4  
 focal muscular hyperplasia of, congenital, 85  
 glands of, 4  
 histologic compartments of, 4  
 inflammatory diseases of, 846–847  
 injury to, iatrogenic, 845–846  
 malformations of, 844–845  
 metastatic lesions of, 849  
 mucoepidermoid carcinoma of, 847, 848f  
 pathology of, 843–852, 844d  
 saber-sheath, 844f, 844–845  
 short, with reduced cartilage rings, 67–68  
 squamous cell carcinoma of, Color Fig. 73-2, 545, 847, 848f  
 traumatic injury to, 182–183  
 tumors of, primary and secondary, Color Figs. 73-2–73-4, 847–849, 848f–850f
- Tracheal agenesis, 65
- Tracheal cartilage sleeve, congenital, 67
- Tracheal intubation, complications of, Color Fig. 73-1, 845, 845f
- Tracheal ring cartilage  
 in midtracheal stenosis, in Down syndrome, 66  
 in sling left pulmonary artery, 72
- Tracheal splint, 67
- Tracheal stenosis, congenital  
 from common origin of carotid arteries, 66–67, 67f  
 diffuse, 67  
 with unilateral pulmonary agenesis, 66
- Tracheitis, infectious, 846–847
- Tracheoarterial fistula, 845, 846f
- Tracheobronchial amyloidosis, 352, 850–851
- Tracheobronchial epithelium, biopsy of, in primary ciliary dyskinesia, 101
- Tracheobronchial syphilis, 441
- Tracheobronchial tree  
 embryology of, 843  
 functions of, 843  
 in relapsing polychondritis, 849
- Tracheobronchitis, necrotizing  
 in herpes simplex virus infection, 467  
 influenza, 469
- Tracheobronchomegaly, congenital (Mounier-Kuhn syndrome), 85
- Tracheobronchopatia osteochondrodysplastica, 850
- Tracheobronchopatia osteoplastica, congenital, 85
- Tracheocele, 844
- Tracheoesophageal fistula, 65–66, 66f–67f, 846, 847f  
 classifications for, 66, 66f  
 embryonic mechanisms of, 66, 67f  
 with and without esophageal atresia, 66, 66f
- Tracheomalacia, localized, 67
- Transbronchial biopsy  
 for acute pulmonary infiltrates, 46, 47f  
 for asbestosis, 49, 50f  
 for atelectasis, 46–47

- for bronchiolitis obliterans organizing pneumonia, 42, 44f
- for chronic interstitial infiltrates, 46–47
- in immunocompromised patients, 46, 47f
- for non-small cell carcinoma, 49–50
- for pneumoconiosis, 49, 50f
- for sarcoidosis, 48, 49f
- for tumor-cell type, 49–50
- for usual interstitial pneumonia, 331
- for Wegener granulomatosis of lung, 47, 47f–48f
- Transplantation**
- heart-lung, 819
- lung, 819–826
- historical, 819
- infections in, 824
- postoperative immunosuppression in, 819
- reimplantation response to, 820
- rejection in, 820–825
- acute, 820–822, 821f–822f
- atypical, 824–825
- biopsy findings in, 825
- bronchiolitis obliterans in, 823, 823f
- chronic, 822–824, 823f–824f
- classification and grading in, 820, 820d
- diagnosis of, 825
- interstitium in, 824
- lymphocytic bronchitis or bronchiolitis in, 821
- pulmonary arteries and veins in, 823–824, 824f
- treatment of, 824–825
- visceral pleura in, 824
- technical considerations in, 819
- tracheal or bronchial suture dehiscence in, 22
- Transplant recipient(s).** *See also under* Immunocompromised patient(s).
- bronchiolitis obliterans in, 319
- cytomegalovirus pneumonia in, 465
- lymphoid lesions in, 640
- Transthoracic fine needle aspiration.** *See* Fine needle aspiration (FNA).
- Trauma**
- aortic, 184
- bronchial, 182–183
- cardiac, 183–184
- chest, 179–184, 180d
- diaphragmatic, 183
- esophageal, 183
- tracheal, 182–183
- Trematode(s)**
- pulmonary eosinophilia due to, 750
- pulmonary manifestations of, 492–495
- Trichinella spiralis*, 500
- Trichomonas tenax*, 492
- Trichomonas vaginalis*, 492
- Trichomoniasis, pulmonary, 492
- Trichosporon beigeli* pulmonary infection, 485
- Trimetallic anhydride pneumonitis, 165
- Trophoblast embolus(i), pulmonary, 176, 177f
- Tropical eosinophilia (Weingarten syndrome), 497, 750–751
- Trypanosoma cruzi*, 492
- Trypanosomiasis (Chagas disease), pulmonary, 492
- L-Tryptophan, pulmonary hypertension due to, 155
- Tuberculosis**, 451–458
- in AIDS, 458, 511
- bronchopleural fistula in, 458
- caseation necrosis in, 452–453, 453f–454f
- caseation liquefaction and cavitation in, 453
- clinicopathologic patterns of, 454–458
- coal worker's pneumoconiosis and, 381
- differential diagnosis of, 453
- drug resistance in, 458, 511
- Ghon complex in, 454, 454f
- historical, 451
- identification of organisms in, 453
- immune response in, 452
- lesion morphology in, 452f–454f, 452–453
- exudative lesion in, 452, 453f
- proliferative lesion (granuloma) in, 452, 452f
- miliary, 458, 459f
- mortality rate due to, 451
- nontuberculous mycobacterial infection vs., 460, 460f–461f
- pathogenesis of, 451–452
- pleural biopsy in, 457
- pleural effusion in, 457–458
- pleuritis in, 456–458, 457f
- primary, 454f–455f, 454–455
- in adults, 455
- in children, 455
- progressive fibrocavitary disease in, 456, 456f–457f
- progressive massive fibrosis vs., 375, 378f
- pulmonary hypertension in, 209
- reactivation or reinfection, 455–456
- routes of spread of, 453–454
- in silicosis, 389
- Simon focus in, 454, 454f
- Tuberculous pleuritis**, 869, 869f
- Tuberculous granulomatous pneumonia**, 452, 453f
- Tuberous sclerosis**, pulmonary lesions in, 348–349
- Tubular myelin**, from alveolar type II lamellar bodies, 9, 10f
- Tularemia**, 438, 439f
- pneumonia, 438, 439f
- syndromic presentations in, 438
- Tumor(s).** *See also under* Carcinoma(s).
- congenital, 85–88
- lung, 523–530
- classification of, 523
- histologic, 523, 525d
- WHO, 523, 524d
- epidemic incidence of, 525
- etiology of, 525–529
- acquired predisposition in, 526–527
- chemical agents in, 526
- cigarette smoking in, 526
- dietary factors in, 527
- familial aggregation in, 527
- genetic predisposition in, 527–528
- genotypic associations in, 527–528
- lung diseases in, 527, 527f
- molecular defects in, 528t, 528–529
- phenotypic associations in, 528
- physical agents in, 526–527
- radon gas in, 526–527, 887
- staging of, 523–525
- carcinoma in situ and, 524–525
- international system for, 524
- mediastinal invasion in, 525
- multicentricity in, 524
- nodal status in, 525, 526f
- obstruction in, 525
- problems in, 524–525
- TNM system for, 523–524
- visceral pleural invasion in, 525
- Tumor embolus(i), pulmonary hypertension due to**, 230–231, 232f
- Tumorlike condition(s), congenital**, 85–88
- Tungsten carbide, hard metal lung disease due to**, Color Fig. 37-1, 412–414, 414f
- U**
- UIP.** *See* Interstitial pneumonia, usual (UIP).
- Ultrastructural techniques**, for biopsy specimens, 46
- Upper airway(s).** *See* Airway(s), upper.
- Uranium miners**, small cell carcinoma in, 556
- Urinary bladder transitional cell carcinoma**, metastasis from, 703
- Uterine carcinoma**, metastasis from, 703
- Uterine cervical carcinoma**, metastasis from, 703
- Uterine leiomyosarcoma**, metastasis from, 705
- V**
- VACTEL association**, 65
- VACTERL association**, 65
- Vallecular diverticulum**, 63
- Vanadium bronchitis**, 165
- Varicella-zoster viral pneumonia**, Color Fig. 42-1, 467–468
- Vascular lesions**, of respiratory tract, in children, 89–90
- Vasculature**, pulmonary, 11–12. *See also individual vessels.*
- in adult respiratory distress syndrome, 132–134, 134f

- Vasculature, pulmonary (*continued*)  
 corrosion casts for, 57, 59  
 mechanisms of growth and development of, 20
- Vasculitides, systemic, pulmonary involvement in, 811-817
- Vasculitis  
 biopsy for, 48-49  
 hypersensitivity, 812d, 812-813, 814f  
 immune complex disease with, diffuse alveolar hemorrhage in, 728f, 728-729  
 necrotizing, drug-induced, 155  
 pulmonary  
 classification of, 811d  
 drug-induced, 155  
 in rheumatoid arthritis, 782, 783f  
 in systemic lupus erythematosus, 783, 785f
- Vasculitis-associated eosinophilic pneumonia, 751
- Vasculopathy, pulmonary, drug-induced, 155, 155f-156f
- VATER association, 65
- Vegetable cell(s), in cytologic diagnosis, 31, 32f
- Ventilation, collateral, 12, 13f  
 in bronchiectasis, 299-300  
 in chronic bronchitis, 290, 291f
- Ventilation-perfusion scan(s), in Fabry disease, 105, 106f
- Ventricle  
 left. *See under* Left ventricular diastolic dysfunction (pulmonary venous hypertension).  
 right. *See under* Right ventricular hypertrophy.
- Vermiculite, pneumoconiosis due to, 392
- Vinyl chloride, lung disease due to, 419
- Viral-induced asthma, 313, 314f, 315
- Viral infection(s), 465-475. *See also under individual viruses.*  
 in AIDS, 510-511  
 cytologic diagnosis of, 33
- Viral-related giant cell interstitial pneumonia, 344, 345f
- Virchow node, 691
- Visceral larva migrans, 499
- Vitamin A, risks of lung cancer and, 527
- W**
- Wallastonite, pneumoconiosis due to, 392
- Wegener granulomatosis, 791-801  
 alveolar hemorrhage syndromes vs., 800  
 antineutrophil cytoplasmic antibodies in, 797-798  
 bronchocentric, Color Fig. 68-4, 796, 799f  
 bronchocentric granulomatosis vs., 800  
 Churg-Strauss syndrome vs., 807  
 classic, 792  
 clinical manifestations of, 791-793, 792d  
 clinical syndromes of, 792, 792d  
 differential diagnosis of, 798d, 798-800  
 diffuse alveolar hemorrhage in, 727, 796  
 diffuse pulmonary hemorrhage in, 793  
 ELK classification of, 791, 792d  
 eosinophilic, Color Fig. 68-3, 794, 796, 798f  
 Churg-Strauss syndrome vs., 800  
 exudative, 794, 796f  
 granulomatous infection vs., 798  
 histologic patterns in, 794, 796d  
 historical, 791  
 Hodgkin disease vs., 800  
 limited, 792-793  
 lymphomatoid granulomatosis vs., 833, 834  
 lymphoproliferative disease vs., 798-800  
 microbial agent in, 833  
 microscopic polyarteritis vs., 800  
 nasal involvement in, 797, 799f, 829, 830f  
 biopsy technique for, 829-830  
 necrotizing alveolitis in, 728, 728f  
 necrotizing sarcoid granulomatosis vs., 798, 805  
 pathologic findings in, 793-797  
 bronchial, 796  
 capillaritis in, Color Fig. 68-1, 793-794, 794f  
 classic pulmonary nodule in, Color Fig. 68-2, 794, 796f  
 extrapulmonary, 797, 799f  
 granulomatous inflammation in, 794, 795f  
 granulomatous vasculitis in, 794, 795f  
 micronecrosis in, 793, 793f  
 protracted superficial, 793  
 rheumatoid arthritis vs., 800  
 sarcoidosis vs., 776  
 transbronchial biopsy for, 47, 47f-48f  
 treatment of, 800  
 of upper airway, 829-833  
 granulomas in, 829-830, 831f  
 laboratory studies in, 830  
 microscopic lesions in, 833  
 vasculitis in, 829-830, 831f-832f
- Weingarten syndrome (tropical eosinophilia), 497, 750-751
- Welder's pneumoconiosis, 416
- Western red cedar dust, occupational asthma due to, 163
- Whipple disease, 441
- Whooping cough (*Bordetella pertussis* pneumonia), 430
- Williams-Campbell syndrome, 73  
 bronchiectasis in, 97, 295, 304-305
- Wilms tumor, metastasis from, 706, 707f
- Wood dusts, occupational asthma due to, 163
- Wuchereria bancrofti*  
 eosinophilic pneumonia due to, 750, 751t  
 pulmonary, 497, 497f
- X**
- Xylohypha bantiana* pulmonary infection, 485
- Y**
- Yellow nail syndrome, bronchiectasis in, 97-98
- Yersinia pestis*, 437-438, 438f
- Young syndrome, 86, 101
- Z**
- Zebra body(ies), in Fabry disease, 107f
- Zeolite, pneumoconiosis due to, 392
- Zeolite body(ies), 397
- Zinc chloride, inhalation of, 166
- Zirconium lung disease, 417
- Zoster (shingles), 467
- Zygomycosis  
 cytologic diagnosis of, 33  
 pulmonary, Color Fig. 43-7, 484